Human serum resistance in Trypanosoma brucei by Capewell, Paul
Glasgow Theses Service 
http://theses.gla.ac.uk/ 
theses@gla.ac.uk 
 
 
 
 
 
Capewell, Paul (2011) Human serum resistance in Trypanosoma brucei. 
PhD thesis. 
 
 
http://theses.gla.ac.uk/2404/ 
 
 
 
 
 
Copyright and moral rights for this thesis are retained by the author 
 
A copy can be downloaded for personal non-commercial research or 
study, without prior permission or charge 
 
This thesis cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the Author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the Author 
 
When referring to this work, full bibliographic details including the 
author, title, awarding institution and date of the thesis must be given 
 
  
 
Human Serum Resistance 
in Trypanosoma brucei 
Paul Capewell 
 
 
 
 
 
 
 
 
 
 
Submitted in fulfilment of the requirements for 
the Degree of Doctor of Philosophy 
 
 
 
 
 
 
Institute of Infection, Immunity and Inflammation 
College of Medical, Veterinary and Life Sciences 
University of Glasgow 
September 2010
Page | i  
 
Abstract 
Trypanosoma brucei is the causative agent of both sleeping sickness in humans and the related 
veterinary disease, Nagana.  Both diseases have a wide distribution across sub-Saharan Africa and 
affect some of the poorest areas of the world.  T. brucei can be segregated into three 
morphologically identical sub-species based on host, geography and pathology.  T. b. brucei is 
limited to domestic and wild animals throughout sub-Saharan Africa and is non-infective to 
humans due to trypanosome lytic factors found in human serum.  T. b. gambiense and T. b. 
rhodesiense are human infective sub-species, named due to their relative geographic locations.  T. 
b. gambiense is the dominant form of the disease, causing over 90% of reported cases.  Study of 
T. b. gambiense is complicated in that there are two distinct groups. Group 1 is invariably resistant 
to lysis and by far the more prevalent group.  Group 2 T. b. gambiense exhibit a variable resistance 
phenotype and are only found at a small number of Côte d’Ivoire disease foci.  There are two 
trypanosome lytic factors in human serum (TLF-1 & 2), both containing the proteins 
Apolipoprotein L1 (ApoL1) and Haptogoblin-related protein (Hpr). It has been conclusively 
demonstrated that the lytic component of TLF is ApoL1, although Hpr is required for maximal lysis 
by facilitating uptake of TLF particles via the HpHbR cell surface receptor. 
This thesis has exposed several features of the human infectivity phenotype in both groups of T. 
b. gambiense, an area of research for which data has been lacking due to the difficulty of working 
with the organism.  Fluorescence microscopy indicated that group 1 T. b. gambiense exhibit 
avoidance of TLF-1 particles by down-regulating HpHbR receptor expression and function.  
However, they are also able to resist the effects of recombinant ApoL1, suggesting an additional 
neutralisation or compensatory mechanism.  Due to group 1 T. b. gambiense avoidance of TLF-1, 
TLF-2 is the more important lytic particle for this sub-species group and future research must take 
this into consideration.  Unlike group 1, group 2 T. b. gambiense displays a variable human serum 
resistance phenotype that involves a neutralisation or compensatory mechanism for ApoL1, with 
no significant avoidance of lytic particles.  Despite the high variability of the phenotype of group 2 
T. b. gambiense, Quantitative Trait Analysis (QTL) using twenty-five F1 progeny from a T. b. brucei 
/ group 2 T. b. gambiense cross indicated a strong heritable component to human serum 
resistance largely determined by a 30 gene locus on chromosome 8.  Finally, a six multi-locus 
genotype population analysis of a Côte d’Ivoire T. b. gambiense focus was conducted, revealing 
little relationship between the two groups of T. b. gambiense in the field. The differences in the 
human serum resistance phenotypes and population genetics of both groups of T. b. gambiense 
revealed both prior and during this study make it appear likely that the two groups have evolved 
distinct human serum resistance strategies.  
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Chapter 1: Introduction to 
Trypanosoma brucei and human 
infectivity 
1.1 General Introduction 
The African trypanosome Trypanosoma brucei is a flagellated protozoan of the class 
kinetoplastida and is a major parasite of humans and animals in sub-Saharan Africa. 
Trypanosomatids are an evolutionary distinct order of eukaryotes, useful in the study of general 
eukaryote biology (Fernandes et al., 1993; Stevens et al., 2001). However, it is their capacity to be 
pathogens of humans and animals that make them especially important for study - the various 
subspecies of T. brucei are the causative agents of sleeping sickness in humans and the related 
veterinary disease, Nagana.  Both diseases have a wide distribution across sub-Saharan Africa and 
deeply affect some of the poorest areas of the world (WHO, 2006). 
There have been numerous outbreaks of African sleeping sickness during the twentieth century 
but due to implementation of a number of control measures, the disease was almost eradicated 
during the 1960s.  Civil unrest and disease control failure since then have led to a resurgence of 
infection. It is estimated that there are half a million human infections and 70,000 deaths a year 
due to the parasite (WHO, 2006). This number is likely to be an underestimate however due to 
several African nations lacking a sleeping sickness monitoring program. In addition, recent studies 
have also indicated that the level of under-reporting of sleeping sickness deaths in endemic areas 
can be as high as 85% (Fevre et al., 2005; Odiit et al., 2005). Sleeping sickness exacts a huge cost 
on affected areas, placing a burden on local finances and healthcare systems.  Few direct studies 
have been made on the size of this burden but at the Buma focus in the Democratic Republic of 
Congo it was estimated that 43% of household income was lost due to the disease, despite 
subsidisation (Lutumba et al., 2007). In addition to the direct human cost, T. brucei in conjunction 
with T. congolense and T. vivax also have an impact on livestock mortality and morbidity.  For 
communities already suffering under the burden of HIV and malaria, sleeping sickness and Nagana 
has a devastating effect on agricultural and economic development throughout sub-Saharan 
Africa (WHO, 2006). The study of T. brucei biology and how certain sub-species can infect humans 
and persist in non-human reservoirs will have important roles in controlling the disease.   
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1.2 Trypanosome morphology 
Trypanosomes have a variable morphology depending on the life cycle stage of the organism.  
There are however several features common to each stage that can be typified in the 
bloodstream and procyclic form (Matthews, 2005). Trypanosomes contain the majority of the 
organelles seen in other eukaryotes, such as a nucleus, a mitochondrion, a lysosome, endoplasmic 
reticulum and Golgi apparatus.  There are however some distinct differences. Most eukaryotic 
cells possess several lysosome organelles, while trypanosomes only possess one large lysosomal 
structure. There are also several organelles unique to the class, including the glycosomes, 
involved in glycolysis, and the kinetoplast. The kinetoplast is diagnostic of the entire class and is 
visible as a geimsa stainable structure separate from the nucleus at the base of the flagellum. It 
was originally thought to be involved in movement of the trypanosome, but it was later shown 
that this structure is actually the genome of the mitochondrion.  The flagellum is attached to the 
DNA of the mitochondria via the basal body.  
The mitochondrial genome itself is arranged in a highly esoteric way when compared to the 
familiar genomes of other eukaryotes. It consists of mini-circles and maxi-circles of DNA arranged 
in a linked chain-like mass. The maxi-circles encode several mitochondrial genes while the mini-
circles encode guide RNA. The guide RNA is important for the RNA editing that takes place in the 
mitochondria of kinetoplastida to ensure correct gene expression (Benne et al., 1986).  The 
flagellum and basal body are important mediators of cell division and it is possible that the 
mechanical connection aids the separation of the complex mitochondrial genome during the 
process.  The flagellum enters the cell body through the flagellar pocket, an invagination in the 
cell surface.  This area is the primary site of endocytosis and the area at which transfer of 
substances across the cell membrane occurs (Overath & Engstler, 2004). Trypanosomes require a 
specific site of endocytosis because the outer cell membrane is covered in a dense, uniform coat 
of variant surface glycoprotein (VSG) (Vickerman, 1969). This masks the cell surface receptors 
normally involved in the transfer of substances involved in endocytosis.  The VSG is a highly 
expressed, uniform protein that forms a thick layer over the majority of the cell surface.  This 
presents a single dominant antigen to the host immune response that can be changed over the 
course of an infection in the process of antigenic variation (Section 1.7). 
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1.3 Lifecycle 
It seems likely from molecular analysis of GAPDH genes that African trypanosomes are 
monophyletic and are likely to have originated as insect gut parasites (Hamilton et al., 2007; 
Hamilton et al., 2004), diverging from the American trypanosome T. cruzi approximately 100 
million years ago (Stevens et al., 1999).  They have since evolved a complex lifecycle to exploit 
several definitive hosts and vectors (Figure 1.1). 
 
Figure 1.1 Schematic representation of the lifecycle of all sub-species of Trypanosoma brucei, 
indicating the key features of each life cycle stage. 
 
Although technically the life cycle can start anywhere, it is customary in parasite biology to begin 
descriptions at the inoculation stage of the mammalian host.  Metacyclic form trypanosomes are 
transferred from the tsetse vector to the tissue of the mammalian host as the insect feeds. After a 
brief time in the lymph and interstitial fluid, the metacyclics differentiate into the bloodstream 
form and begin to replicate asexually by binary fission. It is at this lifecycle stage that the infamous 
antigenic variation used by trypanosomes to evade host immune defences is expressed (Section 
1.7). The mammalian bloodstream is a homeostatically stable environment for a trypanosome, 
with high levels of glucose and other accessible nutrients. The abundance of glucose allows the 
trypanosome to reduce activity of the mitochondrion and instead rely on a high rate of glycolysis 
Procyclic Form
No VSG
Activated mitochondrion
Proliferative
Epimastigotes
Attached
Proliferative
Metacyclics
Expresses VSG
Non-proliferative
Slender Bloodstream Form
VSG
Repressed mitochondrion
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in the glycosomes for its metabolism. Most bloodstream form trypanosomes have a ‘long-slender’ 
morphology but as the infection progresses ‘short-stumpy’ forms develop that are non-dividing 
but are infective to the tsetse. 
The trypanosome enters the vector when a tsetse ingests the stumpy form parasites with the 
blood meal. These stumpy bloodstream forms differentiate into procyclic forms in the gut of the 
tsetse due to cues from temperature, pH change and the presence of enzymes such as trypsin 
(Matthews, 1999). Procyclics lose their VSG coat and instead express a similarly structured but 
less variable procyclin coat (Roditi & Clayton, 1999).  As there is much less glucose in the tsetse 
gut then the mammalian bloodstream, mitochondrion activity increases and more cristae develop 
to facilitate this. Procyclic form cells undergo multiple rounds of replication within the gut of the 
tsetse before individuals migrate to the salivary gland as non-dividing proventricular forms. After 
reaching the salivary glands the proventricular forms morph into epimastigotes and attach to 
epithelial cells with their flagella. The epimastigotes undergo further asexual replication within 
the salivary gland but it is also at this approximate stage that sexual recombination is likely to 
occur (Tait et al., 2007).  The epimastigotes are non-infective for the mammalian host and they 
must first change form one final time to metacyclics - the VSG coat re-develops and 
mitochondrion activity decreases. Finally, the trypanosomes detach from the salivary gland wall 
and the metacyclic form cells are free to infect a new primary host the next time the tsetse feeds 
and thus continue the cycle. 
1.4 Vectors 
African trypanosomes are transmitted exclusively by flies of the Glossina genus (or tsetse - 'fly 
destructive to cattle' in the Tswana dialect of South Africa).  Due to this fact, the geographic range 
of human infective trypanosomes largely overlaps with areas of high tsetse infestation (Figure 
1.2).  This has made targeting the tsetse a possible avenue for disease control with some early 
successes in isolated foci (Barrett et al., 2003).  Unlike many other vector species, both male and 
female tsetse feed exclusively on blood. They tend to feed on large mammals and do so in a 
telmophagic manner, using their mouthparts to tear host skin and feed on the resulting pool of 
blood and lymph. This feeding mechanism makes the bite of a tsetse quite painful.  To assist with 
feeding, the flies secrete chemicals in their saliva to dilate blood vessels and slow coagulation 
(Parker & Mant, 1979). It is at this stage that an infected tsetse can transmit trypanosomes to the 
host.  Although there are around thirty species of tsetse (Lane & Crosskey, 1993), they fall into 
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two broad groups - the riverine palpalis group usually found along the waterways of Western 
Africa and the morsitans group that prefer the drier savannah in Eastern Africa.  The differences in 
the ecologies of the two tsetse groups correlate with the two distinct sub-species of human 
infective trypanosomes.  Trypanosoma brucei gambiense is transmitted largely by palpalis tsetse 
in the West of Africa and T. b. rhodesiense is transmitted by morsitans in the East. 
 
 
Figure 1.2   Distribution of countries with African sleeping sickness (A) and areas with high tsetse 
infestation (B). Adapted from (WHO, 2006) & (Rogers & Robinson, 2004). 
 
1.5 The three T. brucei sub-species 
Trypanosoma brucei can be segregated into three morphologically identical sub-species based on 
host species, geography and pathology.  T. b. brucei is limited to non-human animals throughout 
sub-Saharan Africa and is non-infective to humans due to trypanosome lytic factors found in the 
serum of some old world primates (Section 1.13). T. b. brucei cells exposed to human serum 
quickly swell and lyse in a consistent manner (Pays et al., 2006).   T. b. gambiense and T. b. 
rhodesiense are human infective sub-species due to their ability to resist lysis by human serum.  
The two sub-species are defined by their relative geographic locations (Figure 1.3). T. b. 
rhodesiense is found in eastern sub-Saharan Africa (Rhodesia is the former name for Zimbabwe) 
and is primarily a disease of animals rather than humans, with little human to human transmission 
(Gibson et al., 2002; Radwanska et al., 2002; Welburn et al., 2001).  The human serum resistance 
phenotype in this sub-species shows variable expression between passages, although the 
A B 
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capability to resist lysis is not completely lost despite repeated rodent passage (Willett & 
Fairbairn, 1955).  The disease typically progresses rapidly and is always fatal. Due to its 
amenability to laboratory manipulation this particular human infective sub-species has seen 
intensive study. 
 
 
Figure 1.3 The distribution of countries reporting T. b. gambiense (blue) and T. b. rhodesiense 
(red) across sub-Saharan Africa.  The dark blue area indicates the countries in which Sleeping 
Sickness is epidemic (adapted from (WHO, 2006). 
 
A serum resistance associated (SRA) gene has been described in T. b. rhodesiense and is used as a 
diagnostic test to differentiate it from morphologically identical T. b. brucei sharing the same 
range (Enyaru et al., 2006). There are however several human infective isolates that are 
geographically defined as T. b. rhodesiense but do not possess SRA (De Greef et al., 1989; Enyaru 
et al., 2006). What these particular lines are and how they relate to local populations has not 
been investigated. 
As previously mentioned, T. b. gambiense is transmitted primarily by G. palpalis vectors found 
along waterways, often close to human settlements. It is by far the most prevalent causative 
human infective trypanosome and is responsible for over 90% of reported sleeping sickness cases 
(WHO, 2006).  The disease is typically endemic and although it is believed to be primarily a human 
disease, domestic pigs may serve as a reservoir (Gibson et al., 1978; Gibson, 1986; Paindavoine et 
al., 1986). Other wild fauna have been shown to carry T. b. gambiense, albeit in limited numbers 
(Njiokou et al., 2006).  The T. b. gambiense form of the disease progresses more slowly than with 
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T. b. rhodesiense and tends to be either self-limiting or develop into a chronic disease of the 
lymphatic and nervous systems (Checchi et al., 2008). Research with T. b. gambiense is 
complicated in that there are two discernable groups of T. b gambiense, identifiable by both 
genetic methods and various displayed phenotypes (Gibson, 1986). Isoenzyme and restriction 
fragment length polymorphisms (RFLP) profiles of isolates reveal a dominant group with low 
genetic variability termed group 1, and a second smaller group found only in Côte d’Ivoire. These 
group 2 T. b. gambiense display more genetic variability than group 1 (Gibson, 1986). The two 
groups also differ in human serum resistance phenotype. Group 1 T. b. gambiense possess an 
invariant infective phenotype while group 2 T. b. gambiense show a variable phenotype similar to 
T. b. rhodesiense (Mehlitz et al., 1982). 
1.6 Pathology 
The pathology of the infection of both types of sleeping sickness has been well documented over 
the years and is delineated into two distinct stages (Burri & Brun, 2003; Stich et al., 2002).  The 
initial haemolymphatic stage of infection begins within the first few weeks following inoculation. 
The parasites initially divide asexually in the tissue surrounding the tsetse bite, often 
characterised by a chancre.  This is a large inflammatory structure that forms in response to the 
insect bite and the presence of the parasites, although it is usually painless. The trypanosomes 
then invade the capillaries and enter the circulatory system where they continue to replicate 
within the blood of the host. The acute blood stage infection is often characterised by flu-like 
episodes of fever and headache. In T. b. gambiense the number of parasites in the blood tends to 
be very low and can often be undetectable for extended periods. Patients infected with T. b. 
rhodesiense exhibit comparatively higher parasitaemia and much more defined periods of fever.  
Peaks in parasitaemia are often associated with these symptomatic periods.  As with other T. 
brucei infections, there is often an invasion of the lymphatic system.  In the often long-term and 
chronic T. b. gambiense infections this can lead to numerous physiological changes including 
enlarged lymph nodes (Winterbottom’s sign), weight loss, weakness and oedema.  
In the second encephalitic stage of the infection, trypanosomes cross the blood-brain barrier and 
invade the central nervous system.  The ensuing meningoencephalitis causes numerous 
neurological symptoms that get progressively worse as the infection reaches its conclusion - 
apathy, fatigue, confusion, motor changes and extreme changes in sleep patterns have all been 
reported. These neurological symptoms can occur within weeks of T. b. rhodesiense infection or 
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months or even years in T. b. gambiense infections. If left untreated, the infected person will 
experience convulsions, coma and an eventual painful death. The distinction is made between the 
two stages of the disease as different drugs are needed to combat each. Extremely toxic drugs 
capable of crossing the blood brain barrier must be employed if the disease proceeds to the 
encephalitic stage and should be avoided if possible (section 1.8). 
An important feature of trypanosome infection is that parasitaemia peaks and troughs with some 
regularity. As the trypanosomes multiply, the host immune system responds by producing 
antibodies targeted to the cell surface VSG and after several days the parasitaemia decreases. 
Following the decrease in parasite number, a new wave of parasitaemia forms. The new parasites 
are unaffected by the previous immune response and the host must initiate a new one. This 
process appears to continue indefinitely (until death of the host or treatment). Trypanosomes 
perform this cyclic evasion of the immune response by varying the VSG being expressed on the 
cell surface in the process of antigenic variation (Barry & McCulloch, 2001; Pays et al., 2001). By 
presenting different antigens to the immune system on a regular cycle, the acquired immune 
system is unable to completely clear an infection. 
1.7 Antigenic variation 
Some of the mechanisms of antigenic variation have been elucidated for trypanosomes by 
categorising the antibodies produced by animals inoculated with trypanosomes (Lumsden et al., 
1968). It became clear that trypanosomes could modify the VSG antigen that they presented to 
the immune system to create different variable antigen types (VAT).  Changes in VAT correlated 
with new peaks of parasitaemia (Balber, 1972). While there were many antibodies that clustered 
into discrete families, the true diversity of VSG expression has been revealed by genetic 
techniques.  VSG genes are found throughout the genome, usually at the telomeres or in 
clustered subtelomeric arrays and are transcriptionally silent.  There are also VSG arrays on the 
mini-chromosomes (Vanderploeg et al., 1984). Most VSG genes are represented as pseudo-genes 
and contribute to antigenic variation by serving as a reservoir to create new mosaic VSGs by 
recombination (Marcello & Barry, 2007). All in all, there are many hundreds of VSG genes in T. 
brucei, and nearly 10% of the coding regions of the trypanosome genome are VSG genes 
(Berriman et al., 2005).  In order for a VSG gene to be active it must sit in one of the telomeric 
expression sites that possess the expression site associated genes (ESAG) (Pays et al., 1989).  A 
similar contingent of ESAGs is found in each expression site, although few have been fully 
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characterised.  There are approximately twenty bloodstream expression sites found in the T. b. 
brucei genome but only one is active at a time (Becker et al., 2004). This is likely to be due to a 
physical position that the expression site needs to be in to be transcribed (Navarro & Gull, 2001). 
The expression sites contribute to the antigenic variation of trypanosomes in that each expression 
site is likely to contain a different VSG. By changing expression sites via in situ transcriptional 
switching, they can quickly vary the VSG presented to the immune system. 
Varying expression sites may also contribute to the host adaptability of the parasite by modifying 
the ESAGs being expressed. Although the ESAG complement of each expression site is similar, 
there are subtle differences between genes in different expression sites.  The most studied of 
these ESAGs is the transferrin receptor formed from ESAG6/7 (Ligtenberg et al., 1994; Salmon et 
al., 1994; Steverding et al., 1994; Steverding et al., 1995). These two genes have hypervariable 
regions that differ between copies of each gene in different expression sites and the receptor 
expressed from them appear to have different affinities to various animal transferrins (Bitter et 
al., 1998; Gerrits et al., 2002). It is proposed that expression site switching aids host adaptation as 
T. brucei are able to infect a wide range of definitive hosts (Pays et al., 2001; van Luenen et al., 
2005). The variation found in ESAG6/7 between expression sites can also be exploited to assess 
when an expression site switch has occurred by sequencing the transcript of the expressed ESAGs, 
particularly the sequence of the hypervariable regions of ESAG6/7 (Hertz-Fowler et al., 2008). 
In addition to in situ transcriptional switching, the VSG at the active expression site can be 
swapped for another either using homologous recombination (McCulloch & Barry, 1999).  This 
system utilises the homologous 70bp repeat regions found upstream of the 5’ end of all VSGs and 
in the expression sites. The VSG can either enter the expression site by gene conversion with 
another VSG from the library or by reciprocal exchange from another expression site (Conway et 
al., 2002; Stockdale et al., 2008). Switching occurs spontaneously within a small number of 
trypanosomes and these are selected for by the host immune response.  There is a pattern of VSG 
expression that ensures that gene switching occurs consecutively and some VSGs are more likely 
to be selected for than others (Barry & Turner, 1991). The sequence homology between some 
VSGs can also lead to partial gene recombination with members of the library of pseudo-VSGs, 
creating entirely new ‘mosaic’ VSGs, further increasing the potential for antigenic variation 
(Marcello & Barry, 2007).  By changing the VSGs or modifying them by recombination in varying 
expression sites, trypanosomes have an almost limitless capacity to vary the antigen they expose 
to the host immune system. The most important feature of antigenic variation is that it renders 
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the acquired immune system of mammals largely ineffective. To overcome this, innate resistance 
features targeting the parasites specifically are employed to combat infection (Section 1.13). 
1.8 Drug treatment in humans 
Several drugs are used to treat African sleeping sickness, depending on the stage of the disease 
and the sub-species (Leach & Roberts, 1981; Nok, 2003). Suramin and pentamidine are 
administered during the early stages of the infection before the central nervous system is 
invaded.  Both drugs are relatively toxic and surprisingly old – suramin was introduced in 1920 
and pentamidine in 1941. Pentamidine is less toxic than suramin and has traditionally been used 
to treat T. b. gambiense rather than T. b. rhodesiense despite working efficiently against both sub-
species (Nok, 2003).  If the drugs are administered in the initial stages of the disease the chances 
of survival are high. Rapid and accurate disease identification is therefore essential. This is 
hampered by poor equipment and resources found in endemic sleeping sickness regions, the 
difficulties in defining the disease from clinical symptoms and also the lack of robust methods for 
diagnosing infection. 
For late stage infections, melarsoprol or eflornithine are used. Melarsoprol is extremely toxic, 
requiring hospitalisation and monitoring for at least ten days (Burri et al., 2000). Eflornithine can 
be used for T. b. gambiense infections but not T. b. rhodesiense. Despite the expense of 
manufacture, the WHO has recently negotiated deals with the companies involved to produce all 
of the mentioned drugs at a reduced cost to the organisation.  These are now provided free at the 
point of care to patients in affected area (http://www.who.org/).  However, there are increasing 
incidents of drug resistance being reported in the field (de Koning, 2001; Maser et al., 2003; 
Matovu et al., 2001).  Human trypanomiasis treatment failure has reached 30% in some areas 
where melarsoprol is employed (Legros et al., 1999). 
1.9 Trypanosome genome organisation 
Trypanosomes possess an unusual genomic structure when compared to other eukaryotes, 
reflecting the large evolutionary distance between them. Approximately 20% of the DNA 
component is within the kinetoplast, with the remaining 80% found in the nucleus (Simpson, 
1972). Despite the fact that trypanosome chromosomes do not condense during mitosis, pulse 
field gel electrophoresis has revealed that there are several size classes of chromosome in the 
nucleus of the cell; approximately one hundred mini-chromosomes (50-150kb), one to six 
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intermediate-chromosomes depending on the strain (200-1000kb) and eleven mega-
chromosomes (>1000kb) (Gottesdiener et al., 1990; Melville et al., 1998; Vanderploeg et al., 
1984). The mega-chromosomes contain most of the metabolic and VSG genes while the smaller 
chromosomes contain predominantly VSG genes and pseudo-genes (Melville et al., 1998).  The 
non-telomeric regions of the mega-chromosomes have been sequenced for both the T. b. brucei 
strain TREU927 and the T. b. gambiense strain DAL972 (Berriman et al., 2005; Jackson et al., 
2010).  The complete complement of VSGs has largely been sequenced in the T. b. brucei strain 
Lister 427 and efforts are underway to replicate this in the T. b. brucei genome strain TREU927 
(http://www.sanger.ac.uk).  
An important aspect of parasite biology is the ploidy of the organism.  This attribute has been 
shown to have implications in the emergence of new traits in parasites, such as drug resistance in 
Plasmodium falciparum (Sibley & Hunt, 2003). By comparing isoenzymes, RFLP profiles and total 
DNA content it was shown that the mega-chromosomes of bloodstream trypanosomes are diploid 
(Gibson et al., 1980; Tait, 1980).  The ploidy of the intermediate and mini-chromosomes is still 
undetermined, although they are divided equally between daughter cells during binary fission and 
the patterns of certain features in the mini-chromosome are highly stable over multiple 
generations (Alsford et al., 2001).  Cellular DNA content is similar to blood stage forms in procyclic 
and metacyclic forms so it can be extrapolated that the organism is also diploid in these stages 
(Kooy et al., 1989; Tait et al., 1989).  In fact, no haploid cells have been described despite 
population genetics studies revealing that genetic exchange occurs in trypanosomes (Gibson et 
al., 1980; Tait, 1980; Tait, 1983).  Several triploid cells lines have been described, always arising in 
genetic crosses performed in the laboratory (Gibson et al., 1992; Hope et al., 1999).  The 
prevalence of triploids is related to the strains involved in the crosses and is more likely to occur 
in strains less related to each other (Hope et al., 1999). The existence of triploid cells has not yet 
been demonstrated to occur in the field (MacLeod et al., 2005a). 
The study of trypanosome genetics has been greatly enhanced by the publication of the T. b. 
brucei genome sequence of the coding areas of the mega-chromosomes (Berriman et al., 2005) 
and the subsequent publication of the genome of the group 1 T. b. gambiense DAL972 (Jackson et 
al., 2010) showing that the two subspecies are extremely alike, with an average of 99.2% identity 
between genes (Jackson et al., 2010). There were no differences in gene complement or order. 
There are however important caveats before discounting the potential existence of a gene 
specific to group 1 T. b. gambiense conferring human infectivity. Sub-telomeric regions were not 
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included in the sequencing process due to limitations in the approaches used.  The T. b. 
gambiense reads were also assembled using the T. b. brucei genome as a scaffold – it is possible 
that novel regions of the genome could have been discarded by employing this technique. It is 
also important to remember that non-coding regions were omitted for comparative analysis and 
it is possible that resistance mechanisms may involve the modification of a non-coding region that 
affects of expression of a gene, rather than the presence or absence of that gene in the genome. 
1.10 Experimental genetics of T. brucei 
Sexual recombination has been described under laboratory conditions and shown to occur in the 
tsetse (Jenni et al., 1986). It is not yet known exactly when recombination occurs within the fly, 
although it is likely to occur before the epimastigotes differentiate to metacyclics in the salivary 
glands (Gibson et al., 2006; Tait et al., 2007).  Recent antibody based assays have identified 
attached cells expressing proteins that preceed meiosis, although no haploid stage have yet been 
identified (Peacock et al., 2011).  Recombination is not obligatory in T. brucei and the majority of 
trypanosomes passing through the tsetse possess the same genotype as the parents (Jenni et al., 
1986).  Additionally, self-fertilisation can occur within a single parental line (Gibson & Stevens, 
1999; Tait et al., 1996; Tait & Turner, 1990). There have been numerous population studies and 
several further crosses confirming that sexual recombination is a common phenomenon in T. 
brucei but rates can vary greatly between strains (Gibson, 2009; Gibson & Garside, 1991; Gibson 
et al., 1992; MacLeod et al., 2005a; Schweizer et al., 1994; Sternberg et al., 1988; Tait et al., 1996; 
Turner et al., 1990). The segregation of alleles in three laboratory derived T. brucei crosses 
correlates closely with a Mendelian model and alleles on different chromosomes segregate 
independently (MacLeod et al., 2005a; Turner et al., 1990).  
Mendelian inheritance requires that meiosis and cell fusion are necessary but does not stipulate 
the order of events.  The discovery of triploid cells in association with genetic crosses provided 
possible evidence for fusion preceding meiosis, although recent data suggest that fusion occurs 
after meiosis (Peacock et al., 2011). The first hypothesis proposed was that two parental cells fuse 
to form a tetraploid which then pares down DNA content by an unknown method to create a 
normal diploid cell (Paindavoine et al., 1986). Incorrect destruction of DNA would result in 
triploidy.  In this fusion-loss model however the assortment of the parental alleles would be non-
Mendelian.  It has been shown conclusively that T. brucei reproduces in a Mendelian manner so 
the model is unsuitable for understanding genetic exchange in this species (MacLeod et al., 
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2005a) A different fusion model was also postulated in which the cells fuse to form tetraploid cells 
as before, but the nuclei then undergo meiosis to create eight haploid daughter nuclei (Gibson et 
al., 1995). Two of these haploid nuclei fuse to form the normal diploid cell and the other haploid 
nuclei are destroyed.  This model can result in Mendelian inheritance but no cells with a 
physiology featuring eight haploid nuclei have been described. Triploidy may arise if three haploid 
nuclei fused accidently or more likely if a haploid cell fused with a normal diploid cell.  In addition, 
trisomy has been described for individual chromosomes although this is most likely as a result of 
non-disjunction during meiosis rather than fusion (Hope et al., 1999). The final model proposed to 
explain sexual reproduction in T. brucei is that like many other protozoan parasites, there is a 
haploid gamete stage produced via meiosis.  These then fuse to create standard diploid cells (Tait 
& Turner, 1990).  As with the fusion hypothesis, no cells have yet been identified that feature the 
characteristics of such a haploid cell. At present it is impossible to determine which of the 
proposed models is correct (or if both models are wrong) but efforts are underway with 
laboratory crosses using fluorescent trypanosomes in an attempt to clarify the situation (Gibson 
et al., 2006). 
The publication of the T. brucei genome and the revelation that trypanosome sub-species are 
genetically similar has allowed the development of forward genetic techniques for both T. b. 
brucei and group 2 T. b. gambiense. One such approach is to measure the link between the alleles 
of different genes with a phenotypic trait in the progeny of a genetic cross. Firstly a genetic map 
must be created indicating how close genetic markers are to each other along a chromosome.  
This is estimated by genetic distance in centiMorgans and can be inferred by how often alleles of 
genes are inherited relative to neighbouring alleles in the progeny of isolates. Genes physically 
close to each are more likely to have alleles inherited together. When the distance between genes 
increases, the frequency of a crossover between them also increases. The distance between 
genes can be estimated with no prior knowledge of the genomic sequence of an isolate based on 
the likelihood of recombination between markers (Doerge, 2002). The pattern of inheritance 
reveals the frequency of crossovers between markers and this is used to infer genetic distance 
and produce a genetic map of the chromosomes.  Two genetic maps have been created for T. 
brucei.  The first map was for the fully sequenced T. brucei reference strain TREU927 and 
originated from a cross between TREU927 and the T. b. brucei strain STIB247 (MacLeod et al., 
2005b). A second map has also been created for the group 2 T. b. gambiense strain STIB386 by 
also crossing it with STIB247 (Cooper et al., 2008).  STIB247 was selected to be the second parent 
in each cross due to the fact it is predominantly homozygous along each of the mega-
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chromosomes while STIB386 and TREU927 are largely heterozygous (MacLeod et al., 2005b).  
Differences in the phenotype of the progeny can be attributed to whichever of the chromosome 
homologues the hybrid has inherited from the heterozygous parent. 
Using this methodology, the relationship between the phenotype and the inherited haplotype of 
the hybrids can be ascertained. Relevant alleles are either inherited by the progeny or not and 
likewise the phenotype will either be present or not.  By comparing the parental markers 
inherited by the progeny, markers more likely to be possessed by progeny displaying the 
phenotype suggest that genes close to those markers are involved with the phenotype.  It is 
important that the distance between markers is also considered to take into account random 
crossover events (Churchill & Doerge, 1994).  Using this methodology Quantitative trait loci (QTL) 
analysis is ideal for the study of complex phenotypes that arise due to multi-gene interactions. 
This is revealed as continuous phenotypic response in the progeny, rather than the discrete 
presence or absence of the phenotype in question. In this case the degree that the phenotype is 
displayed in each progeny is also considered in conjunction with the proportion of progeny 
inheriting the marker. Using these methods, several experiments have identified key genes 
involved with cellular processes, despite being part of a complex multi-gene response. For 
example, several regions of the Toxoplasma gondii genome were implicated by QTL analysis as 
being involved with the virulence of the parasite (Su et al., 2002). One locus however contributed 
over 50% of the phenotype and further detailed QTL mapping and experimental analysis of the 
area identified a kinase that is vital to virulence (Taylor et al., 2006).  QTL analysis has also been 
successfully utilised in T. brucei, revealed a primary locus implicated in host pathogenesis and 
suggesting several other regions involved in the phenotype (Morrison et al., 2009). QTL analysis 
can also be applied to phenotypes showing low heritability or penetrance. This is necessary as an 
investigation of human serum resistance using the group 2 T. b. gambiense strain STIB386 would 
need to overcome the fact the phenotype is variable, despite clearly possessing a genetic 
component. Most studies of variable or low penetrance traits are concerned with human 
diseases, predominantly diabetes and cancer (Glazier et al., 2002). In many diabetes studies for 
example, the phenotype has both an environmental and genetic component and the degree of 
expression varies greatly. Despite this, several related diabetes related loci have been identified 
by designing studies with a large enough number of test subjects able to overcome the inherent 
variance (Glazier et al., 2002).  With a large number of progeny and sufficient heritability, the 
methodology applied in these human studies can be transferred to trypanosome phenotypes. 
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1.11 Mating in natural T. brucei populations 
It has been shown that mating can occur in T. brucei under laboratory conditions but it is also 
important to understand whether the phenomenon can occur in the field.  Three theoretical 
positions have emerged to explain the population structures of T. brucei disease foci. At one end 
of the spectrum there is the suggestion that the foci are panmictic populations with high levels of 
genetic exchange and sexual recombination.  This theory was originally based on analysis of allele 
frequencies for several polymorphic isoenzyme markers for parasite populations (Gibson et al., 
1980; Tait, 1980).  At the other end of the spectrum is the clonal theory whereby sexual 
recombination is rare or absent and genetic variation arises exclusively from mutation (Tibayrenc 
et al., 1990). A third option is that populations follow an epidemic structure in that there is some 
background recombination but a successful genotype can become dominant, as might be 
expected in an epidemic (Maynard-Smith et al., 1993). 
Understanding the population structure of a disease focus has important implications for the 
control and treatment of disease. In a clonal population for example, double-drug resistance 
would require two separate mutation events simultaneously, which is an unlikely occurrence. On 
the other hand, if sex is present in a population, double-resistance can arise from recombination 
of two single-resistant parents.  A randomly mating population therefore has the variability and 
capability to evolve more quickly in response to the selective pressure of drug treatment. This 
rapid evolution is not limited to drug resistance and can also occur with other genetic traits, such 
as virulence, pathogenesis or human infectivity. 
Several techniques have been utilised to investigate the population genetics of T. brucei 
populations. All are based on detecting the distribution of alleles within a population to infer 
relationships between isolates. Initially, assays using isoenzymes were utilised to investigate the 
relationships present in T. brucei stocks (Gibson et al., 1978; Godfrey et al., 1987; Kilgour, 1980). 
This technique utilises the differing characteristics of allozymes (such as charge, size and 
conformation) and the affect these have on their rate of passage through starch gels.  
Polymorphisms between enzymes were detected as bands at differing positions in gels from 
which the alleles for single copy genes could be inferred. There are many downsides to this 
technique, such as requiring vast amounts of starting material and synonymous mutations in a 
gene are not detected, even though these would be informative to infer relationships. Parallel to 
this research there have been limited studies utilising restriction fragment length polymorphisms 
(RFLP) to investigate T. brucei populations (Paindavoine et al., 1986; Paindavoine et al., 1989). 
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This method used combinations of restriction enzymes and the unique fragments generated from 
cut genomic DNA when visualised on Southern blots. Relationships between parasite isolates 
were then inferred by the fragments that each possessed. Point mutations in genome sequence 
can lead to the loss or gain of an enzyme restriction site and insertions, deletions or duplications 
also result in changes in the fragment size. Obviously this method misses polymorphisms that do 
not lead to changes in restriction sites or the size of fragments. Additionally, substantial amounts 
of starting material are required and this precluded the use of this method for many field studies, 
especially with T. b. gambiense which has low parasite densities in the host.  There is a benefit to 
both methods in that knowledge of the genome sequence of the organisms is not required.  The 
development of the polymerase chain reaction (PCR) has overcome the limitations of needing 
large initial sample amounts somewhat, allowing amplification of very small amounts of DNA. It 
has also allowed development of newer techniques for studying population genetics. 
One technique which utilises PCR is the amplified fragment length polymorphism (AFLP) 
technology (Agbo et al., 2001; Agbo et al., 2002). This system first digests genomic DNA with a 
selection of restriction enzymes.  Adapters are ligated to the ends of these genomic fragments 
and PCR targeted to these adapters amplify the fragments. The amplified fragments are then 
visualised on polyacrylamide gels and the pattern of sizes in the fragment lengths can be used to 
infer relationships and inheritance.  The use of PCR allows much smaller starting amounts of 
material to be used compared to previous techniques, but it is still not ideal for parasites that 
show low density in the host. Also the genome positions of polymorphic loci are unknown and the 
potential for mixed-genotype infections cannot be discerned. 
Further refinement of PCR technology has led to the development of highly sensitive mini and 
microsatellites techniques. These have been made possible by the publication of the T. brucei 
genome (Berriman et al., 2005). Mini and microsatellites are heritable sequences of tandemly 
repeated DNA found throughout eukaryotic genomes (Jeffreys et al., 1990; Jeffreys et al., 1985; 
Weissenbach et al., 1992). Minisatellites are usually between 10-100bp in length and 
microsatellites are between 2-6bp. Microsatellites are far more abundant then minisatellites and 
show a larger degree of variation in copy number making them ideal to determine relationships 
between individuals of a population – the unique variation in the copy number of each 
microsatellite acts as a genetic fingerprint. The T. brucei genome sequencing project revealed the 
presence of many microsatellites of larger than 12 repeats equally spaced throughout the mega-
chromosomes (Berriman et al., 2005).  By using PCR amplification of a DNA sequence containing a 
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microsatellite and gel electrophoresis of the amplicon in a high percentage agarose gel, it is 
possible to distinguish between microsatellite repeat sizes and assign alleles to individuals. This 
technique has been utilised in several modern studies of trypanosome population genetics, 
including T. b. gambiense (Morrison et al., 2008).  Band ambiguity can be alleviated using 
technology such as Genescan® which fluorescently tags the PCR product, allowing it to be 
accurately sized against standard markers using capillary electrophoresis 
By employing these various techniques, population structures have been described for several T. 
brucei populations. T. brucei has different population structures in different geographical foci; 
clonal (Koffi et al., 2009; Mathieu-daude & Tibayrenc, 1994; Morrison et al., 2008), epidemic (Hide 
et al., 1994; MacLeod et al., 2000; MacLeod et al., 2001; Stevens & Tibayrenc, 1996) and 
panmictic (Tait, 1980). Epidemic and panmictic populations structures strongly indicate that 
mating occurs at these foci (MacLeod et al., 2000).  With regards to the human infective 
trypanosomes, microsatellite studies with T. b. rhodesiense isolates have shown that although the 
overall T. brucei population in a given geographic location appears to be epidemic in eastern 
Africa; the T. b. rhodesiense population itself is clonal.  This population has remained stable for 
several decades, separate from the T. b. brucei population (MacLeod et al., 2001). T. b. gambiense 
have been less thoroughly studied than other T. brucei sub-species but several group 1 foci exhibit 
clonal population structures (Koffi et al., 2009; Morrison et al., 2008; Tibayrenc et al., 1990; Truc 
& Tibayrenc, 1993). It is also known that they show a much less diverse VSG and ESAG repertoire 
then other T. brucei subspecies (Dero et al., 1987; Hertz-Fowler et al., 2008). Group 2 T. b. 
gambiense are far less prevalent and even less well characterised then group 1.  RFLP and 
isoenzyme studies indicate that group 2 are genetically distinct from group 1 and are more closely 
related to T. b. brucei then group 1 T. b. gambiense (Gibson, 1986; Hide et al., 1994). Despite this, 
the two groups of T. b. gambiense are still placed into the same sub-species based on historical 
and geographical grounds. If group 1 T. b gambiense are truly clonal then they may have lost the 
ability to undergo genetic recombination – no genetic cross with a group 1 T. b. gambiense has 
yet been performed in the laboratory and this would preclude forward genetic analysis. However, 
the well characterised group 2 T. b. gambiense strain STIB386 has been shown to undergo sexual 
recombination in the laboratory in a Mendelian manner and would be ideal for such analysis 
(MacLeod et al., 2005a; Turner et al., 1990). 
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1.12 Primate resistance to trypanosomes 
Due to antigenic variation, T. brucei can largely avoid the effects of the mammalian adaptive 
immune system indefinitely.  However, some species of primate have evolved an innate 
resistance mechanism to combat infection. This innate immune mechanism quickly lyses T. b. 
brucei, although T. b. gambiense and T. b rhodesiense are able to resist lysis and still infect 
humans. The lytic effect of human serum on non-human infective trypanosomes was first shown 
in the early 20th century (Laveran & Mesnil, 1912). When observed by microscopy, trypanosome 
lysis by human serum proceeds rapidly along a well defined path. After a lag phase of 
approximately thirty minutes, the cell experiences gross changes to morphology as it swells 
rapidly until it ruptures within one to two hours (Rifkin, 1978; Rifkin, 1984).   Microscopic 
evidence indicates that the swelling of the cell and lysis is due to the lysosome swelling (Pays & 
Vanhollebeke, 2009; Pays et al., 2006).  The serum from several old world primates, including 
gorillas, baboons and mandrills were also shown to lyse non-human infective trypanosomes but 
with differing rates of activity (Laveran & Mesnil, 1912).  
There have been several studies on primate serum and lysis (Laveran & Mesnil, 1912; Lugli et al., 
2004; Seed et al., 1990). The ability to lyse trypanosomes is confined to old world primates and 
may have originated on two different occasions (Poelvoorde et al., 2004) – once in the 
Cercopithecidae group (baboons & mandrills) and once in the Hominidae group. The high 
similarity of the genes involved in trypanosome lysis make it more likely that the trait evolved 
prior to the split between the two groups of primates, approximately 25 million years ago.  The 
serum of the Papio genus (baboon) primates has a much higher lysis efficiency compared to 
Hominidae and also lyses human infective T. b. rhodesiense.  It is interesting to note that 
Hominidae of the Pan genus (chimpanzees) do not posses trypanocidal serum despite the close 
evolutionary links with the Gorilla gorilla and Homo sapiens. The simplest explanation is that 
chimpanzees have lost the ability to combat trypanosome infection rather than the lytic effect 
arising separately in other Hominidae.   
1.13 Trypanosome lytic factors, TLF-1 & TLF-2 
The earliest observations of trypanosome lysis indicated that the mechanism was not associated 
with the classical immune system components of immunoglobin or complement but rather uses 
some unknown factor in human serum (Laveran & Mesnil, 1912). It has also been known for 
nearly a century that the serum of humans is highly toxic to multiple trypanosome species (Hajduk 
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et al., 1994; Laveran & Mesnil, 1912). While this might have evolved as a specific anti-
trypanosome measure, it may also have arisen as a general protozoa defence strategy as the 
trypanolytic component of human serum also produces measurable physiological effects in 
Plasmodium falciparum  (Imrie et al., 2004) and two Leishmania species (Samanovic et al., 2009). 
Nevertheless, most work on elucidating the mechanisms behind the lytic effect has been 
performed using T. brucei. By testing the trypanocidal effect of separated fractions of HDL on T. b. 
brucei, it was shown that the majority of the lytic effect was associated with the densest fraction 
of human serum – the high density lipoprotein (HDL) component (Rifkin, 1978).  Purified human 
HDL from the same fraction size also clears T. b. brucei infections in mice (Rifkin, 1978).   
HDL bodies are spherical, soluble amalgams of phospholipids, cholesterol and apolipoproteins 
(Pays et al., 2006) and in addition to a trypanocidal effect, appear to have an important role in 
controlling both blood pressure and cholesterol levels (Castelli et al., 1977; Forde et al., 1977; 
Miller, 1978).  HDLs are a diverse family of particles, containing several different protein families 
(Blanche et al., 1981). The importance of HDL to trypanosome lysis was confirmed in experiments 
that showed that the level of HDL in serum correlates with the efficiency of lysis, depletion of HDL 
reduces lytic activity and that anti-human HDL antibodies can inhibit lysis (Gillett & Owen, 1991; 
Hajduk et al., 1989).  Physiological evidence was provided by the characterisation of the human 
condition Tangiers disease in which patients have a reduced HDL component in their serum and 
no corresponding trypanolytic effect (Rifkin, 1978).  
Most HDL bodies are not trypanocidal but one particular particle found in separation studies was 
shown to be highly lytic. This was termed the Trypanosome Lytic Factor (subsequently TLF-1 after 
the discovery of a second TLF) (Hajduk et al., 1989). Western blots identified two proteins unique 
to TLF-1 not found in other HDL particles. In the same series of experiments it was noted that lysis 
was inhibited when trypanosomes were incubated below 17°C, the same temperature at which 
endocytosis is greatly reduced in eukaryotes (Dunn et al., 1980). This fact, coupled with the initial 
thirty minute lag phase before observable lysis effects provided compelling evidence that TLF-1 is 
internalised by endocytosis before it can mediate lysis.  Two different receptors for TLF-1 have 
been suggested to exist based on data from low-temperature binding assays - a high affinity 
receptor that has approximately 350 copies per parasite and a low affinity receptor that has 
60,000 receptors per cell (Drain et al., 2001).  In addition to TLF-1, a second TLF has since been 
described in a larger sized fraction of HDL (Raper et al., 1999; Tomlinson et al., 1997). The larger 
size of the TLF-2 particle is due to its association with IgM molecules on the particle surface.  TLF-2 
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contains much less lipid then TLF-1 but possesses similar lytic characteristics and is found at a 
similar concentration in blood (Raper et al., 2001). It does however possess a much shorter half-
life then TLF-1 and so is difficult to characterise further.  The receptor for TLF-2 is less well 
characterised, although it is known that it has low affinity, high turnover and haptoglobin does 
not compete for the receptor, unlike TLF-1 (Vanhollebeke et al., 2007b). It has been suggested 
that IgM is the ligand for entry of TLF-2 into the cell as this particular immunoglobin has been 
shown to weakly bind VSG on the trypanosome surface with a characteristic low affinity 
(Vanhollebeke & Pays, 2010). TLF-2 would therefore be internalised as part of the normal surface 
recycling mechanism found in all trypanosome species. 
1.14 ApoA1, Hpr and ApoL1 
The protein component of TLF-1 and TLF-2 consists of the apolipoproteins L1 (ApoL1) and A1 
(ApoA1) (Tytler et al., 1995) and haptoglobin-related protein (Hpr) (Smith & Hajduk, 1995; 
Tomlinson et al., 1997). TLF-2 is also found bound to IgM, contributing to the larger size of the 
particle (Raper et al., 2001). ApoA1 is a ubiquitous apolipoprotein contained within 70% of all HDL 
particles and is predominantly involved in providing structure. Both recombinant ApoA1 and 
transgenic mice expressing human ApoA1 are unable to kill T. b. brucei indicating that direct 
involvement in lysis can be discounted (Owen et al., 1992). However, the binding of TLF-1 
particles to the low affinity receptor was competed by other HDL particles , including non-lytic 
bovine partiles, suggesting that the ligand could be ApoA1 (Vanhamme & Pays, 2004). As ApoA1 is 
often bound to cholesterol, a receptor to scavenge this protein is unsurprising due to the fact 
trypanosomes are cholesterol auxotrophs but have extremely high cholesterol requirements due 
to rapid turnover of the VSG coat (Seyfang et al., 1990). 
Of the remaining two proteins, haptoglobin-related protein appeared to be the most likely 
candidate to be the lytic factor.  Hpr is a close paralogue to haptoglobin protein (Hp) which has 
been shown to possess a toxic peroxidase effect when bound to haemoglobin in low pH 
conditions similar to those within the lysosome (Bonkovsky, 1991; Connell & Smithies, 1959).  It 
was hypothesised that a similar toxicity may be present in Hpr and several experiments have 
implicated Hpr in trypanosome lysis.  It was shown that the then unknown high affinity TLF-1 
receptor is not competed for by other HDLs but by Haptoglobin bound to Haem, indicating Hpr is 
the likely ligand in this case (Drain et al., 2001; Smith & Hajduk, 1995). It can be conjectured that a 
Haptoglobin receptor would be useful for trypanosomes to take up bound haemoglobin for iron, 
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with the binding of Hpr a cross-reaction.  Trypanosome lines that do not have efficient uptake of 
TLF-1 do not survive if transferrin is removed from serum, highlighting the importance of iron to 
the parasite and why they would need to bind Haptoglobin bound to haem (Hager & Hajduk, 
1997). Anti-haptoglobin antibodies have been shown to cross react with Hpr and also protect 
trypanosomes from lysis in the presence of TLF-1 (Smith & Hajduk, 1995). It was also noted that 
non-lytic serum from chimpanzees does not contain Hpr due to a frame-shift mutation in the 
gene, adding further weight to the argument that Hpr is the lytic factor (McEvoy et al., 1988). 
It was proposed that Hpr was the trypanolytic component of HDL with a working hypothesis that 
haemoglobin-bound Hpr enters the parasitic cell via endocytosis. After Hpr enters the low pH 
environment of the lysosome, an iron-based Fenton peroxidase reaction occurs which damages 
the membrane and initiates lysis (Smith & Hajduk, 1995).  Adding catalase to the parasite to 
reduce peroxide concentration also reduced lysis, seemingly supporting the peroxidase 
hypothesis. It was also shown that the end-products of lipid peroxidation were found in lysed cells 
and application of DPPD (an inhibitor of the lipid degrading peroxidase effect) prevented lysis 
(Bishop et al., 2001). These conclusions that Hpr is the lytic component of TLF are however 
disputed. It has since been shown that Hpr may not bind haemoglobin after all so there can be no 
associated peroxidase Fenton reaction (Muranjan et al., 1997).  Also, no peroxidase 
intermediaries were shown to be formed during interaction with TLF-1 so it may be that the 
observed end-products of peroxidation are formed coincidentally (Portela et al., 2000).  It has 
been insinuated that the observed peroxidase effect was due to contamination by haemoglobin 
bound to Haptoglobin (Vanhamme et al., 2003).  More recent studies of the effect of catalase on 
lysis have also been unable to repeat earlier results of lysis inhibition (Raper et al., 2001). Finally, 
recombinant Hpr has not been shown to be lytic (Vanhollebeke et al., 2007b). 
An alternate hypothesis was put forward that the trypanocidal protein of TLF was a different 
common component of both TLF particles - ApoL1. ApoL1 arose as a possible lytic factor candidate 
when it was shown to co-localise with the serum resistance associated (SRA) protein of T. b. 
rhodesiense (Section 1.17) (Vanhamme et al., 2003).  ApoL1 possesses a pore forming domain 
under low pH conditions that is similar to that of bacterial colicins and the mammalian Bcl2 
proteins involved in apoptosis (Perez-Morga et al., 2005). This domain is essential to the lytic 
function of the protein (Perez-Morga et al., 2005).  The protein localises with the lysosome 
membrane marker p67 after endocytosis, suggesting that it embeds in the lysosomal membrane 
after entry (Vanhamme et al., 2003).  Both naturally derived and recombinant ApoL1 lyses 
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trypanosomes with a swollen lysosome morphology similar to that seen after exposure to human 
serum, although unbound ApoL1 lyses at a slower rate than normal human serum (Vanhamme et 
al., 2003; Vanhamme & Pays, 2004; Vanhollebeke et al., 2007b).  It was proposed that ApoL1 
induces the formation of pores in the lysosome that in turn create an influx of chloride ions 
(Vanhamme et al., 2003).  The influx of ions upsets the osmotic balance of the lysosome, causing 
it to rapidly swell and rupture. 
Like Hpr, ApoL1 is present in higher primates but due to a premature stop codon it is inactive in 
chimpanzees, explaining the lack of lytic activity in this species (Poelvoorde et al., 2004). Hpr has 
also recently been revealed to be present in all old world primates, even those with non-lytic 
serum (Vanhollebeke & Pays, 2010) suggesting it evolved before ApoL1 or innate immunity to 
trypanosomes. Strong evidence for ApoL1 being the lytic factor of TLF came from the discovery of 
a unique medical case of a human in India found to be infected by the animal trypanosome T. 
evansi.  Normally this trypanosome species is not human infective although it is closely related to 
T. brucei. The evidence indicates that the patient’s infection is likely due to two frame-shift 
mutations, one in each allele of their ApoL1 gene.  This has rendered the protein non-functional. 
The patient’s Hpr gene has no major deviations in sequence from that of other humans 
(Vanhollebeke & Pays, 2006).  The addition of natural or recombinant ApoL1 to the patient’s 
serum fully rescued the lytic phenotype. 
1.15 A consensus hypothesis for the mechanism of trypanosome 
lysis 
In light of the mounting evidence that ApoL1 and Hpr are both vital for efficient trypanosome 
lysis, a consensus involving both proteins has begun to form (Figure 1.4). Reconstituted HDL 
containing both purified ApoL1 and Hpr causes 99% lysis while those that contain Hpr or ApoL1 
separately are twenty times less effective over the same time-span (Shiflett et al., 2005).  It has 
been argued that both Hpr peroxidation and ApoL1 pH dependent pore generation are needed for 
the full lytic effect due to the killing effect seen in naturally derived Hpr (Shiflett et al., 2007). 
There is some evidence that the killing effect of naturally derived Hpr is actually due to the 
uncleaved signal peptide which exhibits trypanocidal effects by disrupting the fluidity of the 
plasma membrane.  This effect is only seen with bloodstream form trypanosomes. The killing 
effect may explain the disparity between recombinant Hpr assays (in which the signal peptide is 
cleaved) and naturally derived Hpr where it remains uncleaved (Harrington et al., 2010). However, 
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the morphology of trypanosomes killed by Hpr signal peptide does not match that of exposure to 
human serum or TLF (Harrington et al., 2010). Experiments investigating recombinant ApoL1 with 
serum from the patient with a defective ApoL1 gene have come to a similar conclusion that both 
ApoL1 and Hpr are necessary for efficient lysis.  Recombinant ApoL1 on its own lysed 
trypanosomes at a slower rate than normal human serum but when added to the serum from the 
patient with defective ApoL1, normal human serum activity was restored (Vanhollebeke et al., 
2007b).  The rate at which ApoL1 lysed parasites was also increased when added to recombinant 
Hpr, although they found no evidence that Hpr has a direct killing effect on trypanosomes due to 
the fact that the patient with non-functional ApoL1 had perfectly normal Hpr. This suggests that 
Hpr has no direct impact on combating trypanosome infection unless paired with ApoL1.  This is 
not the case with ApoL1, as even transgenic animals expressing human ApoL1 are resistant to T. b. 
brucei infection, even without co-expression of Hpr (Molina-Portela et al., 2008; Thomson et al., 
2009).  It appears likely that Hpr is the ligand that facilitates the uptake of TLF-1 and ApoL1 and a 
receptor that binds both haptoglobin bound to haem and Hpr has recently been described, 
termed HpHbR (Vanhollebeke et al., 2008). 
The HpHbR receptor is a GPI anchored protein of approximately 300 copies found on the cell 
surface of the parasite. This closely matches the characteristics of the proposed high affinity 
receptor for TLF-1 (Drain et al., 2001).  Down-regulation of the receptor in T. b. brucei leads to 
complete protection against the lytic effects of TLF-1, but not normal human serum or TLF-2.  
Therefore, the current hypothesis of innate immunity to trypanosomes in humans is that the TLF 
particles bind to receptors on the trypanosome surface (Drain et al., 2001; Vanhollebeke et al., 
2008), are internalised by endocytosis (Hager et al., 1994) and transported to the lysosome 
(Shimamura et al., 2001) where they cause disruption of the lysosomal membrane and eventual 
cell death (Hager et al., 1994; Lorenz et al., 1994).  ApoL1 is the component of TLF-1 that causes 
lysosome disruption. The protein undergoes a conformational change when exposed to the low 
pH environment of the lysosome, embeds in the lysosomal membrane and forms channels that 
allow chloride ions to enter. This upsets the osmotic balance of the organelle, causing expansion 
and eventual rupture of the lysosome.  Hpr facilitates lysis by efficiently binding TLF-1 to the 
HpHbR receptor so that ApoL1 can enter the lysosome. There may also be secondary toxic effects 
caused by the Hpr signal peptide that lower the fluidity of the lysosomal membrane, making it 
more susceptible to ApoL1.  The presence of ApoL1 in TLF-2 makes it likely that this particle also 
uses the protein as a lytic mechanism, although uptake of TLF-2 is not by Hpr and may instead 
involve the weak binding of IgM to VSG (Vanhollebeke & Pays, 2010). 
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Figure 1.4 An overview of the current model of TLF-1 mediated lysis in T. b. brucei (adapted from 
(Pays & Vanhollebeke, 2009; Pays et al., 2006).  The TLF particle contains Hpr (Orange), ApoL1 
(Green) and ApoA1. The TLF particle binds to the HpHbR receptor with the Hpr protein as the 
ligand. It is then internalised by endocytosis and transferred into early endosomes (pH 7).  As the 
endosomes mature and eventually integrate with the lysosome, the pH of the organelle falls to 
5.3 causing the release of ApoL1 (green) from the TLF particle. ApoL1 undergoes a pH mediated 
conformational change, exposing the pore-forming and membrane addressing domains. This new 
structure allows the integration of ApoL1 into the plasma membrane of the lysosome.  When 
integrated within the membrane, ApoL1 acts as an ion channel that allows Cl- to freely enter the 
organelle and disrupt osmotic balance. Water then enters the lysosome along the new osmotic 
gradient, causing uncontrolled swelling of the organelle and eventually lysing the trypanosome.  
TLF-2 acts in a similar manner to TLF-1, although the ligand is not Hpr and is instead believed to be 
internalised due to weak interactions with TLF-2 bound IgM and the surface VSG.  
pH 5.3
TLF-1 Particle
Lysosome
Endosome
HpHbR
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1.16 Measuring human serum resistance 
Understanding the animal and vector reservoir of human infective trypanosomes and 
distinguishing human infective sub-species from T. b. brucei are important factors in sleeping 
sickness control. To this end, several tests have been formulated over the years to identify human 
infective trypanosomes.  The most decisive test for human infectivity is clearly whether a 
trypanosome can infect a human, and such a methodology was used in the famous Tinde 
experiments (Willett & Fairbairn, 1955).  There are however obvious ethical and legal reservations 
with inoculating viable, deadly parasites into humans. As a substitute, assays have been 
developed based on the long known fact that the trypanolytic factor is a component of human 
serum. 
Early diagnostic tests used whole blood or purified serum and direct observation of lysis with 
limited numbers of trypanosomes (Laveran & Mesnil, 1912).  This crude analysis led to a 
standardised test for human serum resistance (HSR) in the Blood Incubation Infectivity Test (BIIT) 
(Rickman & Robson, 1970). BIIT initially assessed parasite survival rates in mice injected with 
human serum and was primarily designed for identification of T. b. rhodesiense from T. b. brucei 
(Rickman & Robson, 1970).  The BIIT was then later modified to assess parasite survival by 
incubation with human serum ex vivo and then injecting the cells into a rodent model (Targett & 
Wilson, 1973).  Although the technique is expensive and time consuming, it has helped confirm 
numerous animal reservoirs of human infective trypanosomes (Geigy et al., 1973; Gibson & 
Wellde, 1985). 
Over the years, alternate methods have been developed to assess serum resistance in 
trypanosomes in more quantitative ways.  For example, an assay of the number of metacyclics 
that convert to bloodstream forms in the presence of serum (Brun & Jenni, 1987). The test is 
laborious, takes several days and there is inherent inaccuracy due to the fact that only a minority 
of metacyclics exhibit a resistant phenotype (Brun & Jenni, 1987). Another option is to use blood-
stream form trypanosomes and simply observing cell death or gross changes in morphology over 
time when exposed to lytic components. This method is favoured by most researchers (Hajduk et 
al., 1994; Jenni & Brun, 1982; Vanhollebeke et al., 2007a). Although highly accurate with modern 
microscopes and culturing techniques, the assay is labour intensive and requires highly trained 
observers.  These increasingly accurate techniques have also revealed that the simple human 
serum resistant/sensitive phenotype is too crude a distinction - there are also intermediate levels 
of resistance. Although noted in BIIT tests (Rickman & Robson, 1970) it was unclear if this was due 
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to mixtures of resistant and sensitive lines or whether resistance had a continuous distribution.  
Assays using cloned lines showed that an intermediate phenotype of slower lysis is a true 
phenomenon in some lines (Turner et al., 2004).  Interestingly, the T. b. brucei reference strain 
TREU927 possesses an intermediate phenotype (Turner et al., 2004; Vanhamme et al., 2004).   
More modern serum resistance assays use automated procedures to estimate cell lysis by 
employing dyes and fluorescence. A method based on the release of intracellular enzymes from 
lysed trypanosomes and the cleavage of Calcein-AM into fluorescent products has been 
successfully employed (Tomlinson et al., 1995). Unfortunately, when this method was compared 
to microscope determined survival controls there was a degree of variability and discrepancy.  An 
alternate approach is to use two dyes with differing affinities to live or lysed trypanosomes.  For 
example, the dyes Syto 10 and DEAD Red used in conjunction.  Syto 10 is a membrane permeable 
dye that stains nucleic acid with a fluorescent marker visible in the green spectrum. DEAD Red 
stains nucleic material with a red marker but is not membrane permeable. Thus trypanosomes 
that have compromised membranes due to the interactions with TLF will show both red and 
green fluorescence, while healthy cells will only show green.  This allows for an accurate 
estimation of the percentage death and the resistance to lysis of an isolate using fluorometers or 
FACS (Turner et al., 2004). 
An interesting facet of human serum resistance that has been revealed by these resistance assays 
is that the phenotype is lifecycle stage specific. The procyclic form trypanosomes in the insect gut 
are fully resistant to human serum. While this was believed to be because procyclics exhibit ten-
fold lower rates of endocytosis then blood stream forms (Morgan et al., 2001), genetically 
modified T. b. brucei with high rates of endocytosis remain human serum resistant (Natesan et al., 
2010). This suggests that procyclic forms of T. brucei are constitutively resistant to human serum 
and it is unclear why bloodstream forms of T. b. brucei are not able to utilise the same method.  
Why procyclic forms have developed to be resistant to human serum is unknown although it was 
hypothesised that because tsetse feed often, trypanosomes will be exposed to human serum 
several times during infection.  However, procyclics quickly move to the ectoperitrophic space 
after gut infection and it is unknown if TLF particles can cross the peritrophic matrix.  Counter-
intuitively, the metacyclic stage of the life-cycle appear to be human serum sensitive (Brun & 
Jenni, 1987). Human infective trypanosomes such as T. b. gambiense and T. b. rhodesiense must 
somehow survive the initial exposure to human serum until they become bloodstream form 
(approximately 24 hours). This may be explained by the initial period spent by the invading 
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parasites in the interstitial fluid in the skin and the development of a chancre before full 
conversion to bloodstream forms and exposure to TLF. 
1.17 Trypanosoma brucei rhodesiense & SRA 
It was observed early in human infectivity studies that T. b. rhodesiense showed an inconsistent 
human serum resistance phenotype. Although the serum resistance phenotype was retained 
during animal passage, individual passages exhibit the phenotype to different degrees (Targett & 
Wilson, 1973; Willett & Fairbairn, 1955). Unfortunately, this also invalidated the BIIT somewhat 
for the original purpose of T. b. rhodesiense identification. It was noted that resistance appeared 
to be related to antigenic variation and changes to the variable antigen type (VAT) of the 
populations. Isogenic clones of the ETat strain of T. b. rhodesiense that differed only in VAT 
expression showed different serum resistance phenotypes (van Meirvenne et al., 1976).  A 
particular VAT type was identified as correlating with human serum resistance- ETat 1.10. This 
VAT was always present in resistant lines and not in sensitive lines. Gene switching of the VSG did 
not reduce resistance to lysis, implicating an ESAG rather than the VSG itself (Rifkin et al., 1994). 
Some VAT clones other than ETat 1.10 do show some levels of human serum resistance, although 
it is unclear if this is contamination by the presence of ETat 1.10 (van Meirvenne et al., 1976).  All 
of these data indicate the presence of a gene in an expression site that was differently expressed 
depending on the expression site being used.  Although the likely location of the serum resistance 
element was now understood, the actual gene was unknown. 
In an attempt to narrow down the options, mRNA was compared between isogenic resistant and 
susceptible lines. A transcript associated with resistance was identified and predicted to be for a 
VSG-like gene (De Greef et al., 1992) lines possessed the gene for the protein but only resistant 
lines expressed it. The gene was later confirmed to be an ESAG in the ETat 1.10 expression site by 
Southern blot analysis with probes for this serum resistance associated (SRA) gene.  Conclusive 
proof that human serum resistance in T. b. rhodesiense was due to a single gene was shown when 
transgenic T. b. brucei expressing SRA gained resistance to lysis (Xong et al., 1998).  Harking back 
to the earlier days of trypanosome research, the result was confirmed by inoculation into a 
human when a T. b. brucei-SRA line infected a researcher in the Pays laboratory (Gibson, 2005).  
Unlike the pioneering work of the Tinde experiment, this human inoculation was accidental but it 
clearly demonstrated that SRA gene was sufficient to confer human serum resistance to a T. 
brucei line. 
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SRA has been shown to be present in the vast majority of studied T. b. rhodesiense lines (Gibson, 
2005) although this has become a somewhat circular argument - SRA is diagnostic of T. b. 
rhodesiense, so T. b. rhodesiense always possess SRA.  However a recent study in Uganda has 
identified several human infective T. brucei in a T. b. rhodesiense focus that did not PCR amplify 
with SRA primers (Enyaru et al., 2006). Additionally, in a study comparing serum sensitive and 
resistant isogenic lines expressing the same ETAT, the SRA transcript was not present in all 
resistant lines (De Greef et al., 1989; Rifkin et al., 1994).  It is unknown as to whether these 
phenomena are due to mutations in the SRA gene, the expression site or an entirely new 
resistance trait arising in a T. brucei population. Structurally, SRA appears to be a truncated VSG 
with a large deletion of a region in the centre of the N-Terminal domain (De Greef et al., 1992; De 
Greef & Hamers, 1994; Xong et al., 1998).  SRA is present on the cell surface (Milner & Hajduk, 
1999), where it is internalised in the flagellar pocket during cell surface protein turnover, leading 
to SRA presence in the endosomes and lysosome (Oli et al., 2006; Shiflett et al., 2007; Vanhamme 
et al., 2003). This correlates well with what is known about the localisation of human TLF in the 
lysosome before lysis. 
Genetically, SRA is well conserved in T. b. rhodesiense, with less than 3% sequence variation 
between strains (Gibson et al., 2002). This would make it seem likely that the gene arose only 
once (Campillo & Carrington, 2003).  The slight differences present in SRA sequence segregate 
into northern and southern groups (Gibson et al., 2002; MacLean et al., 2004).  This coincides with 
a previous distinction of T. b. rhodesiense into two sub-groups based on RFLP, minisatellite 
analysis (Gibson et al., 2002; Godfrey et al., 1990; MacLeod et al., 2000) and disease severity 
(MacLean et al., 2004).  However, the differing genotypes and phenotypes may also be due to 
genetic exchange between strains resulting in the transfer of the SRA gene (and other traits) to T. 
brucei of different genetic backgrounds.  This is supported by the fact that some populations of T. 
b. rhodesiense are more related to neighbouring T. b. brucei then other T. b. rhodesiense 
populations, suggesting that T. b. rhodesiense is a human-infective variant of T. b. brucei 
(MacLeod et al., 2001). This leads to a working hypothesis that on entry into the human 
bloodstream, a few trypanosomes are expressing SRA at an active expression site.  These are 
selected for and the population within the host become resistant.  In non-human animals this 
selective pressure is not applied, explaining the variable nature of serum resistance when T. b. 
rhodesiense is passaged through these species.   
Page | 34  
 
Although SRA is now well described in the literature, theories of SRA mechanism are somewhat 
polarised. The prevailing theory is that SRA inhibits the activity of ApoL1 based on the observed 
co-localisation of the two proteins in parasite cells and in vitro (Vanhamme et al., 2003).  The 
deletion of 126 amino acids in SRA removes two surface loops normally present in a VSG protein, 
exposing the internal α-helices (Campillo & Carrington, 2003). Based on modelled tertiary 
structure it was proposed that the deletion resulted in human serum resistance as it allows an 
inter-chelating interaction between the exposed helices and the helical section of ApoL1, either in 
the lysosome or on the cell surface (Vanhamme et al., 2003; Vanhamme et al., 2004).  The 
alternative hypothesis is that SRA somehow disrupts internal trafficking of TLF to the lysosome 
and it remains within pre-lysosome vesicles (Oli et al., 2006; Shiflett et al., 2007).  These 
trafficking experiments however used the laboratory adapted T. b. brucei strain Lister 427 
ectopically expressing SRA and may not necessarily be indicative of what occurs in T. b. 
rhodesiense.  
Regardless of the mechanism, the discovery of SRA has led to advancements in diagnosis and 
suggested preventative action to combat sleeping sickness caused by T. b. rhodesiense.  With the 
advent of specific PCR markers for SRA, trypanosomes with the potential to infect humans can be 
identified without the need for laborious human serum resistance assays such as the BIIT (Gibson 
et al., 2002; Radwanska et al., 2002; Welburn et al., 2001). This has proved useful in 
understanding the role of wildlife and livestock in the epidemiology of the disease. For example, 
traditional microscopy techniques and HSR assays estimated the number of livestock cattle to be 
carrying human infective T. b. rhodesiense at approximately 1%. Modern analysis has indicated 
that instead this value is closer to 18% (Welburn et al., 2001).  This cross-sectional study may itself 
also be an underestimation - long term additive studies show the trypanosome burden of cattle 
herds could be higher by a further 20% (Maudlin  2006, personal communication). 
The importance of the cattle reservoir of T. b. rhodesiense may become increasingly important in 
countries such as Uganda that are now leaving a period of long-term political unrest and 
population migration is increasing.  In the town of Soroti in Uganda, a recent T. b. rhodesiense 
outbreak has emerged that appears to coincide with a recent movement of cattle from a 
traditional endemic focus of sleeping sickness in Busoga district (Fevre et al., 2001).  There is a 
significant correlation between the presence of the disease and distance from the Soroti cattle 
market since 1998. Cluster analysis also identified the market as a statistically significant risk 
factor in contracting sleeping sickness.  Although the evidence is circumstantial, the emergence of 
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a T. b. rhodesiense disease focus in Soroti would seem to correlate with the recent movement of 
cattle into the area (Fevre et al., 2001; Hutchinson et al., 2003). 
The knowledge of how SRA acts to inhibit the lytic component of TLF has also led to an 
explanation of how the serum of baboons is able to lyse T. b. rhodesiense.  The ApoL1 present in 
this species possesses two amino acid substitutions in the C-Terminal helix of the protein. Normal 
T. b. rhodesiense SRA is unable to bind this protein variant and cannot inactivate the pore forming 
domain (Lecordier et al., 2009; Perez-Morga et al., 2005; Thomson et al., 2009). It is proposed 
that the distribution of bull sperm from transgenic cattle expressing the modified baboon ApoL1 
could be distributed at foci in Africa to generate herds of cattle resistant to both T. b. brucei and 
T. b. rhodesiense. In addition to the astronomical cost of the endeavour, the lack of widespread 
acceptance of transgenic animals by the African public would make the scheme appear 
unfeasible. The removal of T. b. brucei, T. b. rhodesiense, T. vivax and T. congolense by the 
application of these transgenic animals is also likely to see selection for trypanosomes that do not 
possess the SRA gene as a serum resistance mechanism, such as T. b. gambiense or local T. b 
rhodesiense that do not posses SRA. Without the competition from T. b. brucei or T. b. 
rhodesiense it is impossible to predict how other trypanosomes will evolve to exploit the new 
niche – past experience indicates that it is unlikely to be in our favour. An alternative use of 
baboon ApoL1 would be the creation of a stable delivery system to deliver modified ApoL1 to 
people infected with T. b. rhodesiense. This method has already been used with limited success in 
vitro on T. b. rhodesiense by conjugating the pore-forming domain of ApoL1 with a single domain 
antibody that enters the cell after binding to the VSG (Baral et al., 2006). 
Although the discovery of SRA has been a major boon to the understanding of T. b. rhodesiense 
genetics and biology, it is unable to be applied to the dominant human infective trypanosome T. 
b. gambiense. SRA is not present in either group of T. b. gambiense (De Greef et al., 1992; 
Radwanska et al., 2002; Turner et al., 2004) nor in the intermediate phenotypes such as TREU927 
(Turner et al., 2004).  An ‘SRA-like’ motif has been located in the TREU927 genome but it is not 
involved in resistance (Vanhamme et al., 2004).  Elucidating the mechanism of human serum 
resistance in T. b. gambiense is vital for future disease control in Africa.  The hope is to take what 
has been learned from the process of investigating SRA and T. b. rhodesiense and apply it to T. b. 
gambiense with more modern techniques.  
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1.18 Trypanosoma brucei gambiense 
In comparison to T. b. rhodesiense, very little is known about the serum resistance mechanism of 
T. b. gambiense.  As previously mentioned, there are two groups of T. b. gambiense (Gibson & 
Borst, 1986). Group 2 has a similar serum resistance phenotype to T. b. rhodesiense, with a great 
deal of variance in the degree of human serum resistance displayed. Group 2 T. b. gambiense may 
be in a similar situation to T. b. rhodesiense in that an ESAG has become modified to inhibit TLF. 
The fact that a T. b. brucei strain artificially selected in vitro to be human serum resistant shows 
some changes in ESAG expression indicates that ESAG modification linked to human serum 
resistance can occur out with T. b. rhodesiense (Faulkner et al., 2006).  However, in this particular 
line it has been shown that these changes to VSG and ESAG are probably unrelated to the 
resistance phenotype and rather it is down-regulation of the expression of the HpHbR gene that 
has conferred TLF resistance (Kieft et al., 2010).  There have been few studies on the human 
serum resistance phenotype in group 2 T. b. gambiense.  Preliminary in vivo studies with the 
group 2 T. b. gambiense strain TxTat have shown a correlation between the VAT of the parasite 
and resistant or sensitive phenotypes, suggesting it is linked to VSG and ES switching (Ortiz et al., 
1994). It was also shown in the same line that resistant TxTat clones depleted the lytic potential of 
human serum more slowly than the sensitive clones (Ortiz-Ordóñez & Seed, 1995). It has however 
come to light that there is some confusion as to the exact identity of some TxTat lines, with some 
derivatives being revealed to actually be T. b. rhodesiense (Grab & Kennedy, 2008).  Lineage data 
for the TxTat used in the ex vivo assays was unavailable so it may be possible it has been 
misidentified as a type 2 T. b. gambiense. If expression site switching is not related to resistance in 
group 2 T. b. gambiense, there could be other mechanisms involved that vary transcription in a 
similar manner, such as the stochastic expression that emerges from gene network interactions 
found in some eukaryotes (Li et al., 2010). Indeed, all T. b. brucei exhibit expression site free, 
transcriptionally regulated, variable human serum resistance in that procyclic forms are always 
human serum resistant while bloodstream forms always sensitive, even in the same isogenic line 
(Natesan et al., 2010).  This suggests that every T. b. brucei has the potential to become human 
infective merely by modifying expression of pre-existing genes.  
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Very little is known about the resistance mechanisms in group 1 T. b. gambiense due to the 
difficulty of working with it under laboratory conditions. BIIT tests indicate it has a robust and 
invariant resistance phenotype (Gibson, 1986).  This would indicate a genetic mechanism of 
resistance that is being constitutively expressed, completely unlike the expression linked system 
of T. b. rhodesiense or group 2 T. b. gambiense.  In order for T. b. gambiense to resist lysis, the 
parasite must either have the ability to reduce uptake of TLF, neutralise TLF or to compensate for 
the effects.  If resistance is due to modified uptake of TLF it could be due to modification of 
receptors shown to be involved in TLF uptake, such HpHbR.  If the mechanism is a neutralisation 
of ApoL1 or its effects in the parasite cell, any number of processes involved in cell lysis could be 
involved and locating a specific gene or protein would be more difficult.  The inability to conduct 
forward genetics with this particular group of the sub-species restricts the range of approaches 
that can potentially be used to investigate the resistance mechanism of group 1 T. b. gambiense. 
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Chapter 2: Materials & Methods 
2.1 T. b. gambiense, T. b. brucei & T. b. rhodesiense experimental 
lines  
STIB247 is a human serum sensitive T. b. brucei clone, first isolated from a Hartebeest in Serengeti 
in 1971 (Geigy & Kauffmann, 1973). Lister 427 is the standard laboratory T. b. brucei strain it is 
believed to have been isolated from a sheep in 1960 (Peacock et al., 2008). The human serum 
resistant strain of Lister 427 was generated after repeated passage with increasing exposure to 
lytic human HDL (Faulkner et al., 2006).  The human serum resistant group 2 T. b. gambiense 
strain STIB386 was originally isolated in 1978 from an infected patient in Côte d’Ivoire (Felgner et 
al., 1981). The cloned strain was adapted to grow in vitro in HMI9 medium (Hirumi & Hirumi, 
1989) supplemented with 1.5 mM glucose, 1 mM methyl cellulose, 250 µM adenosine and 150 
µM guanosine. To generate resistant and sensitive isogenic lines of STIB386, several culture 
adapted sub-lines were assayed for their ability to resist lysis in human serum. The most resistant 
STIB386 line (STIB386R) was identified and maintained in culture in the presence of 10% human 
serum/10% foetal bovine serum. The most sensitive line (STIB386S) was also identified and 
maintained without human serum. Eliane is a group 1 T. b. gambiense strain isolated from a 
human in 1952, also from Côte d’Ivoire. This isolate was maintained in modified HMI9 
supplemented with 20% human serum.  Human serum resistance phenotypes for these three 
isolates have been described previously (Turner et al., 2004). Other T. b. gambiense group 1 
strains used were isolated from infected individuals and include: MHOM/CM/75/ITMAP1789 BIM 
and MHOM/CM/74/ITMAP1787 MOS from Cameroon, MHOM/CG/80/ITMAP1843 PA from the 
Democratic Republic of Congo, MHOM/CI/83/DAL596 TOBO and MHOM/CI/83/DAL607 ISTI from 
Côte d'Ivoire (Mehlitz et al., 1982). These isolates were grown in ICR mice and analysed ex vivo. 
The T. b. rhodesiense strain Baganzi was isolated from a human in South-Eastern Uganda in 1990 
and maintained in the supplemented HMI9 medium with 20% foetal bovine serum. STIB386S, 
STIB386R and Baganzi lines were regularly assayed for human serum sensitivity to ensure their 
phenotypes had not varied.  
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2.2 Côte d’Ivoire Isolate library 
The library of T. brucei strains used for population analysis was collected from Daloa, Côte d’Ivoire 
by D. Mehlitz, Freie Universität Berlin. The parasites were collected from several hosts, including 
human and non-human animals between 1978 and 1983 (Table 6.1).  Samples were either 
provided as purified DNA from A. Tait, University of Glasgow or blood spots on Whatman FTA 
cards from W. Gibson, University of Bristol.  DNA from the FTA cards was washed and prepared as 
per the manufacturer’s instructions before analysis (Whatman).  The collection is comprised of 
both group 1 and 2 T. b. gambiense and T. b. brucei isolated from the field then cloned and 
passaged in rodents to create stabilates.  The different sub-species designations were determined 
using a 5 rodent BIIT test (Rickman & Robson, 1970; Targett & Wilson, 1973) and the host from 
which the strain was isolated.  Isolates that showed 5 successful rodent infections after exposure 
to human serum were designated group 1 T. b. gambiense, 0 infections after exposure were 
labelled as T. b. brucei and any that gave an intermediate infection number were termed group 2 
T. b. gambiense. In addition to the main sample library, the group 1 T. b. gambiense genome 
strain DAL927 (DNA gifted by W. Gibson, University of Bristol), the T. b. brucei strain STIB247, the 
Côte d’Ivoire group 2 T. b gambiense strain STIB386 and group 1 T. b. gambiense strain Eliane 
were also genotyped. 
2.3 Genotyping 
Samples were genotyped for population analysis using nested PCR for seven microsatellite 
markers; Ch1/18, Ch1/D2/7, Ch2/PLC, Ch2/5, Ch5/JS2, Ch11/110 and Ch4/M12C12 (MacLeod et 
al., 2005b; Morrison et al., 2008) Primer sets are named with the convention that C & D are the 
first round combination and A & B are the second (Table 2.1). The Ch4/M12C12 marker proved 
to be monomorphic for these samples and was excluded.  Markers on the same chromosome are 
at opposite ends of the chromosome to each other so are unlikely to be linked (MacLeod et al., 
2005b).  All of the primers used to amplify the microsatellites have been previously identified and 
verified for both T. b. brucei and T. b. gambiense populations (MacLeod et al., 2005b; Morrison et 
al., 2008).  The PCR conditions for both rounds for each the reaction were 95˚C 50 secs, 55˚C 50 
secs and 65˚C 60 secs, for 30 cycles.  PCR was performed in a total volume of 30µl with the 
primers at a final concentration of 10µM each and a Taq polymerase concentration of 0.25 
units/µl (Thermo Scientific). To determine allele size, one of the second round primers was tagged 
using either AFAM or HEX fluorescent dye to be used for Genescan capillary analysis.  When run 
on a capillary system against ROX labelled size standards (Dundee Sequencing Unit), the size of 
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the tagged PCR product can be accurately measured to within 2bp using the Peak Scanner® 
software package (Applied Biosystems). PCR products of differing sizes were concluded to be 
different alleles. Alleles were separated into binning groups according to the measured size. Bins 
were created with the methodology that differences between sizes was accurate to within 2bp, so 
alleles that differed by this amount or less could not be reliably distinguished.   Each distinct bin 
was given an allele number and the two alleles for each locus was catalogued for each isolate.  
This allowed the creation of a multilocus genotype for each isolate (MLG).    In addition to the 
Genescan allele sizing technique used to create the MLG, a diagnostic PCR for presence/absence 
for TgsGP was also performed.  An improved set of nested TgsGP primers was used (Table 2.1) 
(Morrison et al., 2008; Radwanska et al., 2002), using PCR conditions; 95˚C 50 secs, 55˚C 50 secs 
and 65˚C 120 secs, for 35 cycles.  PCR was performed in a total volume of 10µl with the buffers 
and concentrations previously described. 
2.4 Identification of sub-species by PCR 
To test the presence/absence of SRA and TgsGP in experimental lines, primer sets SRA-F with SRA-
R and TgsGP-A with TgsGP-B were used to amplify from prepared genomic DNA (Primer 
sequences: Table 2.1). The SRA primer set were amplified using the following condition with Taq 
polymerase; 30 cycles of 95°C for 50 seconds, 55°C for 50 seconds and 65°C for 60 seconds white 
the TgsGP primers were amplified with the following; 30 cycles of 95°C for 50 seconds, 60°C for 50 
seconds and 65°C for 90 seconds.  PCR was performed in a total volume of 10µl with the buffers 
and concentrations previously described. 
2.5 Sequencing 
The HpHbR open reading frame (ORF) and the upstream and downstream sequences containing 
the UTRs were amplified from genomic DNA by PCR using the following conditions with PFU 
polymerase; 30 cycles 95°C for 50 seconds, 55°C for 50 seconds and 65°C for 120 seconds. PCR 
was performed in a total volume of 20µl with the buffers and concentrations previously 
described. The gene and UTRs were split into two halves and sequenced separately using primers 
HpHbR A F with HpHbR A R and HpHbR B F with HpHbR B R (Table 2.1). 
PCR products were ligated into the TOPO PCR 2.1 plasmid (Invitrogen) and amplified using TOP10 
(Invitrogen) competent cells as per the manufacturer's instructions. Plasmid was purified using a 
Qiagen miniprep kit and sent for DNA sequencing at DNA Sequencing & Services (MRCPPU, 
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University of Dundee, www.dnaseq.co.uk) using Applied Biosystems Big-Dye Ver 3.1 chemistry on 
an Applied Biosystems model 3730 automated capillary DNA sequencer. As STIB386 proved to be 
heterozygous for HpHbR, 8 clones were created and sequenced.  These clones aligned into two 
groups with differing homologues. Homologue A contained 6 individuals and homologue B 
contained 2. For the five group 1 T. b. gambiense lines, 3 clones were used for each. Both the 
HpHbR ORF and UTRs were identical across all 15 sequences so this gene was assumed to by 
homozygous for this sub-species. 
The variable region of the transferrin receptor genes (ESAG6 and ESAG7) were amplified from 
cDNA prepared as previously described. Primer sets ESAG6F & ESAG6R and ESAG7 F & ESAG7R 
(Table 2.1) were used under the following PCR conditions with PFU polymerase; 30 cycles 95°C 
for 50 seconds, 55°C for 50 seconds and 65°C for 60 seconds. PCR was performed in a total 
volume of 10µl with the buffers and concentrations previously described and the products were 
sequenced also as described previously. 
2.6 Real-time Quantitative PCR  
Total trypanosome RNA was extracted from approximately 5x107 cells using a Qiagen RNAeasy® 
mini kit. The RNA was subjected to three DNase I (Invitrogen) digests to remove all genomic 
contamination. Omniscript® RT Kit (Qiagen) was used to generate cDNA from 1µg of total RNA as 
per the manufacturer’s instructions. Real-time-PCR was performed using cDNA from an 
equivalent of 50ng of total RNA, 30µM forward and reverse primers (HpHbR RT F and HpHbR RT R 
(Table 2.1)), 12.5µl SYBR green PCR master mix (Applied Biosystems) to a final volume of 25μl. 
Primer sequences are given in table 2.1. Real-time PCR conditions were: one cycle of 50°C for 2 
mins, 95°C for 10 mins, followed by 40 cycles of 95°C for 15s, 60°C for 1 min. The relative amounts 
of specific cDNA between samples were calculated using CT methodology (Livak & Schmittgen, 
2001) calculated with the Applied Biosystems SDS v1.4 software. The endogenous control gene 
was GPI8 using primers GPI8F and GPI8R primers (Table 2.1). Four replicates were performed for 
each parasite line. All primers were designed using the Primer3 software (Rozen & Skaletsky, 
2000). Mean levels of expression were compared using 1-way ANOVA and a Tukey’s post hoc test.  
2.7 RT-PCR  
Total trypanosome RNA was extracted from approximately 5x107 cells and used to generate cDNA 
as previously described. Semi-quantitative RT PCR was performed using cDNA from an equivalent 
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of 50ng of total RNA amplified using the following condition with Taq polymerase; 28 cycles of 
95°C for 50 seconds, 55°C for 50 seconds and 65°C for 60 seconds. PCR was performed in a total 
volume of 10µl with the buffers and concentrations previously described.  The PCR was then run 
out on a 3% agarose gel for approximately 1.5 hours and visualised under ultraviolet illumination. 
The primer pairs used to estimate the relative transcript of each gene in the polycistron 
containing HpHbR are listed in Table 2.1. A loading control was performed using primers specific 
to the gene Triose phosphate isomerase (TIM). 
2.8 ApoL1 ORF Plasmid 
An Invitrogen Gateway®-compatible entry vector containing the ApoL1 ORF was purchased from 
Genecopoeia Inc, USA. To confirm the presence of a correct ApoL1 ORF, the plasmid was sent for 
DNA sequencing using T7 and T7Rev standard primers at DNA Sequencing & Services (MRCPPU, 
University of Dundee, www.dnaseq.co.uk) using Applied Biosystems Big-Dye Ver 3.1 chemistry on 
an Applied Biosystems model 3730 automated capillary DNA sequencer. 
2.9 Wheatgerm Cell-free Protein Expression 
The Endext® Wheatgerm expression PCR kit was purchased from CellFree Sciences, Japan.  This in 
vitro expression system uses crude extracts of lysed Triticum cells containing essential elements of 
the molecular machinery involved in protein translation including the  ribosomes, tRNAs, 
aminoacyl-tRNA synthetases, initiation, elongation and termination factors. Initiation of 
translation in this system requires the ORF of interest be preceded by a proprietary expression 
promoter sequence. This can be added to the ORF via two separate rounds of PCR. The first round 
uses a primer consisting of ccacccaccaccacca followed by the first 15 bases of the ORF and the 
second adds the full promoter sequence using ccacccaccaccacca as the second reverse primer 
target for the proprietary second round primers. PCR conditions were supplied by the 
manufacturer.  If the PCR method to add the initiation sequence is unsuitable, a plasmid is also 
available that contains the same promoter sequence preceding an insertion zone that contains 
sites for various enzymes. The ApoL1 ORF was removed from the Gateway® entry vector by 
incubating 1mg of uncut plasmid overnight with SpeI and SmaI enzymes. The cut plasmid was 
then run on a 1% agarose gel, visualised with ultraviolet light and the ApoL1 ORF band extracted 
using a Qiagen Gel Extraction Kit. This product was ligated into the Endext® wheatgerm plasmid 
using T4 Ligase (Invitrogen) as per the manufacturer’s instructions. The plasmid was transformed 
into DH5α competent E. coli cells to be bulked up and provide enough template for the 
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wheatgerm expression system.  After construction of either the PCR or plasmid template, it is 
added to the wheatgerm extract mix and the reaction proceeds as per the manufacturer’s 
instructions.  After the protein was generated, a small sample was to be removed for analysis via 
a Western and Coomassie gel. The rest of the reaction was to be used for protein purification 
under non-denaturing conditions. 
2.10 Invitrogen Expressway® E. coli Cell-free Protein Expression 
The Invitrogen Expressway® system is an in vitro cell free system that uses crude extracts of lysed 
E. coli cells.  Expressway® is fully compatible with Gateway® technology and requires only a T7 
promoter region upstream of the ORF in order to initiate translation.  The T7 promoter is found 
on all Invitrogen Gateway® destination vectors so no further modification is needed once an ORF 
has been efficiently transferred into the destination vector.  An Invitrogen compatible Gateway® 
entry vector containing the ApoL1 ORF (Genecoepia) was transferred into the pExp1® destination 
vector (Invitrogen). This plasmid was then used in an 8 hour 37°C Expressway® cell-free reaction, 
as per the manufacturer’s instructions (Invitrogen). The reaction was fed once after two hours 
with further amino acids as recommended by the manufacturer.  After the reaction had 
terminated, a small sample was removed for analysis via a Western blot and Coomassie gel. The 
rest of the extract was re-suspended in native binding buffer (0.5 M NaCl, 10 mM Imidazole) and 
used for protein purification under non-denaturing conditions.  
2.11 Invitrogen Gateway® E. coli Protein Expression 
The Invitrogen Gateway ® E. coli protein expression system is a classical live cell expression 
system, although with key improvements to efficiency and ease of use.  An Invitrogen® 
compatible Gateway® entry vector containing the ApoL1 ORF (Genecoepia) was transferred into 
the pDest17 destination vector (Invitrogen) and transformed into BL21-AI competent E. coli cells. 
The pDest17 vector features a 6xHis-tag that precedes the ORF and can be used for purification of 
the protein using a nickel column. Cells were selected on 100µg/ml ampicillin agar plates 
overnight and colonies were checked using PCR with ApoL1 specific primers (ApoL1_F & Apol1_R 
(Table 2.1)) to confirm the presence of the expression vector. Transformed colonies were grown 
overnight in 400ml L-broth in the presence of 100µg/ml ampicillin for 8 hours and then expression 
was induced using 1% L-Arabidose for a further 16 hours. Cells were lysed with pH 7.8 
guanidinium lysis buffer (6 M Guanidine Hydrochloride, 0.02 M Sodium Phosphate, 0.500 M NaCl) 
for 5 minutes and the cellular detritus removed with a 0.2 micron micro filter (Sartorius). A small 
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aliquot was removed for analysis with a Western blot and Coomassie stain and the remainder was 
used for protein purification under denaturing conditions. 
2.12 Non-denaturing Protein Purification 
This protein purification method used pH buffers suitable for purifying soluble protein while 
maintaining it in a native functional conformation. The cell-free media slurry was bound to Ni-NTA 
beads (Invitrogen) for one hour at pH 7.8 and then washed twice with wash buffer (0.5 M NaCl, 20 
mM Imidazole). Finally, bound protein was eluted with elution buffer (0.5 M NaCl, 250 mM 
Imidazole). The protein was concentrated and re-suspended in a PBS buffer using 10,000MW 
Vivaspin columns (Sartorius). Protein purity was estimated using a Nanodrop® spectrometer 
(Nanodrop) and SDS-Page. A Western blot using an antibody raised against an ApoL1 peptide 
(Sigma-Aldrich) was used to check that the bands present were ApoL1. 
2.13 Denaturing Protein Purification 
This protein purification method was suitable for removing protein from insoluble inclusion 
bodies. Its use can create difficulties when re-folding the protein into a functional conformation 
but a method for re-folding ApoL1 has been published (Lecordier et al., 2009). The lysed cells 
were bound to Ni-NTA beads (Invitrogen) for one hour at pH 7.8 and then washed twice with 
wash buffer (either 4M, 6M or 8 M Urea 0.02 M Sodium Phosphate, 0.5 M NaCl) at each of pH 7.8, 
pH 6 and pH 5.8. Finally, bound protein was eluted with wash buffer at pH 4. The protein was 
dialysed overnight with 0.2 M acetic acid and 0.05% Tween20 and concentrated using 10,000MW 
Vivaspin columns (Sartorius). Protein purity was estimated using a Nanodrop® spectrometer 
(Nanodrop) and SDS-Page. A Western blot using an antibody raised against an ApoL1 peptide 
(Sigma-Aldrich) was used to check that the bands present were ApoL1. 
2.14 PBS Buffered HSR Fluorescence Death Assay  
Trypanosomes were diluted to 107 per ml in PBS supplemented with 0.1% glucose and incubated 
in 25% human serum or foetal bovine serum (FBS) in a 500μl volume in a standard 24 well plate. 
After 4 hours the cells were re-suspended in 100μl PBS 0.1% glucose containing 0.2% Syto10 and 
0.4% RedDead dye. After 15 minutes the fluorescence buffer was removed and the cells were 
fixed for one hour in 2.5% glutaraldehyde at 4°C.  Finally, the cells were re-suspended in 50 μl PBS 
and the ratio of red:green emitted wavelengths measured using a fluorometer. A control group of 
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trypanosomes killed by immersion in 100% ethanol was used to determine the 100% death 
red:green fluorescence ratio and all progeny scored as a percentage of this control to indicate 
survival. 
2.15 PBS Buffered Survival Assay 
Trypanosomes were isolated from the mammalian host and either subjected to a 1 hour chilling 
period before transfer to the assay buffer or were re-suspended immediately.  Trypanosomes 
were diluted to 106 per ml in PBS supplemented with the various factors to be investigated and 
incubated in 25% human serum or foetal bovine serum (FBS) in a 1ml volume in a standard 24 
well plate. The numbers of cells in each well were counted with a haemocytometer for the 0 time 
point. The cells were incubated with 5% CO2 at 37°C and the number of surviving trypanosomes in 
each well was counted by phase contrast microscopy at 4 hours to calculate percentage survival. 
Human serum results were normalized against the FBS controls. 
2.16 HMI9 Buffered Human Serum Resistance Assay 
During development of the assay, trypanosomes were isolated from a mammalian host and either 
subjected to a 1 hour chilling period before transfer to the assay buffer or were re-suspended 
immediately.  Trypanosomes were diluted to 106 per ml in modified HMI9 and incubated in 25% 
human serum or foetal bovine serum (FBS) in a 1ml volume in a standard 24 well plate. The 
numbers of cells in each well were counted with a haemocytometer for the 0 time point. The cells 
were incubated with 5% CO2 at 37°C and the number of surviving trypanosomes in each well was 
counted by phase contrast microscopy at several time points to calculate percentage survival. 
Human serum results were normalized against the FBS controls.  After development of the assay, 
all subsequent assays on the parents and progeny were performed using a 6 hour time point. 
2.17 ApoL1 Survival Assay 
Trypanosomes were diluted to 106 per ml in modified HMI9 with 25% foetal bovine serum (FBS) in 
a 1ml volume in a standard 24 well plate. A dilution series of recombinant ApoL1 was formulated 
that would result in the desired final concentration and made up to equal volumes with protein 
free buffer (0.2 M acetic acid and 0.05% Tween20). A control containing equal volume of buffer 
was also prepared.  As the concentrations of purified ApoL1 were quite high, only very small 
volumes of buffer and protein were needed (no more than 20µl in the 1ml reaction). It is unlikely 
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the Tween20 was at a physiological relevant level.  Each protein volume and the control were 
aliquoted into different wells.  The numbers of cells in each well were counted with a 
haemocytometer for the 0 time point. The cells were incubated with 5% CO2 at 37°C and the 
number of surviving trypanosomes in each well was recorded at 24 hours to calculate percentage 
survival.  A positive control of 25% normal human serum was ran alongside these experiments for 
each strain to ensure the cells reacted accordingly. 
2.18 Fluorescence microscopy of TLF uptake  
Trypanosomes were re-suspended in serum-free HMI9 medium at a concentration of 106 cells/ml 
and incubated in 10µg/ml of Lysotracker® (Invitrogen) and 5 µg/ml of purified human HDL that 
contained predominantly TLF-1 (Raper et al., 1999).  The presence of the lytic component of TLF-1 
was confirmed with a Western blot for ApoL1. The TLF-1 was labelled with AlexaFluor®488 
(Molecular Probes, Invitrogen) using the manufacturer’s instructions. In control experiments, 
bovine HDL of a comparable density to TLF (Raper et al., 1999) was also AlexaFluor tagged. The 
cells were incubated at 37oC for 30 minutes, 1 hour, 2 hours and 4 hours. At each time point, cells 
were washed once in serum-free HMI9 medium and fixed by immersion in chilled 2.5% 
glutaraldehyde (Sigma-Aldrich) in phosphate buffered saline for 5 minutes. The cells were re-
suspended in 50% glycerol, 0.1% DAPI, 2.5% DABCO in PBS and spread onto lysine coated slides 
which were then protected with cover-slips sealed using ethyl acetate. The slides were imaged 
using a Deltavision Core system and SoftWorx package (Applied Precision) with the standard filter 
sets (DAPI/FITC/Texas-Red and Light transmission). Approximately 30 serial sections through each 
trypanosome were taken for each filter. The images were composited and the brightness, 
contrast and colour levels normalized between samples and exposures using the ImageJ software 
package (US National Institute of Health). Approximately thirty trypanosomes were imaged per 
time point to give an indication of the uptake in the population - these were selected at random 
from random fields of view. The Pearson's correlation co-efficient between the TLF and 
Lysotracker® fields was calculated using the Pearson-Spearman Correlation (PSC) Plug-in for 
ImageJ (http://www.cpib.ac.uk/~afrench/coloc.html). 
2.19 Fluorescence microscopy of ApoL1 uptake 
Trypanosomes were re-suspended in HMI9 medium containing 20% foetal bovine serum at a 
concentration of 106 cells/ml and incubated in 10µg/ml of Lysotracker® (Invitrogen) and several 
concentrations of purified recombinant ApoL1. The cells were incubated at 37°C for 4 hours. After 
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this period, cells were washed once in serum-free HMI9 medium and fixed by immersion in chilled 
2.5% glutaraldehyde (Sigma-Aldrich) in phosphate buffered saline for 5 minutes. The cells were 
washed once more in chilled PBS and then re-suspended in PBS with an AlexaFluor®488 antibody 
raised against a 6xHis-Tag (Molecular Probes, Invitrogen) The cells were gently agitated for 1 hour 
and then washed twice with chilled PBS and finally re-suspended in 50% glycerol, 0.1% DAPI, 2.5% 
DABCO in PBS and spread onto lysine coated slides which were then protected with cover-slips 
sealed using ethyl acetate. The slides were imaged using a Deltavision Core system and SoftWorx 
package (Applied Precision) with the standard filter sets (DAPI/FITC/Texas-Red and Light 
transmission). Approximately 30 serial sections through each trypanosome were taken for each 
filter. The images were composited and the brightness, contrast and colour levels normalized 
between samples and exposures using the ImageJ software package (US National Institute of 
Health).   Approximately fifteen trypanosomes were imaged per time point to give an indication of 
the uptake in the population - these were selected at random from random fields of view. The 
Pearson's correlation co-efficient between the ApoL1 and Lysotracker® fields was calculated as 
previously described. 
2.20 HpHbR Phylogeny Analysis 
The phylogeny of the HpHbR gene between isolates was assessed using the Seaview 4 interface 
for PHYLIP’s v3.52 dnapars program (Felsenstein, 1989). A parsimony tree was built using aligned 
DNA sequences and a neighbour joining algorithm, bootstrapped with 100 replicates for Eliane, 
STIB386, the T. b. brucei genome reference strain TREU927 and the Tanzanian T. b. brucei STIB247 
2.21 Quantitative trait loci (QTL) analysis 
Twenty-five STIB247/STIB386 progeny created during the formulation of the group 2 T. b. 
gambiense genetic map were used for QTL analysis (Cooper et al., 2008).  All strains were grown 
initially in ICR mice and analysed ex vivo in a 6 hour HMI9 buffered survival assay.  The inheritance 
of the human serum resistance trait in the progeny from the T. b. brucei strain STIB247 and group 
2 T. b. gambiense strain STIB386 genetic cross was examined for co-segregation of genetic 
markers on the genetic map of the group 2 T. b. gambiense strain STIB386 (Cooper et al., 2008).  A 
quantitative trait analysis (QTL) by maximum likelihood was conducted using MapManager QTX 
software (Manly et al., 2001) employing a significance level based on the χ2 statistic. Genome-
wide significance (P<0.001) was determined by performing 1000 permutations. Interval mapping 
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on each chromosome was performed using 1cM increments. QTL analysis was also repeated using 
linear regression by QTL express (Seaton et al., 2002). 
2.22 Population Analysis 
The multi-locus genotype (MLG) of each isolate studied was used to create a dendrogram to infer 
relationship within the Côte d’Ivoire T. brucei population.  Clustering calculator 
(http://www.biology.ualberta.ca/jbrzusto/cluster.php) was used to create a Phylip Drawtree 
string (analysed using un-weighted arithmetic average clustering and Jaccards’s similarity 
coefficient).  A bootstrap with 100 iterations was also generated.  This Drawtree string was then 
converted into a dendrogram using Treeview software 
(http://taxonomy.zoology.gla.ac.uk/rod/treeview.html).  Heterozygosity, Nei’s genetic distance 
and Fst were calculated using the GenAlEx software package for Microsoft Excel 
(http://www.anu.edu.au/BoZo/GenAlEx/).  Nei’s genetic distance and FST both compare the 
proportion of the total genetic variance contained in a subpopulation relative to the total genetic 
variance (Nei & Roychoudhury, 1974; Wright, 1978) These statistics indicate how similar 
populations are to each other, with 1 being completely different and 0 being identical.  Hardy-
Weinberg calculations were also performed using GenAlEx and indicate if alleles in the population 
are in an ideal Hardy-Weinberg state, usually as a result of completely random mating. Linkage 
disequilibrium calculations were performed using GenePop v4.0 software 
(http://genepop.curtin.edu.au/) and reveal if the same alleles in a population are usually inherited 
together or whether the inheritance of alleles is completely random. High levels of mating will 
cause alleles to be inherited in an apparently randomly assorted manner and will exhibit linkage 
equilibrium, while a population with little mating or strong selection will have similar alleles 
inherited together and exhibit linkage disequilibrium.   Finally, a principal coordinate analysis 
(PCA) was performed on the three populations using genetic distance to generate the vectors and 
the GenAlEx software package for Microsoft Excel (http://www.anu.edu.au/BoZo/GenAlEx/).  This 
analysis method performs a multi-dimensional comparison using genetic distance between 
individuals for both axes.  The factor that causes the greatest genetic distance between 
individuals in the populations is used for one axis, and the feature that causes the next most 
distance is the other.  In this way the structure of a population can be visualised. 
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2.23 General Statistics 
Several statistical tests were performed during this thesis, all using the Minitab Software package 
(Minitab Solutions Ltd).  One-way analysis of variance (ANOVA) tests were performed using the 
default settings with a Post-hoc Tukey's test to infer which sample variances statically differed 
from each other. General linear models (GLM) were constructed using percentage survival as the 
response factor and trypanosome strains and experimental conditions as the input parameters.  
2.24 Solutions 
Modified HMI9 Medium (500ml) 
365ml Iscoves modified Dulbecco’s medium + glutamax 
5ml Hypoxanthine (store @ 4oC) 
1.5ml Kanamycin (10mg/ml) (store@ -20oC) 
5ml (store @ -20oC) Penicillin / Streptomycin (5000u pen +5000u strep) 
25ml βBCPT 
500mg Glucose 
67mg Adenosine 
71mg Guanosine 
0.55g Methyl cellulose 
 
Add above ingredients and leave overnight to dissolve on a stirrer then add heat-inactivated, 
sterile-filtered foetal calf serum to a concentration of 20% (v/v) to medium before use. 
 
Phosphate Buffered Saline (PBS) (Qiagen Standard formulation) 
137 mM NaCl 
2.70 mM KCl 
4.30 mM Na2HPO4 
1.47 mM KH2PO4 
 
The final solution was adjusted to pH 7.4 before use in lysis assays wash steps. 
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2.25 Primer Sequences 
 
Table 2.1 The primer sequences used throughout the thesis 
Primer Sequence 
Tb927.6.350_F TTACATAATCGAGCATCCCGC 
Tb927.6.350_R ATGACGATTCAAGCCGTATCG 
Tb927.6.360_F TCACGAAGCCACTACATGCGT 
Tb927.6.360_R ATGCTACTTCCCCTCTACCTA 
Tb927.6.370/380_F TCAGCACACAATTGCGAGGGA 
Tb927.6.370/380_R ATGGGCACTGAGATAAGCATG 
Tb927.6.400_F TCACTGCTTATGTATCTTTGG 
Tb927.6.400_R ATGCAGGTTGATTGGGGTGCA 
Tb927.6.410_F TCAGCATCTGTAACGAACTAC 
Tb927.6.410_R ATGACACAACCAGATATATTC 
Tb927.6.430_F TATGCCTCATCCAGGGCCTGA 
Tb927.6.430_R GAAAACAATTGCGTTATCCAC 
Tb927.6.440_F CTACACCACCACCTGGAGCATAC 
Tb927.6.440_R AGAAACCGTCTTGCAGG 
Tb927.6.560_F CTACGCCGTGTTGGGTGCAAG 
Tb927.6.560_R ATGCATCTCATGGTGCCTGC 
Tb927.6.740_F CGGATCCAAAACACCAAAACA 
Tb927.6.740_R ATGAACCAGAAGCGATGCGAA 
HpHbR RT F GCCCTATGCTTATGCACATGATC 
HpHbR RT R ACCTCCGCCAGAGAAAATCTC 
HpHbR A F ACAAAGTGGCAGGTGCGTTG 
HpHbR A R ATT TTC GAT CGG GTT CCC AT 
HpHbR B F ATG GGA ACC CGA TCG AAA AT 
HpHbR B R AATCAGTTTTTTAGGGCGGC 
ESAG6 F CCGGAATTCGCTATTATTAGAACAGTTTCT 
ESAG6 R GTGTTAAAATATATC 
ESAG7 F CCGGAATTCGCTATTATTAGAACAGTTTCT 
ESAG7 R GCTCTAGACATCACTGCATTTTTTGCTTC 
SRA F GACAACAAGTACCTTGGCGC 
SRA R CAGCAACCATATTCAGAGCC 
TgsGP F TCACGGCCATCAGACGGAGA 
TgsGP R GCCATCGTGCTTGCCGCTC 
JS2 F GATTGGCGCAACAACTTTCACATACG 
JS2 R CCCTTTCTTCCTTGGCCATTGTTTTACTAT 
ApoL1_F AGGCAGATGAGCTCCGTAAA 
Apol1_R GCCAGAGGAAATGCTGAGAG 
Ch1/D2/7-C ACATTTTGGTTGTCCTGTTGG 
Ch1/D2/7-D GATCGAAGATAATAAATGCACAT 
Ch1/D2/7-A GTTGGCCGCATTATTCGATGC 
Ch1/D2/7-B GACAAGTAACACACAGGTGCACCA 
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Table 2.1 continued 
Ch5/JS2-A GATTGGCGCAACAACTTTCACATACG 
Ch5/JS2-B CCCTTTCTTCCTTGGCCATTGTTTTACTAT 
Ch5/JS2-C AGTAATGGGAATGAGCGTCACCAG 
Ch5/JS2-D GATCTTCGCTTACACAAGCGGTA 
Ch11/110-A GASTGCGAGGATTATGACTGTAGCG 
Ch11/110-B CCAATCTTATGCATACATGCAAGC 
Ch11/110-C TTTCTACGTCTCATTTCAACG 
Ch11/110-D ACTGCACAAACGGGTAAGGAG 
CH11/51-A AACCGATCATTCCTGTTCC 
CH11/51-B TGAGATGGTACTTGAAGAAAG 
ch11/51-C CTTACCCACAGGGCCAAA 
ch11/51-D AATGATTACGCACAAGCACA 
CH1/18-A TGTGAGAATGGTACTCACGCGCTG 
CH1/18-B ACAACGTTAGCACACAATTCCTGTG 
CH1/18-C TATAATGCGTTTGTGAGAAT 
Ch1/18-D GAAGGGAGGGAACAGAAGCAGGG 
Ch2/PLC-A TTAAGTGGACGACGAAATAACAACA 
Ch2/PLC-B CCACTGACCTTTCATTTGATCGCTTTC 
Ch2/PLC-C TTCAAACACCGTCCCCCTCAATAAT 
Ch2/PLC-D CAACGACGTTGGAAGAGTGTGAAC 
TIM-F TGCCGTTGAGTGGGTGAAGATAGC 
TIM-R CTCCCTGCTACCTGTCTTTACATC 
TgsGP-A TCACGGCCATCAGACGGAGA 
TgsGP-B GGGCTCCTGCCTCAATTGCTGCA 
TgsGP-C GTGGCAATTACTAGCAATAGCG 
TgsGP-D GCCATCGTGCTTGCCGCTC 
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Chapter  3:  TLF-1  interactions with 
T. b. gambiense and HpHbR 
3.1 Introduction 
Humans possess two trypanosome lytic factors (TLF-1 & TLF-2) that can kill most trypanosome 
species. The human infective sleeping sickness parasites T. b. rhodesiense and T. b. gambiense are 
able to resist lysis by human serum and establish bloodstream infections. How these sub-species 
have achieved this has been researched for several years, with a particular focus on T. b. 
rhodesiense due to its ease of use in experimental procedures.  One proposed mechanism for 
human serum resistance for T. b. rhodesiense stemmed from observations that a T. b. rhodesiense 
line failed to transport TLF to the lysosome and it was believed that T. b. rhodesiense employed a 
TLF avoidance strategy to resist lysis (Hager & Hajduk, 1997). However, a more widely employed 
resistance mechanism utilised by the majority of T. b. rhodesiense lines has since been described 
which involves the expression of a serum resistance associated (SRA) protein (De Greef & Hamers, 
1994; Xong et al., 1998).  The SRA gene is found in a bloodstream expression site and its 
expression is therefore is closely linked to antigenic variation. When the expression site with SRA 
is activated the sub-species is able to resist lysis by human serum. However if the SRA containing 
expression site is silenced the parasite is sensitive and exhibits a lysis phenotype indistinguishable 
from T. b. brucei. This explains the observation that T. b. rhodesiense parasites possess a variable 
human serum resistance phenotype. SRA is postulated to bind to the ApoL-1 component of TLF-1 
in the early endosomes as it is trafficked to the lysosome, neutralising it and preventing lysis (Oli 
et al., 2006; Vanhamme et al., 2003).  SRA has been found to be present in the majority of T. b. 
rhodesiense isolates but absent in all strains of T. b. brucei (Picozzi et al., 2005; Radwanska et al., 
2002; Welburn et al., 2001). However, while it is clear that SRA is responsible for human 
infectivity in a large number of T. b. rhodesiense isolates; there are a small number of human 
serum resistant T. b. rhodesiense which have been shown to lack SRA (De Greef et al., 1989; 
Enyaru et al., 2006).  
More importantly, the SRA gene has not been found in any isolates of the most prevalent human 
infective trypanosome, T. b. gambiense (De Greef et al., 1992; De Greef et al., 1989; Gibson et al., 
2002). This demonstrates that an alternative mechanism of human serum resistance exists in this 
sub-species. An additional complicating factor is that T. b. gambiense parasites fall into two 
Page | 53  
 
distinct "groups" that differ in genotype and phenotype. Isoenzyme data show that group 1 and 
group 2 T. b. gambiense populations are reliably distinguishable from each other and that group 2 
is more akin to T. b. brucei than group 1 (Gibson et al., 1980; Godfrey & Kilgour, 1976; Mehlitz et 
al., 1982; Tait et al., 1984; Zillmann et al., 1984). Group 2 T. b. gambiense exhibit a variable 
human serum resistance phenotype using the BIIT in a manner superficially similar to T. b. 
rhodesiense, while group 1 T. b. gambiense strains are invariably resistant even after prolonged 
passage in laboratory rodents (Mehlitz et al., 1982; Zillmann et al., 1984). In vivo studies with the 
group 2 T. b. gambiense TxTat strain did find a correlation between changes in the VAT and 
human serum resistance, indicating that specific VATs were always found within resistant 
populations after rodent passage (Ortiz et al., 1994). Additional ex vivo work with the same 
parasite line showed that the human serum sensitive group 2 T. b. gambiense line depleted 
human serum of its lytic potential faster than resistant lines derived from the same isolate (Ortiz-
Ordóñez & Seed, 1995). This suggests that this resistant group 2 T. b. gambiense strain is 
depleting TLF from the media more slowly than isogenic sensitive lines.  It has come to light 
however that there is some confusion as to the exact identity of some TxTat lines, with some 
derivatives revealed to be T. b. rhodesiense (Grab & Kennedy, 2008).  Lineage data for the TxTat 
used in the ex vivo assays was unavailable so it may be possible it has been misidentified as a type 
2 T. b. gambiense. Even less research has been performed concerning human serum resistance in 
the more important group 1 T. b. gambiense. 
There are a number of possible approaches to resist lysis by human serum that T. b. gambiense 
could utilise. One such strategy involves neutralisation of the active components of the TLF 
particle.  This is the tactic employed by most T. b. rhodesiense strains using SRA to inhibit ApoL-1. 
Another strategy would be to inhibit uptake of the lytic particles. Manipulation of the uptake of 
lytic particles in trypanosomes has been shown to be a viable resistance mechanism in artificially 
generated systems. For example, knocking-down the HpHbR receptor involved in TLF-1 uptake 
conferred partial human serum resistance to T. b. brucei (Vanhollebeke et al., 2008). Parallel to 
this, a T. b. brucei line generated by in vitro selection with lytic human HDL showed a failure to 
take up TLF-1 due to down-regulation of expression for HpHbR, a TLF-1 receptor (Kieft et al., 
2010). It is possible that the resistance mechanism utilised by T. b. gambiense may also involve 
TLF avoidance rather than neutralisation, perhaps by modification of the expression or function of 
this gene.  However, while knocking-down  expression of the HpHbR receptor in T. b. brucei 
conferred full resistance to TLF-1, it had no effect on resistance to TLF-2 and little effect on 
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resistance to normal human serum (Vanhollebeke et al., 2008). While relevant, this gene is far 
from the whole story. 
This chapter aims to characterise features of the human serum resistance mechanism that have 
evolved in T. b. gambiense and in what ways they may differ between the two T. b. 
gambiense groups and compared with T. b. rhodesiense. The chapter will focus on the interactions 
of the predominant lytic particle TLF-1 with different parasite lines and an investigation of the 
HpHbR receptor. This work has been facilitated by the development of culture conditions that 
allow T. b. gambiense lines to be grown in vitro with stable expression of either human serum 
sensitivity or resistance. 
3.2 Results 
3.2.1 Identification of trypanosome lines 
The aim of this series of studies was to investigate the nature of human serum resistance in the 
different T. b. gambiense groups in relation to other sub-species. Representative isolates from 
each sub-species, STIB247 (T. b. brucei), Eliane (group 1 T. b. gambiense), STIB386 (group 2 T. b. 
gambiense) and Baganzi (T. b. rhodesiense) were examined for the presence of the sub-species 
specific genes SRA (T. b. rhodesiense specific (Turner et al., 2004)) and TgsGP (group 1 T. b. 
gambiense specific (Radwanska et al., 2002)) by PCR amplification in order to verify their sub-
species classification (Figure 3.1). The SRA gene was found to be present in the T. b. rhodesiense 
Baganzi strain and the TgsGP gene was present in the group 1 T. b. gambiense Elaine strain, 
confirming their sub-species status. The strains T. b. brucei STIB247 and group 2 T. b. gambiense 
STIB386 do not possess either gene (Figure 3.1) but can be distinguished based on human serum 
resistance phenotype (Turner et al., 2004). 
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Figure 3.1  2% agarose gel showing presence/absence in various trypanosome strains of (A) SRA, 
(B) TgsGP and (C) microsatellite marker JS2 as a template control. A 1kb ladder (NEB) was used for 
SRA & JS2 and 100bp (NEB) used for TgsGP. PCR conditions & primer sequences are given in 
Chapter 2: Materials & methods. 
3.2.2 Human Serum Resistance Phenotypes  
Group 2 T. b. gambiense has a variable human serum resistance phenotype and different 
populations of STIB386 contain representatives of both sensitive and resistance forms in varying 
ratios (Figure 3.2a). By culturing the group 2 strain STIB386 in the presence of 10% human 
serum in an in vitro system we selected a population of human serum resistant parasites 
(STIB386R; Figure 3.2b). Several sub-lines of STIB386 gave a range of human serum resistance 
phenotypes of which one sensitive line was chosen that was consistently sensitive to human 
serum in continuous culture (STIB386S; Figure 3.2b). The group 1 T. b. gambiense strain Eliane 
was adapted to the culture medium. After a period of 2 weeks low growth it grew well and was 
consistently resistant to human serum. T. b. brucei STIB247 had been previously adapted to 
culture media and was always sensitive (Figure 3.2). 
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              A                          B 
 
Figure 3.2a Percentage survival of several replicates of unselected ex vivo parasite lines exposed 
to human serum for 6 hours normalised against trypanosomes exposed to foetal bovine serum. 
Figure 3.2b Mean percentage survival of in vitro culture-adapted parasite lines exposed to 
human serum for 6 hours, normalised against trypanosomes exposed to foetal bovine serum (n=4 
+ standard error). Both sensitive and resistant clones of type 2 T. b. gambiense are shown, in 
comparison with culture adapted T. b. brucei (STIB247) and group 1 T. b. gambiense (Eliane) lines. 
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3.2.3 Group 2 T. b. gambiense bloodstream expression site analysis 
Previous in vivo studies indicate that the switching of resistance in one group 2 T. b. gambiense 
strain correlated with a change in expression of the variable antigen type (VAT) implying that 
group 2 T. b. gambiense human serum resistance may be associated with expression site (ES) 
switching in a similar manner to T. b. rhodesiense (Ortiz et al., 1994). In order to determine if a 
change in ES expression is associated with a switch in human serum resistance phenotype in 
STIB386, we examined the ES expressed in both sensitive and resistant lines. Different copies of 
the two genes, ESAG6 and ESAG7 are found in each expression site and are well-characterised 
components of a transferrin receptor. They contain polymorphisms that are unique to each 
expression site, which can be used as markers to reveal which ES is currently active at any one 
time point (Ligtenberg et al., 1994; Salmon et al., 1994; Steverding et al., 1994; Steverding et al., 
1995). RT-PCR using primers for ESAG6 and ESAG7 was performed and the PCR product was 
cloned.  Sequencing several clones for each ESAG revealed no sequence differences between the 
expressed ESAG 6 and 7 hyper-variable regions (Figure 3.3) or whole gene (Appendix 1) in 
STIB386S and STIB386R lines suggesting that there is no association between ES usage and the 
human serum resistant phenotype. 
 
386R_ESAG6(BES126) CATCACAGTTTTGCATAAGCACGGGGAAGACTGGGCCAGCAGAATACAACAACTTGCAAG 
386S_ESAG6(BES126) CATCACAGTTTTGCATAAGCACGGGGAAGACTGGGCCAGCAGAATACAACAACTTGCAAG 
 
386R_ESAG7(BES126) GGAGAATACGGTGATGTCAGTTCCCACGATGCGGTACGGTGGACCGAAGATCCTAGTAAA 
386S_ESAG7(BES126) GGAGAATACGGTGATGTCAGTTCCCACGATGCGGTACGGTGGACCGAAGATCCTAGTAAA 
 
Figure 3.3 The sequence of the hyper variable regions (highlighted red) and surrounding bases of 
the expressed ESAG6 and ESAG7 in sensitive and resistant STIB386 derived from the same parent. 
The full gene sequences are presented in Appendix 1. Sequencing primers are given in Chapter 
2: Materials & methods. 
Page | 58  
 
3.2.4 TLF-1 Uptake and Localisation 
An important requirement of the lytic mechanism of TLF-1 is that it must be trafficked to the 
parasite lysosome and exposed to the low pH of the lysosome (Hager et al., 1994).  It has been 
shown in one resistant T. b. rhodesiense line that TLF is maintained in the late endosomes rather 
than being transported to the lysosome (Hager & Hajduk, 1997). A possible human serum 
resistance mechanism in T. b. gambiense therefore is that TLF-1 is not internalised or that it is not 
trafficked to the lysosome. We investigated the uptake and localisation of TLF-1 in our 
trypanosome lines using Alexafluor®488 tagged TLF-1 and the commercial dye Lysotracker®. T. b. 
brucei, T. b. rhodesiense and group 2 T. b. gambiense (both STIB386S and STIB386R) all showed 
internalisation of AlexaFluor labelled TLF-1 within one hour (Figure 3.4). No labelled TLF-1 was 
detected in the group 1 T. b. gambiense parasites, indicating a lack of TLF-1 uptake.  This result 
has also been replicated independently using a FACS analysis method (Kieft et al., 2010). 
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Figure 3.4 The localisation of fluorescently tagged TLF-1, Lysotracker® & DAPI in several parasite 
lines after one hour exposure.   The mean correlation co-efficient (R) of the TLF-1 and 
Lysotracker® field was estimated for each parasite line: for STIB247, R=0.9 (n=14); STIB386S, R= 
0.68 (n=18); STIB386R, R=0.63 (n=19); Baganzi, R=0.72 (n=28) indicating that TLF-1 was not only 
internalised but also trafficked to the lysosome in these strains.  There was no calculated R value 
(n=34) for Eliane indicating no correlation between TLF-1 and the Lysotracker® dye. 
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3.2.5 TLF Uptake Time course 
In order to investigate if there was a difference in the rate of uptake of TLF between the different 
strains, TLF uptake was examined over a four hour time course. Trypanosomes were counted as 
positive for uptake if they possessed either detectable TLF-1 within the main body of the parasite 
or had lysed, estimated by a percentage change in population. The majority of parasites in the T. 
b. brucei, T. b. rhodesiense and group 2 T. b. gambiense STIB386S lines all internalised TLF-1 within 
one hour whereas the group 2 T. b. gambiense STIB386R reached an asymptote of approximately 
60% of the population exhibiting uptake of TLF-1 (Figure 3.5a). In contrast, group 1 T. b. 
gambiense showed no detectable uptake. 
3.2.6 Non-lytic HDL Uptake and Localisation 
The group 2 T. b. gambiense STIB386R strain showed a reduced degree of uptake of TLF along a 
time course compared to the other studied strains. In order to examine whether the reduced 
uptake was specific to lytic HDL suggesting changes to specific receptors, or whether the effect 
was due to a general down-regulation in the amount of HDL being ingested by the parasites, we 
analysed the uptake of bovine serum HDL of a similar size to the TLF fraction. Bovine HDL does not 
contain ApoL-1 or Hpr, which was confirmed using protein-specific antibodies in western blots 
(data not shown). All strains of T. brucei internalised the bovine HDL, although group 1 T. b. 
gambiense did so at a slower rate than the other sub-species (Figure 3.5b).   This suggests that 
the reduced uptake of lytic HDL by the resistant group 2 T. b. gambiense strain is not due to a 
general down-regulation of uptake of all HDL but is specific to for TLF-1.  In contrast, the group 1 
T. b. gambiense strain displayed a complete lack of uptake of the lytic TLF-1 particle as well as 
reduced uptake of a non-lytic HDL. 
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Figure 3.5a The proportion of parasites in each parasite line that exhibit uptake of TLF-1, either 
by  the presence of visible concentrations of AlexaFluor tagged TLF-1 (Eliane, STIB386S, STIB386R 
and Baganzi) or a combination of percentage death and visible uptake (STIB247 and STIB386S). 
Cell death in these lines was attributed to the presence of TLF-1 as there was no death in cells 
suspended in TLF-1 free media, or B-HDL.   
Figure 3.5b Uptake of bovine HDL (B-HDL) of a comparable size to TLF-1, measured by visible 
concentrations of AlexaFluor® tagged B-HDL in the parasite body. No death was observed in the 4 
hour time course.  
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3.2.7 Relative HpHbR Expression 
The differential uptake of TLF shown in the group 1 and group 2 T. b. gambiense STIB386R strains 
compared to T. b. brucei strain may be due to the variation in the levels of expression of the 
recently described HpHbR receptor, as a reduction of expression of this gene by RNAi or gene 
knockout confers some resistance to human serum in T. b. brucei (Vanhollebeke et al., 2008). To 
investigate the expression of the gene in our lines the relative amount of transcript for the gene 
was measured using quantitative real-time PCR. STIB247, STIB386S, STIB386R and Baganzi strains 
all expressed similar levels of transcription for the HpHbR gene relative to a GPI8 endogenous 
control (Figure 3.6a). The STIB386R strain showed a slight decrease in mean level of expression 
of the gene compared to STIB386S but this was not statistically significant using a one way ANOVA 
(F7=4.03, p = 0.091). However, the group 1 T. b. gambiense strain expressed a five-fold lower 
mean transcript level compared to the other parasite lines and comparing expression across all 
five strains identified significant difference (F18=36.51, p < 0.01). Post-hoc Tukey's tests indicated 
Eliane to be different to all other lines whilst all comparisons between the other four lines were 
not significant. 
To investigate whether the low levels of HpHbR expression seen in the Eliane strain was a general 
feature of group 1 T. b. gambiense, expression levels were also measured in group 1 T. b. 
gambiense isolates from the Democratic Republic of Congo, Côte d’Ivoire and Cameroon. These 
isolates were examined ex vivo and Eliane was also investigated ex vivo for comparison (Figure 
3.6b). The down-regulation of transcript for the gene compared to the T. b. brucei STIB247 is 
consistent across all group 1 T. b. gambiense strains (F29=158.97, p < 0.01).  The down-regulation 
of transcription is more pronounced with ex vivo Eliane compared to the in vitro adapted line, 
however the trend is unchanged. 
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Figure 3.6a The relative abundance of transcripts for the HpHbR gene in each in vitro cell line 
relative to GPI8 as an endogenous control. All samples were normalised against the mean STIB247 
CT value (n = 4 for each line and standard error of the mean CT values is shown).  
Figure 3.6b The relative abundance of transcripts for the HpHbR gene in several group 1 T. b. 
gambiense isolates relative to GPI8 as an endogenous control. All samples were normalised 
against the mean T. b. brucei CT value (n = 4 for each line and standard error of the mean CT values 
is shown). 
Real-time PCR conditions & primers are given in Chapter 2: Materials & methods.  
A
B
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3.2.8 Gene expression within the HpHbR polycistron 
The down-regulation of HpHbR as a response to prolonged exposure to lytic human HDL has been 
demonstrated in an artificially selected human serum resistant line of T. b. brucei strain Lister 427 
(Faulkner et al., 2006).  This particular line has evolved down-regulation of the expression of 
genes across the polycistron containing HpHbR and the neighbouring polycistron (Kieft 2009, 
unpublished). The human serum resistant line of Lister 427 therefore acts as an HpHbR null 
mutant.  To investigate whether a similar chromosome regional down-regulation had occurred in 
a group 1 T. b. gambiense strain, RT-PCR was performed for genes along the polycistron 
containing HpHbR for the group 1 T. b. gambiense Eliane in comparison with Lister 427 and the 
Lister 427 HpHbR null mutant (Figure 3.7). Unlike the Lister 427 null mutant, HpHbR is down 
regulated independently of neighbouring genes in the Eliane group 1 T. b. gambiense strain. This 
implies that local modification in the 3’UTR of the HpHbR gene that affects the amount of 
transcript is more likely to be the determining factor in the low levels of HbHbR expression than a 
regional down-regulation as observed in the serum resistant Lister 427. 
  
Page | 65  
 
 
Figure 3.7 2% agarose gels showing RT PCR of the approximate relative amount of transcript for 
genes within the same polycistron as HpHbR (Tb927.6.350 - Tb927.6.430) and a neighbouring 
polycistron (Tb927.6.560 &  Tb927.6.740) for (A) T. b. brucei L427, (B) an artificially selected 
human serum resistant L427 and (C) group 1 T. b. gambiense Eliane. A TIM loading control is also 
shown. PCR conditions and primer sequences are given in Chapter 2: Materials & methods. 
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3.2.9 HpHbR ORF & 3'UTR sequence  
The HpHbR gene has been shown to be closely involved in the uptake of TLF-1 by T. brucei 
(Vanhollebeke et al., 2008).  We have shown that this gene is down-regulated in group 1 T. b. 
gambiense.  In addition, parallel work using the HpHbR null mutant Lister 427 line has indicated 
that the group 1 T. b. gambiense version of the gene has lowered functionality (Kieft et al., 2010).  
Ectopically expressing the T. b. brucei version of HpHbR in the null mutant restores full human 
serum sensitivity to the line.  However, ectopically expressing the group 1 T. b gambiense version 
of the gene does not result in a rescue of the sensitivity phenotype (Kieft et al., 2010).  The open 
reading frame (ORF) and 3’ UTR of the HpHbR gene were therefore sequenced to determine if 
there were any group 1 T. b. gambiense specific polymorphisms that might correlate with the 
differences in activity and expression.  Modifications to the ORF may indicate mutations that 
affect function and changes in the 3’ UTR may reveal features that affect gene expression due to 
the fact that T. brucei gene expression is largely regulated by mRNA stability mediated by the 3’ 
UTR (Clayton & Shapira, 2007).  The group 2 T. b. gambiense strain STIB386 both expresses the 
HpHbR gene and takes up TLF-1, indicating it has functional alleles of both the ORF and 3’ UTR.  
STIB386 is heterozygous for the gene and 3’ UTR, while the group 1 T. b. gambiense strain Eliane 
and T. b. brucei strain TREU927 are both homozygous for the ORF and 3’ UTR (Appendix 2). The 
gene is very highly conserved in group 1 T. b. gambiense, with individuals from disease foci in 
Cameroon, Democratic Republic of Congo and Côte d’Ivoire possessing the same homozygous 
ORF and 3’ UTR sequence (Appendix 3).  Even between sub-species and groups, the open 
reading frame of the gene is highly conserved with only 9 non-synonymous nucleotide 
polymorphisms between the three different sub-species and groups. These mutations are 
clustered at the 3’ end of the gene. There are 4 synonymous mutations clustered at the 5’ end.  
STIB386 is heterozygous at 6 of these sites (Figure 3.8). There is one non-synonymous 
polymorphism unique to group 1 T. b. gambiense (Ser209Leu) that may result in the lack of gene 
function when the group 1 T. b. gambiense HpHbR is  ectopically expressed in the HpHbR null 
mutant Lister 427 line (Kieft et al., 2010). 
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Figure 3.8 Pictorial representation of the distribution of synonymous mutations (green) and non-
synonymous mutations (red) found in the HpHbR alleles of Eliane and STIB386 compared to the T. 
b. brucei reference strain TREU297.  Full gene sequences are given in Appendix 2. 
 
The polymorphisms found in the group 2 T. b. gambiense strain do not seem to affect the function 
of the receptor in either resistant or sensitive lines but one homologue of the STIB386 gene shows 
strongest identity with the group 1 T. b. gambiense lines, with only five differences between 
them.  A parsimony tree was constructed using the nucleotide sequence of HpHbR to infer any 
possible relationships between the Eliane allele, the two STIB386 alleles and the alleles found in 
the T. b. brucei STIB247 and TREU927.  This indicated that STIB386 allele A is more similar to the 
group 1 T. b. gambiense allele then either STIB386 allele B or the T. b. brucei alleles. It also 
indicates that the allele B of STIB386 and the alleles found in the T. b. brucei STIB247 and 
TREU927 are more alike (Figure 3.9). One hypothesis for this arrangement is that group 2 T. b. 
gambiense emerged as a hybrid between a group 1 T. b. gambiense and a T. b. brucei. 
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Figure 3.9  Parsimony analysis tree constructed using the nucleotide sequence of HpHbR from 
STIB247, Eliane, TREU927 and both STIB386 alleles. A neighbour joining algorithm with 100 
replicates was utilised and bootstrap values above 10 are indicated. 
In addition to the loss of function in the group 1 T. b. gambiense allele of HpHbR, the expression 
of the gene is strongly down regulated in several group 1 T. b gambiense foci. Gene regulation in 
trypanosomes is largely mediated by post-transcription initiation, controlled by mRNA stability 
and generally associated with the 3’ UTR sequence of each gene (Clayton & Shapira, 2007). The 
region downstream of the gene containing the 3' UTR was therefore sequenced to investigate 
whether there were sequence polymorphisms (Figure 3.10). The length of the 3’ UTR in HpHbR 
is approximately 1000bp (R. Kieft, personal communication). Like the ORF for the gene, group 1 T. 
b. gambiense and TREU927 possess a homozygous 3’ UTR while STIB386 possesses a variant for 
each allele.  There are two group 1 T. b. gambiense specific polymorphisms in the 3'UTR that may 
contribute to reduced expression of the receptor. Group 2 T. b. gambiense has normal expression 
of the HpHbR gene and transcripts for both 3’ UTR variants have been shown to be present in 
approximately equal amounts in a DGE transcriptomics study (A. Macleod, personal 
communication) so mutations shared by both groups of T. b. gambiense are unlikely to contribute 
to the down-regulation of HpHbR expression observed in Eliane.   
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Figure 3.10 Pictorial representation of the distribution of mutations found in the 3’ UTR of 
HpHbR for Eliane and STIB386 compared to the T. b. brucei reference strain TREU297.  Eliane 
specific mutations are highlighted in blue.  Full sequences are given in Appendix 2. 
 
3.3 Discussion 
These data suggest that group 1 and 2 T. b. gambiense have evolved different strategies to deal 
with lysis by human TLF-1. Group 1 T. b. gambiense avoid uptake of the particle but group 2 T. b. 
gambiense take up TLF-1 and then either neutralise it or compensate for its effects. Both of these 
mechanisms are distinct from the mechanism based on SRA expression that has evolved in T. b. 
rhodesiense to achieve a human serum resistant phenotype. Group 2 T. b. gambiense exhibits a 
variable phenotype as previously described (Ortiz et al., 1994), but continuous exposure to a low 
concentration of normal human serum maintains the resistant phenotype indefinitely in culture. 
We have been able to show that group 2 T. b. gambiense internalises TLF-1 and traffics it to the 
lysosome like T. b. brucei and T. b. rhodesiense. In SRA expressing T. b. rhodesiense and serum 
resistant group 2 T. b. gambiense, this localisation does not result in cell lysis. Despite the 
similarity of phenotype, the group 2 T. b. gambiense STIB386 strain used in our experiments does 
not possess the SRA gene (Turner et al., 2004). While there are some differences in the rate of 
uptake and a possible down-regulation of the HpHbR receptor between resistant and sensitive 
group 2 T. b. gambiense, it has little impact on the overall uptake of TLF-1 compared to the 
dramatic lack of uptake and absence of receptor expression in group 1 T. b. gambiense. The 
lowered uptake of TLF-1 in STIB386R compared to STIB386S may explain observations that human 
serum incubated with ex vivo group 2 T. b. gambiense becomes less lytic over time suggesting that 
the trypanosomes deplete the media of lytic particles. This effect occurs faster in sensitive lines 
compared to resistant lines (Ortiz-Ordóñez & Seed, 1995). Unfortunately whether the reduced 
uptake of TLF-1 by resistant STIB386 is a true phenomena or an artefact of low biological 
replicates is unable to be answered due to a flaw in the design of the fluorescence microscopy 
experiments. The assays were time consuming and difficult to perform so a large number of 
trypanosomes were surveyed for each line, but only from a single experimental procedure.  In 
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HpHbR 3’UTR 
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hindsight, multiple smaller experiments would have proved more effective and allowed the 
degree of error to be assessed. Nevertheless, we have shown that the resistant group 2 T. b. 
gambiense strain STIB386 internalises and transports TLF-1 to the lysosome, suggesting that there 
is either a SRA-like neutralising agent or a compensatory protective effect within the lysosome of 
the parasite. 
Previous attempts  to characterise human serum resistance/sensitivity in this sub-species using an 
in vivo system suggested that a switch between resistant and sensitive forms of group 2 T. b. 
gambiense was always accompanied by a switch in variable antigen type (VAT), suggesting that 
the resistance mechanism is closely related to antigenic variation (Ortiz et al., 1994) with an 
implication that different VSGs could be expressed from different ESs in a manner similar to that 
seen in T. b. rhodesiense (Xong et al., 1998). Our sequencing data show that the same ESAG6/7 
gene copies are expressed in both strains of STIB386 suggesting that, irrespective of VSG 
expression, the same dominant ES is being used in both sensitive and resistant populations and 
that resistance is unlikely to be related to use of a particular ES as it is in T. b. rhodesiense. An 
alternative hypothesis is that, like group 1 T. b. gambiense strains, STIB386 possesses a limited 
ESAG repertoire (Young et al., 2008). However, group 2 T. b. gambiense have previously been 
shown to be more diverse than group 1 and are more similar to T. b. brucei (Gibson, 1986). It has 
also been shown that group 2 possess ESAGs more similar to those found in T. b. brucei and T. b. 
rhodesiense and not group 1 T. b. gambiense, although at present only the metacyclic ES have 
been investigated (Bringaud et al., 2001).  Indeed, the ESAG6 and ESAG7 being expressed by both 
forms of STIB386 are identical to those found in a T. b. brucei expression site that is absent in 
group 1 T. b. gambiense (Young et al., 2008).  While this suggests group 2 T. b. gambiense has a 
comparable ESAG repertoire to T. b. brucei, a more complete understanding of the ESAG 
repertoire of STIB386 is necessary.  
In contrast to the group 2 T. b. gambiense STIB386, the group 1 T. b. gambiense strain Eliane does 
not appear to internalise and concentrate TLF-1 to any discernable degree within 4 hours and 
employs an avoidance strategy to counter the major lytic particle of humans. This can be 
explained by a substantial down-regulation of the HpHbR receptor that is known to bind TLF-1. 
This decrease in HpHbR transcription is consistent across several group 1 T. b. gambiense lines 
from the Côte d'Ivoire, Cameroon and the Democratic Republic of Congo and so would appear to 
be a common trait of group 1 T. b. gambiense. The sequence of the HpHbR gene and 3' UTR of 
isolates from Cameroon and DRC are also identical to the group 1 T. b. gambiense Eliane lines 
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used in our experiments and may serve as diagnostic marker. The similarity amongst isolates may 
have been expected as this sub-species has been demonstrated to be clonal (Koffi et al., 2009; 
Morrison et al., 2008). Unlike the selected human serum resistant T. b. brucei in which down-
regulation of a genomic region around HpHbR has occurred, in group 1 T. b. gambiense HpHbR is 
down-regulated independently of surrounding genes. As gene expression in trypanosomes is 
largely regulated by transcript stability determined by the 3’ UTR sequence (Clayton & Shapira, 
2007), it is likely that this un-translated region is important to the stability of the HpHbR mRNA 
and consequently the expression levels. There are two group 1 T. b. gambiense specific 
polymorphisms in the 3' UTR that could potentially contribute to mRNA instability and reduced 
expression of HpHbR. Further investigations with 3' UTR modifications would allow this to be 
investigated further. 
Perhaps due to the lack of expression of the gene, the ORF of HpHbR has accumulated 
polymorphisms over time which affected the phenotype and led to a decrease in function of 
HpHbR in group 1 T. b. gambiense. Knocking in and over-expressing the T. b. brucei version of 
HpHbR into an artificially selected L427 HpHbR null mutant restores full TLF-1 and human serum 
sensitivity. Counter to that, over-expressing the group 1 T. b. gambiense version of the gene does 
not restore the full sensitivity phenotype (Kieft et al., 2010).  Our group 2 T. b. gambiense line 
STIB386 is heterozygous for the gene. Interestingly, it possesses one allele more closely related to 
group 1 T. b. gambiense and a second that is more distantly related. While it is known that both 
alleles are expressed in both STIB386R and STIB386S (A. Macleod, personal communication), it is 
possible that the “group 1 like” allele exhibits the same decreased function. In the future, 
successful knock-ins of the two group 2 T. b. gambiense alleles into the HpHbR null T. b. brucei 
mutant may offer insight into which non-synonymous mutations are important for function of the 
gene. The similarity of one of the HpHbR alleles to the group 1 T. b. gambiense allele raises the 
prospect that group 2 are simply the result of very rare mating event of a group 1 individual and a 
T. b. brucei, although evidence to date indicates that group 1 T. b. gambiense does not mate (Koffi 
et al., 2009; Morrison et al., 2008). This would explain the close links between the two groups 
despite a different resistance phenotype.  Population genetic analysis may reveal if this is the case 
(Chapter 6). This would be interesting as it would imply that both group 1 and 2 T. b. gambiense 
possess the same resistance mechanism, but expression of the phenotype in group 2 is not stable. 
Group 2 T. b. gambiense are amenable to forward genetic techniques (such as quantitative trait 
loci analysis), and comparative transcriptomics analysis making them an ideal platform to 
investigate the mechanism of both groups of T. b. gambiense. 
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It has been proposed that TLF particles evolved in primates to exploit the trypanosome's need for 
uptake of haem and lipid (Vanhollebeke et al., 2008). A predicted consequence of this is that 
down-regulation of a receptor in response would incur a fitness cost to the trypanosome in a 
manner analogous to that proposed for SRA in T. b. rhodesiense (Coleman & Welburn, 2004). The 
culture-adapted strain of group 1 T. b. gambiense however, does not show any marked difference 
in growth phenotype from the T. b. brucei and T. b. rhodesiense lines. This may be due to the fact 
that the group 1 T. b. gambiense strain Eliane can internalise non-lytic particles, such as a bovine 
HDL of a similar density to TLF-1, although at a slower rate than other T. brucei sub-species. This 
suggests that this group 1 T. b. gambiense has evolved to discriminate amongst HDL particles that 
do or do not contain lytic components even though the bulk of proteins in these particles are 
identical. Although this implies that the dominant uptake mechanism for TLF-1 is the HpHbR 
receptor and that the predicted low-affinity receptor is less important (Drain et al., 2001), it  was 
not possible to maintain the group 1 T. b. gambiense strain for longer than 4 hours in serum-free 
media to assess whether the parasite internalises TLF-1 via this low affinity receptor over a much 
longer time scale.  Other genes may be involved with the uptake and trafficking of different 
mammalian HDL fractions and group 1 T. b. gambiense can acquire enough metabolites using 
these receptors to grow unhindered. Targets for these receptors could be any of the several other 
major HDL proteins (Heinecke, 2009) not found in TLF-1. It is also pertinent to remember that the 
secondary lytic particle in humans, TLF-2, provides a second barrier that the parasite must 
overcome when evolving human serum resistance. Down-regulation of HpHbR alone does not 
lead to full resistance to the lytic effects of whole serum; rather it is just an decreased 
susceptibility to TLF-1 (Vanhollebeke et al., 2008).  The T. b. rhodesiense SRA gene neutralises the 
active component of both TLF particles, but whether TLF-2 resistance in T. b. gambiense is due to 
a down-regulation of other receptors or an SRA-like neutralising mechanism is unknown. 
However, as TLF-2 is believed to be internalised by interactions between the VSG coat of the 
parasite and TLF-2 bound IgM, it seems unlikely that there is a specific receptor involved in TLF-2 
uptake (Vanhollebeke & Pays, 2010).   
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Chapter 4: Recombinant ApoL1 
interactions with T. b. gambiense 
4.1 Introduction to ApoL1 
The general consensus in the human serum resistance field at present is that the active 
trypanolytic component of TLF particles is ApoL1 (Shiflett et al., 2007; Vanhamme et al., 2003; 
Vanhollebeke et al., 2007). While the Hpr protein may have some toxic potential, it is primarily 
the ligand for the HpHbR receptor and facilitates uptake of TLF-1 and hence ApoL1 into the cell 
(Vanhollebeke et al., 2008).  Recombinant ApoL1 can lyse trypanosomes with the same changes in 
morphology as normal human serum, albeit at a slower rate (Lecordier et al., 2009; Vanhamme et 
al., 2003; Vanhollebeke et al., 2008).  The ApoL1 gene is a member of a gene family with 
homologues found in many multi-cellular metazoa, from fish to humans (Duchateau et al., 1997).  
While ApoLIII appears to be the ancestral ApoL gene in mammals, it has been duplicated and then 
diverged to various degrees in separate lineages (Monajemi et al., 2002). For example, Homo 
sapiens possess six members of the ApoL family while Mus musculus possess fourteen. In Homo 
sapiens, transcripts for the ApoL gene family have been found throughout the body (Duchateau et 
al., 2001; Monajemi et al., 2002), although this is likely to be due to the fact the genes are 
predominantly expressed by the cells of the endothelium (Vanhollebeke & Pays, 2006). 
Most ApoL members are intracellular and are believed to be involved in apoptosis due to 
structural homology with the mammalian apoptosis protein family, Bcl-2 (Vanhollebeke & Pays, 
2006).  While most cell-mediated apoptosis in metazoa involves Bcl-2 proteins and permealisation 
of the mitochondrial membrane, certain cells of the endothelium and immune system do not 
appear to use this system and instead utilise a lysosomal mediated apoptosis system mediated by 
some ApoL proteins (Bidere et al., 2003).  With specific regard to ApoL1, little is known of any 
other functions it may possess in addition to its trypanolytic effects. Expression of ApoL1 has been 
implicated with involvement in tumours, replicative senescence and viral infected cells, from 
which it would appear to have a potential role in apoptosis in some cell types (Vanhollebeke & 
Pays, 2006). 
Unlike the majority of ApoL family members which are intracellular, ApoL1 possesses an 
additional 5’ signal peptide leading to its secretion by the endothelial cells in blood vessels 
(Vanhollebeke & Pays, 2006). The protein is usually located in human serum at a modal 
Page | 74  
 
concentration of approximately 6µg/ml, although this concentration varies a great deal (from 
2.5µg/ml to 30µg/ml) and is closely correlated with the amount of lipid in circulation (Duchateau 
et al., 2000).  The association with lipid concentration is largely due to the fact that ApoL1 is not 
found free in human serum, but bound to other lipoproteins and lipid into discrete high density 
lipoprotein (HDL) particles (Duchateau et al., 1997). ApoL1 is primarily found in two different 
trypanolytic particles of HDL – TLF-1 and TLF-2 (Molina-Portela Mdel et al., 2005; Shiflett et al., 
2005).  TLF-1 is a lipid rich particle internalised by trypanosomes via the HpHbR receptor, with Hpr 
protein acting as the ligand (Vanhollebeke et al., 2008).  TLF-2 contains much less lipid then TLF-1 
but is considerably larger due to the binding of IgM to the particle (Raper et al., 1999; Tomlinson 
et al., 1995). TLF-2 is much less well understood due to its low stability ex vivo, although uptake is 
not Hpr mediated and is instead likely to use the weak interaction between the IgM associated 
with the particle and VSGs on the parasite surface (Vanhollebeke & Pays, 2010). It is believed to 
be internalised passively along with the VSGs as part of the cell surface recycling mechanism of 
the parasite.  
Like other ApoL proteins, ApoL1 possesses three distinct domains - a pore-forming domain, a 
membrane-addressing domain and a non-functional structural domain (Perez-Morga et al., 2005).  
The pore-forming domain shows homology to other well characterised pore forming motifs, such 
as bacterial colicins, diphtheria toxin and the previously mentioned Bcl-2 apoptosis protein family 
(Vanhollebeke & Pays, 2006).  It was demonstrated that the pore forming domain of ApoL1 acts as 
an anionic channel when embedded in a membrane (Molina-Portela Mdel et al., 2005; Perez-
Morga et al., 2005).  These channels allow chloride ions to freely move across membranes, 
depolarising them and perturbing the osmotic potential of cellular compartments. In lysosomes, 
this leads to an uncontrolled osmotic swelling, either lysing the cell directly or indirectly by the 
release of digestive enzymes from damaged lysosomes (Perez-Morga et al., 2005).  The 
membrane-addressing domain is essential for efficient integration of the pore-forming domain 
into the plasma membrane. At a neutral pH it exposes a hydrophobic surface that binds lipid, 
suggesting that HDL particles can assemble passively in situ in the bloodstream (Perez-Morga et 
al., 2005). At an acidic pH, such as that found in the lysosome, this domain changes conformation 
and releases the ApoL1 from the HDL particle. Low pH is essential to the efficiency of the lytic 
function of the protein (Perez-Morga et al., 2005). 
Considerable amounts are known about ApoL1 and its interaction with T. b. brucei and T. b. 
rhodesiense. ApoL1 is taken up into the parasite, usually as part of a TLF particle but also can be 
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internalised if it is unbound, as demonstrated by in vitro experiments using recombinant protein. 
It is then trafficked to the lysosome of both T. b. brucei and T. b. rhodesiense (Molina-Portela 
Mdel et al., 2005; Perez-Morga et al., 2005; Vanhamme et al., 2003).  The serum resistance 
associated (SRA) protein of T. b. rhodesiense was shown to correlate strongly with the position of 
ApoL1 in the lysosome (Vanhamme et al., 2003).  SRA protein inhibits the function of ApoL1 by 
strongly binding to the C-terminal helix and disrupting the pore-forming domain (Vanhamme et 
al., 2003).   As previously described, baboons and the closely related Mandrilla genus possess an 
ApoL1 protein slightly different from that found in the Homo sapiens (Lecordier et al., 2009; 
Thomson et al., 2009).  The ApoL1 found in baboons has mutations to the C-terminal helix with 
which SRA interacts.  Since SRA cannot bind baboon ApoL1 and inhibit the lytic affect of the 
protein, baboon serum can lyse T. b. rhodesiense.   Genetic variants of human ApoL1 that have 
had the SRA binding motif removed to mimic baboon ApoL1 are also able to kill T. b. rhodesiense 
but not T. b. gambiense (Lecordier et al., 2009).  It is hoped that the creation of transgenic animals 
expressing modified or baboon SRA would eliminate T. b. rhodesiense (Thomson et al., 2009) but 
such a strategy is probably also likely to select for T. b. gambiense and SRA negative T. b. 
rhodesiense. 
Due to the fact that the SRA protein of T. b. rhodesiense is able to inhibit normal human ApoL1 
directly, the sub-species is able to resist lysis by both TLF-1 and TLF-2 particles. Unlike T. b. 
rhodesiense, group 1 T. b. gambiense do not internalise TLF-1 and avoid the ApoL1 found in this 
particle (Chapter 3 & (Kieft et al., 2010)).  It achieves this by down-regulating the expression and 
function of the HpHbR receptor (Kieft et al., 2010).  This would suggest that the resistance 
mechanism used by T. b. gambiense is an ApoL1 avoidance strategy.  If this is the case then how 
this particular sub-species group is able to resist lysis by TLF-2 is unknown. Down-regulation of 
expression of the HpHbR receptor in T. b. brucei leads to resistance to TLF-1 but not TLF-2 or 
normal human serum (Vanhollebeke et al., 2008).  In addition, it is unlikely that down-regulating a 
single receptor would be sufficient to avoid TLF-2 lysis due to the proposed IgM mediated uptake 
of the particle (Vanhollebeke & Pays, 2010). It would appear that TLF-2 has the potential to enter 
all T. brucei unhindered unless T. b. gambiense possesses a novel process to remove IgM from the 
VSG on the cell surface. If TLF-2 uptake is unavoidable then group 1 T. b. gambiense must also 
possess a method to resist the lytic effects of ApoL1 despite down-regulating the HpHbR receptor.  
Like other T. brucei strains, group 2 T. b. gambiense do not avoid the TLF-1 particle so must 
possess a mechanism to deal with ApoL1 lysis that extends to both TLF-1 and TLF-2 (Chapter 3). 
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Whilst other studies described in this thesis have revealed considerable insight into the 
interactions of TLF-1 with T. b. gambiense, TLF-2 presents a greater challenge.  TLF-2 is notoriously 
difficult to work with due to low stability ex vivo (Raper et al., 1999; Tomlinson et al., 1995). It is 
possible however to replicate some of features of the particle if a source of recombinant ApoL1 
could be generated.  Like TLF-2, recombinant ApoL1 is not internalised by a receptor using Hpr as 
a ligand. While TLF-2 is likely internalised as part of the general membrane recycling system of 
trypanosomes, free ApoL1 is instead internalised via non-specific endocytosis (Lecordier et al., 
2009). Recombinant ApoL1 has also been shown to be trafficked to the lysosome in a manner 
similar to TLF particles (Perez-Morga et al., 2005; Vanhamme et al., 2003). Unlike recombinant 
Hpr, recombinant ApoL1 kills trypanosomes with morphological changes similar to those seen 
after exposure to normal human serum and TLF, although this occurs at a slower rate (Vanhamme 
et al., 2003). This is probably due to a lowered efficiency of uptake compared to using the HpHbR 
receptor (Vanhollebeke et al., 2008). 
The primary aim of this thesis chapter was to design a robust and reliable protocol to express 
recombinant ApoL1. While several studies utilising recombinant ApoL1 have been described 
(Lecordier et al., 2009; Perez-Morga et al., 2005; Vanhamme et al., 2003; Vanhollebeke et al., 
2007), the exact protocols used were unclear at the time this thesis was commenced. With the 
creation of recombinant ApoL1, several key features of the interaction between the protein and 
the two groups of T. b. gambiense can be investigated.  A prime question to be answered was 
whether the reduced uptake of TLF-1 shown by group 1 T. b. gambiense was the sole resistance 
mechanism. If group 1 T. b. gambiense are inherently sensitive to ApoL1 and must avoid the 
protein, several therapeutic avenues present themselves to exploit this weakness. For example, a 
nanobody conjugated to the ApoL1 pore forming domain would be able to enter the T. b. 
gambiense cell attached to the VSG and lyse it.  This system has proved somewhat successful at 
lysing T. b. brucei and T. b. rhodesiense but has yet to be tried with T. b. gambiense (S. Magez, 
personal communication & (Baral et al., 2006).  The stably sensitive and resistance lines of the 
group 2 T. b. gambiense isogenic strains were also compared to investigate the similarities and 
differences between the two groups of T. b. gambiense.  Much of the examination of recombinant 
ApoL1 interaction with these trypanosome lines can be extended to apply to TLF-2 due to several 
shared features as described above.  
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4.2 Results 
4.2.1 ApoL1 ORF 
The sequencing of the purchased ApoL1 ORF revealed one non-synonymous mutation (Arg8Gly) 
compared to the human reference genome (Appendix 4). However, this region is not implicated 
in the trypanosome killing function of the protein (Perez-Morga et al., 2005). In addition, the 
sequence of an independently derived ApoL1 ORF used by other research groups has been 
published (Lecordier et al., 2009).  The ApoL1 used by these researchers has been shown on 
several occasions to be fully functional despite also possessing the Arg8Gly mutation. This 
indicates that there is variation in the ApoL1 gene in humans, although this particular mutation 
does not impact on the lytic capability of the protein. The commercial ApoL1 ORF was therefore 
considered suitable to be used in further recombinant expression experiments. 
4.2.2 Wheatgerm protein expression 
A protocol for expression of functional recombinant ApoL1 was not available when the project 
commenced so a protocol had to be created.  It has previously been demonstrated that ApoL1 is 
highly toxic to E. coli (Perez-Morga et al., 2005). In order to avoid the ApoL1 toxicity apparent in E. 
coli, a range of cell-free in vitro expression systems were investigated. Initially, a wheatgerm in 
vitro expression system was utilised as, in theory, a eukaryotic model would be most likely to 
provide the most accurate folding and post-translation of the recombinant protein. Attempts to 
use the commercial Endext® system using the PCR construction of the ApoL1 ORF fused to an 
expression promoter sequence did not bear fruit however due to truncation of the PCR product 
after the reaction.  Using the predictive primer affinity function found in the CLC-Bio software 
package, this was determined to be most likely due to the high affinity the first round forward 
primer had to a central region of the ApoL1 ORF (data not shown).  The forward primer sequence 
is pre-defined by the Endext® system so using a different tag was not possible. 
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An alternate method was attempted that used the same Endext® wheatgerm expression system 
but the promoter sequence was located in an Endext® plasmid.  The ApoL1 ORF successfully 
ligated into the correct site within the plasmid and was transformed into competent BL21-AI E. 
coli cells so that the high amount of plasmid DNA necessary could be obtained. Unfortunately, the 
transformed E. coli cells grew disappointingly and it was not feasible to grow to the volume 
needed to create enough plasmid DNA. Poor growth may have been due to “leaky” expression of 
the ORF leading to small amounts of toxic ApoL1 being produced by the bacteria.  The Endext® 
wheatgerm in vitro expression system was determined to be unsuitable for our needs and 
available materials. 
4.2.3 Invitrogen Expressway® system 
A second cell-free expression system was selected for consideration - the Invitrogen Expressway® 
E. coli expression system. This system was selected due to full compatibility with the Invitrogen 
Gateway® vector that had been purchased and verified to be correct. It is also fully compatible 
with the BL21-AI E. coli strain available which would reduce the hypothesised leaky ORF 
expression believed to be present in the Endext® system. The Expressway® system proved to be 
able to produce recombinant soluble ApoL1 protein (Figure 4.1), although with a low yield (≈ 
300μg per production reaction). A non-denaturing purification system was utilised to ensure the 
soluble protein did not require re-folding. 
 
Figure 4.1 Coomassie stained gel (left) and Western blot with an Anti-ApoL1 antibody (right) 
performed on the raw mix from an 8 hour Expressway® protein expression and after purification 
under non-denaturing conditions with a nickel column. The protein band visible is at the expected 
size for ApoL1. 
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After the protein was concentrated and verified to be ApoL1, its lytic ability against T. b. brucei 
was investigated using several different concentrations of protein. Recombinant ApoL1 produced 
from the Expressway® system did not kill human sensitive T. b. brucei strain STIB247, even at 
relatively high concentrations compared to those found commonly in vivo (Figure 4.2). This 
suggests that the Expressway® system does not produced functional ApoL1, even though it is the 
correct size and is detected by an ApoL1 antibody.  It is possible that this particular cell-free 
system does not provide the full suite of post-translational modification needed to create 
functional ApoL1. 
 
 
Figure 4.2 The percentage survival after 24-hours of the T. b. brucei strain STIB247 when 
exposed to various concentrations of recombinant ApoL1 obtained from the Expressway® in vitro 
protein expression system. Standard error is indicated (n=3) and samples are normalised to the 
0μg/ml protein control.  A positive control consisting of STIB247 exposed to 25% human serum 
showed 0% survival after 24 hours. 
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4.2.4 Gateway® E. coli expression system 
The cell-free in vitro expression system could only produce low protein yield with little (if any) 
activity. It was decided that a classical expression system using E. coli would be utilised, despite 
the toxicity of ApoL1 to E. coli. The Invitrogen Gateway® expression system was employed for 
improved efficiency and ease of use compared to other systems. The system was also fully 
compatible with the Gateway® entry plasmid containing the ApoL1 ORF.  The expression system 
proved successful, with large amounts of protein produced after induction.  Unfortunately the 
protein was abundant but present in insoluble inclusion bodies (Figure 4.3). 
The formation of inclusion bodies may arise due to the toxicity of ApoL1 to bacteria (Perez-Morga 
et al., 2005).  As it is difficult to purify recombinant protein from the insoluble fraction, 
temperature conditions were modified to provide slower inductions in the hope of improving the 
solubility of the protein. Solubility was not increased by lower induction temperatures, although 
the yield of protein decreased (Figure 4.3). 
 
Figure 4.3 Coomassie stained gels (left) and Western blots (right) using an anti-ApoL1 antibody 
performed on the soluble and insoluble fractions after expression induction at (A) 16˚C (B) 26˚C 
and (C) 37˚C. 
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The toxicity of ApoL1 is such that inclusion bodies are always likely to result from an induction in 
E. coli - soluble ApoL1 within the transformed cells would quickly lyse them.  Rather than avoid 
inclusion bodies by changing induction conditions, an alternate method would be to solubilise the 
protein using high concentrations of denaturing urea. This can lead to issues with proteolysis of 
the recombinant protein and also presents difficulties when re-folding the protein into the correct 
conformation. Fortuitously, data were published parallel to these experiments suggesting re-
folding of recombinant ApoL1 could be performed using weak acetic acid after urea treatment 
solubilising the inclusion bodies (Lecordier et al., 2009). 8M urea gave the best yield of protein, 
despite some proteolysis (Figure 4.4).  This cell-based protein expression, in combination with a 
nickel column purification system gave consistently high yields of protein (≈ 200mg per protein 
expression).
 
Figure 4.4 Coomassie stained gels (left) and Western blots (right) using an anti-ApoL1 antibody 
performed on the raw reaction mixture and soluble fraction after treatment with wash buffer 
containing (A) 4M Urea (B) 6M Urea and (C) 8M Urea. The predominant protein band is the 
correct size for ApoL1. Some protein degradation is visible. 
 
Unlike the Expressway® in vitro expression system, recombinant ApoL1 from this system causes 
death in T. b. brucei at amounts close to physiological levels (Figure 4.5).  Cells appear to die 
with the characteristic swollen lysosome phenotype, although cell death occurs more slowly than 
with normal human serum, requiring 24 hours for complete lysis of an in vitro T. b. brucei 
population (data not shown). The slower lysis rate of ApoL1 without the Hpr ligand has been 
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observed on numerous occasions and is likely to be due to being internalised via a less efficient 
non-specific endocytosis mechanism (Lecordier et al., 2009). 
 
Figure 4.5  The percentage survival after 24-hours of the T. b. brucei strain STIB247 when 
exposed to various concentrations of recombinant ApoL1 obtained from the Gateway® E. coli 
protein expression system. Standard error is indicated (n=2) and samples are normalised to the 
0μg/ml protein control. A positive control consisting of STIB247 exposed to 25% human serum 
showed 0% survival after 24 hours.  A negative control consisted of a 0µg/ml concentration of 
ApoL1 containing solely protein free buffer. 
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4.2.4 Recombinant ApoL1 assays 
As previously described, there are two distinct groups of T. b. gambiense. Group 2 show a variable 
phenotype with both sensitive and resistant forms, while group 1 are always resistant. The 
capacity for recombinant ApoL1 to lyse both sensitive and resistant forms of group 2 T. b. 
gambiense, in addition to group 1 T. b. gambiense and T. b. brucei, was examined for several 
concentrations of protein. Recombinant ApoL1 is able to lyse sensitive group 2 T. b. gambiense at 
levels similar to those that kill T. b. brucei. Lysis occurs at even low amounts of protein, 
approaching physiological levels.  The resistant group 2 T. b. gambiense strain and the group 1 T. 
b. gambiense strain were unaffected by ApoL1, even at high concentrations (Figure 4.6). 
 
Figure 4.6 The percentage survival after 24-hours of the T. b. brucei strain STIB247, the resistant 
& sensitive isogenic lines of the group 2 T. b. gambiense strain STIB386 and the group 1 T. b. 
gambiense strain Eliane, when exposed to various concentrations of recombinant ApoL1 obtained 
from the Gateway® E. coli protein expression system. Values have been normalised to the 0μg/ml 
control well for that experiment to take into account differing growth rates.  Standard error is 
indicated (n=2) and samples are normalised to the 0μg/ml protein control. A positive control 
consisted of each strain exposed to 25% human serum showed 0% survival for STIB247 and 
STIB386S after 24 hours, while Eliane and STIB386R survived at a level comparable to the negative 
control.  
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Interestingly, procyclic form T. b. brucei are fully resistant to normal human serum (Moore et al., 
1995).  The mechanism is unknown, although it is unrelated to the decreased endocytosis 
displayed in this life cycle stage (Natesan et al., 2010).  The procyclic form of a strain of T. b. brucei 
that is sensitive to ApoL1 in bloodstream form proved able to resist the effects of recombinant 
ApoL1 (Figure 4.7).  While it was not possible to show that procyclic form T. b. brucei internalise 
ApoL1, the phenotype was displayed even at high concentrations of ApoL1 that would 
compensate for the low levels of endocytosis.  This suggests that the innate resistance mechanism 
of procyclic form T. brucei is able to overcome the lytic effects of ApoL1. This mechanism cannot 
involve SRA so there must be transcriptional regulation of genes present in the organism that can 
achieve the same result. 
 
Figure 4.7 The percentage survival after 24-hours of procyclic form T. b. brucei strain STIB247 
when exposed to various concentrations of recombinant ApoL1 obtained from the Gateway® E. 
coli protein expression system. Standard error is indicated (n=3) and samples are normalised to 
the 0μg/ml protein control. A positive control consisting of procyclic STIB247 exposed to 25% 
human serum showed no loss of survival after 24 hours. 
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4.2.5 Fluorescence microscopy of recombinant ApoL1 
There are three possible mechanisms for resistance to the trypanolytic particles found in humans 
– avoidance, inhibition of lytic particles or compensating for their effects. Group 1 T. b. gambiense 
avoid the TLF-1 particle for example (chapter 3 & (Kieft et al., 2010)). While it is known that in T. 
b. brucei and T. b. rhodesiense recombinant ApoL1 is internalised by non-specific endocytosis, it is 
possible that the group 1 T. b. gambiense and resistant group 2 T. b. gambiense do not. It is also 
possible the recombinant protein is not being trafficked to the lysosomal compartment and so 
would not reach the site of action.  To investigate this, the internalisation and location of ApoL1 
was visualised in several T. brucei lines using fluorescence microscopy. All sub-species showed 
visible uptake of recombinant ApoL1 within four hours. The position of highest fluorescence 
correlates with the lysosomal dye in all strains, including the group 1 T. b. gambiense strain Eliane 
and the resistant group 2 T. b. gambiense strain STIB386R (Figure 4.8). This result would indicate 
that both groups of T. b gambiense posses the ability to resist the lytic effects of ApoL1 in the 
lysosome, although expression of the mechanism is variable in group 2 T. b gambiense. 
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Figure 4.8 The localisation of Alexa488 labelled anti-pentaHis antibody, Lysotracker® & DAPI in 
several parasite lines after four hour exposure to recombinant ApoL1 featuring a 6xHis tag.   The 
mean correlation co-efficient (R) of the TLF-1 and Lysotracker® field was estimated for each 
parasite line: for STIB247, R=0.87 (n=16); STIB386S, R= 0.81 (n=13); STIB386R, R=0.89 (n=15); 
Baganzi, R=0.76 (n=15); Eliane, R=0.85 (n=18) indicating that ApoL1 was not only internalised but 
also trafficked to the lysosome in these strains.  
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4.3 Discussion 
These data show that functional recombinant ApoL1 can be made reliably and efficiently using a 
commercial E. coli expression system. The toxicity of ApoL1 to E. coli leads to production of the 
recombinant protein in insoluble inclusion bodies but these inclusion bodies can be solubilised by 
high urea treatment and purified using standard nickel column methods. High urea treatment 
disrupts the conformation of the protein but accurate re-folding can be achieved using a weak 
acidic buffer (Lecordier et al., 2009). There is some proteolysis although a good yield of 
recombinant protein is still achieved.  This production protocol uses common buffers and 
materials, making it ideal for scaling up to produce large amounts of protein. Generation of 
recombinant ApoL1 has allowed further investigation of fundamental questions concerning the 
interaction of the main lytic component of both TLF-1 and TLF-2 with T. b. gambiense.  
As shown in other studies, recombinant ApoL1 kills T. b. brucei and sensitive T. b. rhodesiense with 
a similar morphology to that of normal human serum (Vanhamme et al., 2003).  The killing effect 
occurs more slowly than with normal human serum due to the fact that free ApoL1 is internalised 
via non-specific endocytosis (Lecordier et al., 2009).  The highest trypanosome killing efficiency for 
ApoL1 is achieved via TLF-1 with the associated Hpr protein acting as a ligand for the trypanosome 
HpHbR receptor (Vanhollebeke et al., 2008). Inhibition of ApoL1 has been shown to be central to 
the human serum resistance mechanism of T. b. rhodesiense using the serum resistance 
associated (SRA) gene. SRA co-localises with ApoL1 within the lysosome and blocks the lytic 
activity of the protein by disrupting a helix in the pore forming domain (Vanhamme et al., 2003). 
To date, the activity of recombinant ApoL1 on either group of T. b. gambiense has not been 
investigated.  Our data indicate that both groups of T. b. gambiense internalise recombinant 
ApoL1 and traffic it to the lysosome, probably via non-specific endocytosis in a manner similar to 
that shown in T. b. brucei and T. b. rhodesiense (Vanhamme et al., 2003).  Recombinant ApoL1 
kills the sensitive group 2 T. b. gambiense strain STIB386S at a similar rate to T. b. brucei, but not 
the isogenic resistant group 2 T. b. gambiense strain STIB386R. 
This indicates that the resistance mechanism of group 2 T. b. gambiense is able to either 
neutralise or compensate the effects of ApoL1, although expression of the mechanism is variable. 
Pull-down assays with ApoL1 against lysosomal fractions from resistant forms of group 2 T. b. 
gambiense would reveal if this mechanism was due to the expression of an SRA-like protein that 
interacts with ApoL1.  Unfortunately such specific pull-downs would be particularly difficult to 
achieve as the lysosome is an extremely sensitive organelle and centrifugation often destroys the 
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structure.  It is likely pull-downs could only be performed on crudely separated materials.  It is 
also possible that the resistance mechanism is not a neutralisation mechanism like SRA in T. b. 
rhodesiense. Instead there may be genes that compensate for the pore-forming effects of ApoL1. 
These could be proteins that modify lysosomal membrane integrity or fluidity to increase the 
capacity to resist the osmotic effects. A similar resistance effect could also be achieved via 
transporters that are able to counteract the influx of chloride ions.  In this case, comparisons 
between the transcriptomes of resistant and sensitive lines of the STIB386 strain may reveal 
candidate genes that are differentially expressed and are involved in compensatory mechanisms. 
A quantitative trait locus analysis would also reveal areas of the genome implicated in 
involvement. Both options are available in group 2 T. b. gambiense due to its variable phenotype 
and ability to undergo mating with genes re-assorted in a Mendelian manner (Cooper et al., 2008; 
Morrison et al., 2009; Veitch et al., 2010). 
Group 1 T. b. gambiense are also able to resist the lytic affects of ApoL1, although the mechanism 
is constitutively expressed.  There may possibly be a common mechanism between group 1 and 2 
T. b. gambiense, although the expression of the system is variable in group 2. This may have 
arisen if group 2 is a hybrid generated between a group 1 T. b. gambiense and a T. b. brucei.  If 
there is a common mechanism, this would reveal group 2 T. b. gambiense to be an excellent 
model for group 1.  Resistance to ApoL1 in group 1 T. b. gambiense is interesting as these 
parasites have evolved to avoid the main ApoL1 containing particle TLF-1 by down-regulating 
expression and function of the HpHbR receptor (Kieft et al 2010, submitted manuscript). Down-
regulation of the HpHbR receptor is found at several disease foci and seems to be a fundamental 
feature of group 1 T. b. gambiense (chapter 3 & (Kieft et al., 2010)). Several hypotheses can be 
formulated for why group 1 T. b. gambiense avoid TLF-1 despite its inherent resistance to ApoL1; 
such as the idea that the TLF-1 particle evolved before TLF-2 in primates. T. b. gambiense may 
initially have evolved primate infectivity by simply avoiding the primordial TLF particle.  The sub-
species was then unable to use a similar mechanism to avoid uptake of TLF-2 as it is internalised 
by weak interactions with IgM and the surface VSG (Vanhollebeke & Pays, 2010).  Instead, a 
second resistance mechanism to counteract ApoL1 evolved.  This is pure speculation however as 
nothing is known about the evolution of TLF-2 or the distribution of the particle amongst 
primates. Another hypothesis would involve the recently described phenomena that Hpr signal 
peptide possesses membrane disruptive potential specific to bloodstream form trypanosomes 
(Harrington et al., 2010). Group 1 T. b. gambiense may be especially susceptible to this and so the 
avoidance mechanism has not evolved to combat ApoL1 but rather Hpr signal peptide. While 
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there was no difference between the susceptibility to Hpr signal peptide between T. brucei sub-
species, the peptide in these assays was integrating into the cell surface membrane.  The site of 
action for the Hpr signal peptide would be the lysosomal membrane. The differences between T. 
b. brucei and T. b. gambiense lysosomal structure or membrane integrity have not been 
examined. Another hypothesis is that the T. b. gambiense resistance mechanism is dose 
dependant and by avoiding TLF-1 uptake is able to avoid the majority of the ApoL1 in the human 
bloodstream.  This would suggest that group 1 T. b. gambiense may be susceptible to ApoL1 lysis 
if internalised at high concentrations.  Using an ApoL1-nanobody conjugate to increase the uptake 
rate of ApoL1 above that of standard recombinant ApoL1 may reveal if this is the case (Baral et 
al., 2006).  While several theories can be invoked to explain why group 1 T. b. gambiense do not 
uptake TLF-1, it will be difficult to infer conclusions without greater knowledge of the genes 
involved in ApoL1 resistance. 
Another interesting result revealed by these data is that sensitivity to ApoL1 mediated lysis is 
lifecycle stage-specific. Bloodstream form T. b. brucei are killed by ApoL1 while the procyclic forms 
of the same strain are not. This correlates with data showing that procyclic form T. b. brucei are 
fully resistant to normal human serum despite being quickly lysed when in bloodstream form 
(Moore et al., 1995).  While it was initially believed that resistance in procyclic form T. b. brucei 
was due to a 10-fold decrease in endocytosis, mutant procyclic T. b. brucei that exhibit 
bloodstream levels of endocytosis are still resistant to human serum (Natesan et al., 2010). This 
result suggests there is a mechanism present in procyclics that is rendering them resistant to the 
lytic effects of ApoL1. This process may involve transcriptional regulation of genes already 
present.  One possible gene involved is the lysosomal protein p67.  This gene is up-regulated in 
bloodstream form T. brucei compared to procyclics (Kabani et al., 2009; Veitch et al., 2010) and 
artificially reducing expression of this gene does increase human serum resistance in T. b. brucei, 
although with a stark decrease in survivability (Peck et al., 2008).  Most of the genes identified by 
a transcriptional comparison between procyclic and bloodstream form T. brucei were hypothetical 
and have no known function but may contribute to the phenotype (Veitch et al., 2010).  
Understanding the function of these hypothetical genes may reveal their importance and what 
impact they have on the resistance phenotype of procyclic form T. b. brucei. Why all bloodstream 
T. brucei cannot invoke the procyclic mechanism to resist lysis is unknown although perhaps this is 
the system utilised by T. b. gambiense. Whole transcriptome comparisons between T. b. brucei 
procyclic and bloodstream forms versus T. b. gambiense may reveal if this was the case. 
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Until recently, little was known concerning the interaction of ApoL1 and T. b. gambiense.  The 
series of experiments in this chapter demonstrate that both group 1 and 2 T. b. gambiense 
internalise and transport ApoL1 to the lysosome.  Group 1 and resistant group 2 T. b. gambiense 
are not lysed so both must possess a mechanism to resist the lytic effects of ApoL1. This may be 
an inhibitory effect, such as the binding of the SRA protein to ApoL1 in T. b. rhodesiense 
(Vanhamme et al., 2003).  The mechanism must be considerably different from SRA however as 
modifications to ApoL1 that allow it to kill T. b. rhodesiense by avoiding inhibition do not lyse T. b. 
gambiense (Lecordier et al., 2009). Pull down assays investigating the binding of recombinant 
ApoL1 to fractions of T. b. gambiense cells may reveal any interactions between the protein and 
an inhibitor.  Similar assays would also reveal a possible neutralising agent expressed by T. b. 
gambiense, such as a protease that targets ApoL1. 
If however the resistance mechanism of T. b. gambiense is not by direct inhibition of ApoL1 but 
instead an ability to compensate for the effects of the protein, then association and pull down 
assays will not work.  In group 2 T. b. gambiense, forward genetic and transcriptomic approaches 
using the isogenic resistant and sensitive STIB386 may offer insight into the processes and 
proteins involved (Cooper et al., 2008; Veitch et al., 2010). Unfortunately these systems do not 
appear to be transferable to group 1 T. b. gambiense as this group of does not seem to undergo 
mating in a laboratory setting so there can be no genetic crosses for QTL analysis.  Additionally, it 
is invariably resistant so there is no opportunity to perform comparative transcriptomics with 
resistant and sensitive isogenic lines.  It may be possible to compare the transcriptomes of T. b. 
brucei isolates to that of group 1 T. b. gambiense isolates, although preliminary data suggests that 
there are a great deal of genes that are differentially expressed between these two sub-species 
(N. Veitch, unpublished data).  Instead the application of recombinant ApoL1 and inhibitors of 
cellular processes and enzymes may provide insight into possible mechanisms involved in 
counteracting the effects of the anionic pores formed by ApoL1.  Previously, experiments such as 
these were hampered in that TLF-1 is not internalised by group 1 T. b. gambiense and TLF-2 is too 
unstable to be reliably used.  The recombinant ApoL1 created by our protocol allows us to 
overcome these biological limitations and potentially investigate the resistance mechanism of 
group 1 T. b. gambiense directly.  
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Chapter 5: Quantitative Trait Loci 
(QTL) analysis of the group 2 T. b. 
gambiense human serum resistance 
phenotype 
5.1 Introduction to quantitative trait loci analysis 
Most studies investigating trypanosome phenotypes of interest have used a reverse genetics 
approach.  Genes are manipulated, either by interfering with them in situ or placing them into 
new genetic backgrounds. Several tools exist for such analysis in trypanosomes, including RNA 
interference (Wang et al., 2000) and stable genetic transformation (Burkard et al., 2007). From 
changes in observed phenotype due to the manipulation of the target, the function of the gene in 
the whole organism can be inferred. However, most genes do not function individually and the 
downstream effects of the manipulation can be unpredictable or even unobservable.  Another 
dilemma innate to these studies is that genes unique to trypanosomes are unlikely to be selected 
for reverse genetics approaches due to the fact most candidates for manipulation arise from 
homologous genes identified in other organisms. An alternate strategy to reverse genetics is the 
converse, forward genetics.  While reverse genetics examines the phenotypes caused by specific 
genes, forward genetics seeks to find the genes involved with a phenotype. 
A standard approach when investigating the link between phenotype and genotype starts with 
strongly inbred mutant parental lines that possess a phenotype of interest (Doerge, 2002).  These 
parents are homozygous across their genomes due to continuous inbreeding.  The parental line is 
then bred with another homozygous parent featuring a different response to the phenotype in 
question.  This out-breeding produces heterozygous F1 progeny.  Two F1 progeny are then mated 
and re-assortment due to crossover events causes random inheritance of genes in the F2 progeny.  
The process can be simplified somewhat if the parental lines used possess different phenotypes 
and are already heterozygous for genes associated with the phenotype (if using wild isolates for 
example). In this situation analysis can be performed directly on the F1 progeny. By examining the 
inheritance of alleles and the expression of the phenotype in the progeny it is possible to locate 
alleles that are more likely to be associated with the phenotypic trait of interest.  This quantitative 
trait loci (QTL) analysis has been used to identify important genes in several parasites, including 
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Toxoplasma gondii, Plasmodium falciparum and Trypanosoma brucei brucei (Ferdig et al., 2004; 
Morrison et al., 2009; Su et al., 2002). 
Group 1 T. b. gambiense is the most prevalent group of this sub-species but is unsuitable for 
forward genetics approaches due to its inability to undergo crosses in a laboratory setting. At all 
disease foci studied, group 1 T. b. gambiense have been shown to possess a clonal population 
structure suggesting mating does not occur in this group (Chapter 6 & (Koffi et al., 2009; 
Morrison et al., 2008; Tait et al., 1984).  However, forward genetics approaches can be utilised in 
group 2 T. b. gambiense as it undergoes mating under laboratory conditions and alleles are 
recombined in a Mendelian manner (Cooper et al., 2008; MacLeod et al., 2005a). QTL analysis is 
an ideal technique for investigating phenotypes in this group of T. b. gambiense due to the 
publication of both the T. brucei genome allowing the identification of microsatellite markers 
(Berriman et al., 2005) and the genetic map for both group 2 T. b. gambiense and T. b. brucei 
indicating the likelihood of recombination events between those markers in group 2 (Cooper et 
al., 2008; MacLeod et al., 2005b). The genetic map of the group 2 T. b. gambiense strain STIB386 
comprises of 127 microsatellite markers distributed across the mega-chromosomes.  The 
frequency of a crossover event between two markers indicates the genetic distance between 
them.  By comparing markers on the genetic map with the inheritance of the phenotype in the 
progeny, markers that co-segregate with the phenotype can be identified. This allows an estimate 
of the likelihood of linkage to the phenotype to be made (Doerge, 2002). A statistical value is 
appended to each marker that indicates the logarithm of the odds (LOD) value of the likelihood 
that there is genetic linkage at that marker relating to the phenotype. The statistically significant 
LOD value used for diploid cells is usually 3, which suggests that the odds are a thousand to one in 
favour of genetic linkage to the phenotype (p < 0.001) (Van Ooijen, 1999). 
The progeny of the cross between human serum resistant group 2 T. b. gambiense strain STIB386 
and the human serum sensitive T. b. brucei strain STIB247 created to formulate the genetic map 
of STIB386 may prove useful to investigate the human serum resistance phenotype in group 2 T. 
b. gambiense. STIB247 is predominantly homozygous, including the majority of the 127 
microsatellite markers (93%), in contrast to STIB386 which is heterozygous for all of them 
(MacLeod et al., 2005b). While there will be an inherited contribution to the progeny phenotypes 
attributable to the STIB247 parent, the high homozygosity of this line means there is only a 7% 
chance it will segregate in the progeny. This means that differences in the phenotypes of the 
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progeny are more likely to be attributed to whichever of the chromosome homologues the 
individual progeny have inherited from the heterozygous STIB386 parent.   
Using this methodology, the relationship between the phenotype and the inherited haplotype of 
the progeny can be ascertained. The simplest model of inheritance is one in which one parent is 
heterozygous for a single gene involved in a phenotype.  The relevant alleles will segregate in the 
progeny so that the progeny will either inherit the allele or not and likewise the phenotype will 
either be inherited or not.  By comparing the parental markers inherited by the progeny, markers 
more likely to be possessed by progeny displaying the phenotype suggests that genes close to 
those markers are involved with the phenotype.  While the technique can be used to reveal 
phenotypes arising from single genes, such analysis is also ideal for the study of complex 
phenotypes that arise due to multi-gene interactions to create a quantitative trait. This is revealed 
as a continuous phenotypic response in the progeny, rather than the discrete presence or 
absence of the phenotype in question. In this case the degree to which the phenotype is displayed 
in each progeny is also considered in conjunction with the proportion of progeny inheriting the 
marker.  Several mathematical and software solutions exist for quantitative trait locus analysis 
and have already been validated in T. brucei, revealing a major locus implicated in host 
pathogenesis (Morrison et al., 2009).  
The major strength of the linkage mapping approach is that it can identify genes involved in a 
phenotype where no obvious candidate genes exist.  One such phenotype is human serum 
resistance.  Group 2 T. b. gambiense can infect humans while T. b. brucei cannot. Fortunately a 
genetic cross has been performed in the laboratory between a group 2 T. b. gambiense and a T. b. 
brucei leading to the generation of hybrid progeny that can be used for a linkage analysis (Cooper 
et al., 2008). An important consideration for QTL analysis with the group 2 T. b. gambiense 
progeny is that the phenotype in the parent is variable (Gibson, 1986). However, it is possible to 
identify loci of interest despite large amounts of variation if there is a strong heritable and 
therefore genetic component (Glazier et al., 2002). This has been demonstrated in numerous 
human diseases in which there is a strong environmental or social components in addition to the 
genetic basis, such as type 2 diabetes mellitus (Glazier et al., 2002).  Preliminary QTL analysis for 
human serum resistance has been performed using the progeny from the group 2 T. b. gambiense 
and T. b. brucei cross (A. Macleod, unpublished data).  The assay used to phenotype the progeny 
measured percentage survival after four hours incubation in human serum using a commercially 
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available system.  This assay measures the fluorescence ratios of two different dyes that stain 
nuclear material (Turner et al., 2004). 
The two dyes used were RedDead which exhibits red fluorescence under excitation but is unable 
to cross an intact plasma membrane. The second dye, Syto 10, fluoresces green at the same 
excitation wavelength and is able to cross the plasma membrane.  It was shown that progeny that 
were human serum sensitive would possess compromised plasma membranes after 4 hours 
exposure to human serum as they lysed (Turner et al., 2004).  A compromised plasma membrane 
allow both the RedDead and Syto 10 dyes to enter the cell and stain nuclear material red/green 
(observed as yellow) and conversely progeny that were human serum resistant would still possess 
intact plasma membranes and their nuclear material would only be stained green.  The proportion 
of red and green cells can be quickly and accurately measured by fluorometry and compared to 
the control of 100% dead cell killed by immersion in ethanol. During the assay, cells were buffered 
in phosphate buffered saline (PBS) supplemented with glucose to reduce any cross-contamination 
in fluorescence caused by the HMI9 medium normally used to culture the trypanosomes.  Forty 
progeny created in the formulation of the group 2 T. b. gambiense genetic map were assayed 
using this protocol (Figure 5.1).  The phenotype segregates strongly, indicating the presence of a 
strong single gene effect. QTL analysis indicated strong linkage for a section of chromosome 2 that 
was involved in the human serum resistance phenotype measured by this assay (A. Macleod, 
unpublished data). 
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Figure 5.1  The percentage survival of different clones of progeny from the T. b. brucei strain 
STIB247 and group 2 T. b. gambiense strain STIB386 cross after exposure to human serum for 4 
hours. Survival was assayed using the ratio of red:green fluorescence using RedDead/Syto 10 
fluorescent dyes buffered in PBS supplemented with 0.1% glucose. The standard error is shown. 
Progeny clearly segregate into two distinct populations, one showing high survival, the other 
exhibiting sensitivity to the assay. 
 
This large area containing approximately 300 genes was subsequently fine mapped to an area 
containing just 30 genes (A. Macleod, unpublished data).  There are several candidate genes 
located in this area, including a family of tandemly repeated genes that encode for Invariant 
Surface Glycoprotein 65 (ISG65) - a receptor of unknown function with approximately 60,000 
copies expressed on the cell surface (Ziegelbauer & Overath, 1993). 
In completely separate parallel studies, low-temperature binding assays have indicated that there 
are two possible receptors for TLF-1; a high affinity receptor that has approximately 350 copies 
per parasite and a low affinity receptor that has 60,000 receptors per cell (Drain et al., 2001).  The 
high affinity receptor, HpHbR, has since been identified and characterised while the low affinity 
receptor remains elusive (Vanhollebeke et al., 2008).  It was hypothesised that ISG65 was the low 
affinity receptor for TLF-1 and the gene was taken forward for analysis as the prime candidate for 
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involvement with the human serum resistance phenotype in group 2 T. b. gambiense.  Progeny 
that were identified as sensitive to human serum consistently possessed one particular haplotype 
of ISG65 genes. This haplotype was also shown to be possessed by a group 2 T. b. gambiense 
STIB386 selfer line that was homozygous for this region of chromosome 2. This STIB386 strain 
formed by self-fertilisation was shown to be sensitive to human serum in the same assay used to 
identify the hybrids (A. Macleod, unpublished data).  These data heavily implicated ISG65 as a 
potential candidate for involvement in human serum resistance in group 2 T. b. gambiense. 
However, shortly after starting this thesis it was noted by phase microscopy that there was 
significant cell death in some trypanosome lines compared to others when buffered in PBS media.  
The cell death was not revealed by the RedDead/Syto 10 fluorescence assay as visual cell counts 
were not performed during the experiment and instead comparative proportions of fluorescence 
were used as the assay metric and so a general decrease in cell viability occurred in both test and 
control cells (Turner et al., 2004). This large amount of cell death may have an impact on any 
perceived QTL from the original data as the assay was potentially measuring an amalgam of two 
phenotypes rather than one - human serum resistance and PBS sensitivity.  In addition, questions 
were raised concerning the consistency of the assay procedures, with several formulations of PBS 
being used at different points and the addition of variable chilling periods prior to the assay. This 
chapter investigates the effects of buffering human serum resistance assays in PBS compared to 
HMI9 medium that can sustain trypanosome growth in culture. A new assay using modified HMI9 
and visual cell counting was then formulated and preliminary phenotype studies on the progeny 
of the T. b. brucei and group 2 T. b. gambiense cross were performed using this new method to 
conduct a new QTL analysis. 
5.2 Results 
5.2.1 Differences between assays 
It is known that trypanosomes can survive for several hours in PBS supplemented with glucose 
and it is commonly used as a laboratory buffer. However the strain routinely used in laboratory 
experiments is the highly derived Lister 427 line (Peacock et al., 2008).  This line is heavily 
laboratory adapted and is able to survive in media that some trypanosome strains cannot, for 
example unmodified powdered HMI9 (L. Sweeny, personal communication).  Often adaptation to 
culture of new lines requires specific and customised media formulations (Hirumi & Hirumi, 1989).  
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It has previously been ascertained that the strains used in this thesis grow best in culture in the 
presence of modified HMI9 (Chapter 2: Materials & Methods).  It is possible that strain specific 
differences in response to the PBS buffer used in the assay was responsible for the original QTL 
rather than response to human serum.  In order to ascertain how much affect the experimental 
buffer was potentially exerting on the assay, it was first necessary to distinguish if the parental 
lines differed in their response to the PBS media. If this was the case then the measured linkage to 
chromosome 2 is at least partly due to exposure to PBS and the presence of FBS merely reduces 
the killing effect of PBS. However, there was no significant difference in survivorship between 
STIB247 and STIB386 in either PBS or PBS supplemented with 0.1% glucose (Compared using a 
GLM with survival as the response factor; PBS: F7=1.58 p=0.327, PBG+0.1% Glucose: F7=2.13 
p=0.239) (Figure 5.2). 
 
Figure 5.2 The percentage survival of the parental strains STIB247 and STIB386 over a time 
course in serum free PBS and PBS supplemented with 0.1%. The standard error of the mean is 
shown (n=2).  
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After discounting PBS as the sole determining variable involved in survivorship in the original 
assay, the response of trypanosomes in buffer with serum was investigated for several lines to 
quantify the differences between the PBS and modified HMI9 buffer assay.  Assays were 
performed for the same 4 hour time course utilised in the original assay for both PBS with 0.1% 
glucose and modified HMI9. Trypanosomes exposed to foetal bovine serum (FBS) grew equally 
well in PBS with glucose and HMI9 buffer (Figure 5.3a). As expected, trypanosomes exposed to 
human serum showed varying amounts of death after 4 hours (Figure 5.3b).  However, the 
survivorship seen in the PBS buffered assays in the presence of human serum was considerably 
lower. For example, the parental group 2 T. b. gambiense strain STIB386 cells derived from the 
same mouse passage showed approximately 45% survival after four hours exposure to human 
serum in modified HMI9 but less than 10% survival after exposure in the PBS with glucose buffer.  
This indicates that while the buffering of cells in PBS does not directly cause cell death, it does 
increase the effects of human serum on the strains. 
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Figure 5.3a The percentage survival of the parental strains STIB247 and STIB386 and several 
progeny after 4 hour exposure to 25% FBS in both PBS with 0.1% glucose and modified HMI9 
buffer. The standard error of the mean is shown. 
Figure 5.3b The percentage survival of the parental strains STIB247 and STIB386 and several 
progeny after 4 hour exposure to 25% human serum in both PBS with 0.1% glucose and modified 
HMI9 buffer. Standard error of the mean is shown. 
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5.2.2 Differences between PBS & HMI9 buffers that may contribute 
to the phenotype 
There are clear differences in the degree of lysis in the presence of human serum between PBS 
with glucose and the modified HMI9 buffer.  Several factors were examined in order to investigate 
which may be contributing to the differences in phenotype response. A prime candidate that 
could be involved in the increased cell death by human serum between PBS and HMI9 was final 
glucose concentration.  The PBS used in the original assays used 0.1% glucose by volume.  It is 
known that low glucose concentration can cause death in trypanosomes with a phenotype 
superficially similar to human serum lysis, exhibiting gross changes in morphology and a swollen 
internal vacuole (Ter Kuile & Opperdoes, 1991).  In the case of glucose starvation though, this 
large vacuole is comprised of a large vesicle at the flagellar pocket rather than swelling of the 
lysosome that is caused by the presence of normal human serum.  Supplementing PBS with 
glucose greater than that present in modified HMI9 (≈0.5% by volume) resulted in the same 
increased sensitivity to human serum when in PBS compared to modified HMI9 buffer (Figure 
5.4). This result suggests that lack of glucose is not the determining factor. However both the 
parental line STIB386 and progeny clone number 30 showed higher capacities to resist lysis 
compared to the other lines, suggesting that there may a heritable component that was measured 
by the original QTL analysis (Figure 5.3b & Figure 5.4). 
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Figure 5.4 The percentage survival of the parental strains STIB247 and STIB386 and several 
progeny after 4 hour exposure to 25% human serum in both PBS supplemented with 1% glucose 
and modified HMI9 buffer. The human serum survival assays were normalised against the 
equivalent FBS controls and the standard error of the mean is shown (n=2, except for progeny30 
for which n=1). 
 
A second major difference between PBS and HMI9 that may be a factor is the ionic component of 
the buffer, specifically chloride and calcium ions. It is known that chloride ions are intimately 
involved in the lysis process (Pays et al., 2006).  HMI9 contains considerably more chloride ions in 
the form of CaCl2 then PBS (0.165mg/ml) and this may impact on the osmotic potential of the 
cells.  There was no difference however in lysis between normal PBS with glucose and PBS 
supplemented with the approximate equivalent CaCl2 concentration found in modified HMI9. 
Trypanosomes in both buffers showed lower survival after exposure to human serum then when 
assayed in modified HMI9 buffer (Figure 5.5).  This suggests that these ionic factors are not the 
sole determinant between PBS and modified HMI9. 
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Figure 5.5 The percentage survival of the parental strains STIB247 and STIB386 and two progeny 
after 4 hour exposure to 25% human serum in PBS supplemented with 0.1% glucose and several 
concentrations of CaCl2, in comparison to a modified HMI9 buffer. The human serum survival 
assays were normalised against the equivalent FBS controls and the standard error of the mean is 
shown (n=2). 
 
The original PBS buffered assays featured a brief period of chilling before each experiment 
(maximally one hour).  Trypanosome cells buffered in blood were kept on ice during transport 
between the animal host used to grow the strains and the assay site.  This step was not 
performed in more recent assays. It is possible that the higher degree of killing exhibited by 
human serum in the PBS buffer may be attributable to this chilling period. One hypothesis is that 
lowering the temperature reduces the fluidity of the trypanosome plasma membrane. The period 
of chilling does not have an effect on the survival of trypanosomes exposed to human serum, 
although there is markedly less survival in assays buffered with PBS media rather than modified 
HMI9 (Figure 5.6). 
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Figure 5.6 The percentage survival of the parental strains STIB247 and STIB386 and two progeny 
after 4 hour exposure to 25% human serum in PBS supplemented with 0.1% glucose or modified 
HMI9 buffer. Cells were either assayed immediately after removal from the animal host or 
subjected to a one hour chilling period to mimic the original assay.  The human serum survival 
assays were normalised against the equivalent FBS controls and the standard error of the mean is 
shown (n =2) 
 
In addition to the described factors, cell density and the experimental vessel used (either 1.5ml 
eppendorf or 24 well plate) were also examined for one trypanosome strain. Neither was found to 
have an effect on human serum resistance assays for that strain when buffered in modified HMI9 
(data not shown).  It does not appear that any single difference between the modified HMI9 used 
to culture the cells and the PBS used in the original QTL analysis is key to determining the 
difference in phenotype.  However the use of PBS as a buffer for the original assay appears to 
magnify the lytic effects of human serum, perhaps due to a stress response initiated by a 
combination of various features of PBS.  This suggests that the original QTL identified was unlikely 
to be directly involved in human serum resistance in group 2 T. b. gambiense, but may indicate 
secondary effects linked to the phenotype that can modify it, though it is unclear at this stage 
what these may be. 
5.2.3 Development of a new assay 
As the potential number of assayable differences between modified HMI9 and PBS buffer could 
be vast it was decided to develop a replacement assay using modified HMI9 buffer.  The amount 
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of human serum used for exposure during the assay was maintained at 25%.  In order to 
determine the optimal time course for the new resistance assay, T. b. brucei strain STIB247 and 
group 2 T. b. gambiense strain STIB386 were assayed at various time points to determine when 
the two parents differed most. This time course was limited to a maximum of 8 hours to minimise 
any potential effects of adaptation to culture.  It was shown that the greatest difference between 
survival percentages of the two parental lines in response to human serum occurred at 6 hours 
(data not shown).  
In conjunction with Dr. N Veitch, University of Glasgow, multiple 6 hour survival assays were then 
performed on the parental lines STIB247 and STIB386 ex vivo (Figure 5.7).  The T. b. brucei 
STIB247 proved to be consistently sensitive to lysis caused by short term exposure to human 
serum. The group 2 T. b. gambiense exhibited the characteristic variable phenotype (Gibson, 
1986).  However there is a statistically significant difference between the distribution and mean 
phenotype response between parental lines when analysed by a one-way ANOVA (F16=22.09 p < 
0.01 ). If this difference contains a heritable component when assayed in the progeny then the 
contribution of different alleles can be measured by QTL analysis. 
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Figure 5.7  Percentage survival of several replicates of unselected parasite lines exposed to 
human serum for 6 hours normalised against trypanosomes exposed to foetal bovine serum. The 
assay was buffered in modified HMI9 media. 
5.2.4 Phenotyping hybrids with new assay 
To investigate if the human serum resistance phenotype segregates in the progeny of the 
STIB247/STIB386 cross and to test the feasibility of using a QTL approach to identify the genes 
involved, 25 progeny were assayed using the modified HMI9 buffered 6 hour survival assay.  
Approximately half of these assays were performed by Dr. N Veitch, University of Glasgow.  Unlike 
the phenotype in the progeny previously described in the PBS buffered assays, the phenotypes 
measured using the modified HMI9 media buffer did not clearly segregate into two populations 
(Figure 5.8). Interestingly there are several progeny that show stronger expression of the human 
serum resistance phenotype then the STIB386 parent. This indicates transgressive segregation in 
which some progeny have possibly lost detrimental alleles during recombination and is evidence 
for a complicated  multi-gene response (Rieseberg et al., 1999). 
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Figure 5.8 The percentage survival of different clones of progeny from the T. b. brucei STIB247 
and group 2 T. b. gambiense STIB386 cross exposed to human serum (blue). The parental lines are 
also shown, STIB247 (green) and STIB386 (red) to highlight the transgressive segregation effect. 
Survival was assayed using the survival of cells visualised by microscopy. The experiments were 
buffered in modified HMI9 media. The standard error of the mean for each strain is shown, except 
for progeny 332 in which n=1 and the addition of further replicates has not been possible. 
 
The mean percentage survival of the progeny is statistically different from each other using a one-
way ANOVA (F65=2.57, p=0.004) and there is greater variation between progeny than within 
biological replicates (R2=56.79%).  This indicates that there is a genetic component to the 
phenotype.   
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Analysis by P. Johnson, University of Glasgow has indicated that the most likely estimated 
heritable component for the phenotype in the progeny is 61% with a 95% confidence interval 
being approximately 35% to 84% (Figure 5.9).  This evidence also strongly suggests the presence 
of a heritable component that would facilitate examination of the phenotype by QTL analysis. 
 
Figure 5.9 The estimated probability density of the relationship between phenotype for several 
values of heritability (P. Johnson, University of Glasgow).  Repeat progeny assays were treated as 
twins and intra-clone variance was assumed to represent the environmental component of the 
phenotype.  Different progeny clones were treated as siblings compared to each other and inter-
progeny variance used to predict the genetic component.  A standard inheritance model 
(Vg/(Vg+Vt) where Vg = genetic variance and Vt = total variance of the trait) was used to estimate 
the probability density that several heritability values fit the model (red).  The mean value is 61% 
with a 95% confidence interval of approximately 35% to 84%. In addition a standard inheritance 
model including the parents (blue) and a non-standard model 2Vb(2Vb+Vw) (black) was also 
considered.  The non-standard model is a custom formulation by P. Johnson, University of 
Glasgow in which Vb is the variance between progeny and Vw is variance within. 
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5.2.5 QTL Analysis 
Linkage analysis was performed as a quantitative trait where no assumptions are made as to the 
number of loci involved using the group 2 T. b. gambiense genetic map (Cooper et al., 2008). 
Genome wide linkage analysis was performed using the mean percentage survival of progeny 
after a 6 hour exposure to human serum. Intra-strain variance was included in the analysis to take 
non-genetic effects into account.  Analysis of the 127 markers covering the 11 mega-
chromosomes of T. b. gambiense identified one marker on chromosome 8 that has significant 
genome-wide linkage (P < 0.001) to the phenotype (Figure 5.10).  
Figure 5.10 Genome-wide interval mapping analysis of human serum resistance. The likelihood 
ratio statistic is a measure of the significance of the linkage. The markers of the 11 chromosomal 
linkage groups are positioned sequentially along the horizontal axes with distances given in cM. 
There are between 7 and 24 markers per chromosome. The dashed line represents the threshold 
p = 0.001 (the probability of obtaining the LRS by chance from 1000 permutations, equivalent to 
LOD = 3.0). 
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Strongest linkage is found at microsatellite marker TB8/21 (Cooper et al., 2008). The locus is 
estimated to account for 53% of the heritable variance seen in the human serum resistance 
phenotype between the progeny using MapManager QTX (Manly et al., 2001). These results were 
confirmed using an alternative QTL approach of linear regression by QTL express (Seaton et al., 
2002) (data not shown). The identified locus spans 94,636bp of coding region and covers 30 genes 
(Table 5.1).  The marker is the final chromosomal marker and therefore includes the telomere 
which has not been sequenced. This region may therefore also include non-annotated genes, 
ESAGs or VSGs. No other significant QTLs were identified by whole genome analysis, even when 
the effect on the phenotype associated with the QTL on chromosome 8 was fixed. 
  
Page | 110  
 
Table 5.1   Annotated genes found within the identified QTL on chromosome 8 
Name Description 
Tb927.8.8060 UDP-Gal or UDP-GlcNAc-dependent glycosyltransferase 
Tb927.8.8070 Hypothetical - expressed in procyclic form 
Tb927.8.8080 UDP-Gal or UDP-GlcNAc-dependent glycosyltransferase 
Tb927.8.8090 UDP-Gal or UDP-GlcNAc-dependent glycosyltransferase 
Tb927.8.8100 UDP-Gal or UDP-GlcNAc-dependent glycosyltransferase 
Tb927.8.8110 Hypothetical - zinc finger-like protein 
Tb927.8.8120 Hypothetical - GPI signal peptide, localised to plasma membrane 
Tb927.8.8130 Hypothetical 
Tb927.8.8140 Small GTP-binding rab protein 
Tb927.8.8150 Hypothetical -(De Maio, 1999) localised to plasma membrane 
Tb927.8.8170 Hypothetical - localised to mitochondrial RNA binding complex 1 
Tb927.8.8180 Hypothetical - localised to mitochondrial RNA binding complex 1 
Tb927.8.8190 Hypothetical 
Tb927.8.8200 Hypothetical – present in flagellum proteome 
Tb927.8.8210 Hypothetical 
Tb927.8.8220 Amino acid transporter 
Tb927.8.8230 Amino acid transporter 
Tb927.8.8240 Amino acid transporter 
Tb927.8.8250 Amino acid transporter 
Tb927.8.8260 Amino acid transporter 
Tb927.8.8270 Hypothetical - PDEase-like 
Tb927.8.8280 Hypothetical 
Tb927.8.8290 Amino acid transporter AATP5 
Tb927.8.8300 Amino acid transporter 
Tb927.8.8310 Chaperone protein DnaJ 
Tb927.8.8320 Hypothetical 
Tb927.8.8330 Calpain 
Tb927.8.8340 Hypothetical 
Tb927.8.8350 Mitotic centromere-associated kinesin (MCAK) 
Tb927.8.8360 Receptor-type adenylate cyclase GRESAG 4 
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5.3 Discussion 
From these data it was not possible to determine any one factor that contributed to the increased 
human serum mediated cell lysis observed in PBS buffered assays compared to the equivalent 
modified HMI9 buffered assays.  Such a large difference in survival may mask any possible linkage 
to the phenotype in question and casts considerable doubt on the conclusions of the first QTL 
analysis. In addition, the low survivorship was not revealed by the RedDead/Syto 10 fluorescent 
assay so it was determined that it was not suitable for this particular phenotype.  However the 
linkage to chromosome 2 identified is statistically robust and several genes in the locus may be 
involved in the phenotype response, even if the phenotype is not directly related to lysis by 
human serum.  There was no killing effect shown by the PBS buffer in the presence of FBS 
indicating that by itself PBS is not toxic to trypanosomes in the short-term. However, when 
trypanosomes are subjected to the presence of human serum, the added stressful effects 
imposed by the PBS buffer become apparent. 
It would appear that a combination of the dual stresses of human serum and the PBS buffer is the 
phenotype being measured by the original fluorescence assay. If the response is largely mediated 
by stress, the most likely candidate to explain the trait is not the gene for the cell surface receptor 
ISG65 but the adjacent heat shock protein gene, HSP78. Different homologues of this gene 
segregate within the progeny in a manner identical to ISG65 and heat shock proteins are strongly 
implicated in responses to many stressful factors (De Maio, 1999; Maresca & Carratu, 1992).  They 
are also usually transcription factors so may affect the expression of the genes responsible for the 
resistance mechanism found in group 2 T. b. gambiense. While HSP78 protein has been described 
as involved with a thermotolerance in yeast, its function in T. brucei is unknown (Krzewska et al., 
2001). It is also possible that any of the other 28 genes within the originally identified QTL 
contribute to the phenotype but this is outside of the scope of the thesis. 
The possible linkage that the identified region of chromosome 2 and HSP78 has to a buffer-
mediated stress response is interesting in that it increases the sensitivity of resistant strains to 
human serum. If HSP78 was validated by reverse genetic approaches to genuinely increase 
sensitivity to human serum then either drugs targeted to modify function of the protein or 
alternatively factors in the host bloodstream could be modified to initiate the HSP78 stress 
response and possibly allow the normal lytic factors to kill the parasite. Unfortunately heat shock 
proteins are a large ancestral gene family found throughout the eukaryotes and it is unlikely that 
a therapeutic agent would be specific enough to target just trypanosome HSP78. Eliciting the 
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stress response by modifying the host bloodstream is likely to also stress the patient. Finally, the 
process of examining the exact feature of PBS that causes the response is akin to finding a needle 
in the proverbial haystack. A more profitable approach is to utilise an assay that stresses 
trypanosomes less and allows the identification of genes involved directly in resistance to human 
serum in group 2 T. b. gambiense. 
The newly derived assay using a modified HMI9 assay is hypothesised to be less stressful to 
trypanosomes than PBS in the short-term due to the fact that the strains used in these 
experiments can be quickly adapted to the media (L. Sweeny, personal communication).  When 
survival to short-term exposure to human serum was assayed using direct observation in a 
modified HMI9 buffer, the survival phenotype did not segregate in the progeny in a clear manner 
as before. This indicates a more complicated multi-gene mediated response being displayed by 
the progeny than initially believed. There is a strong heritable genetic component that can be 
investigated using QTL analysis, although there is also a non-heritable component.  The variability 
of the phenotype itself is an obvious cause of the non-inheritable component but it is possible 
that some of the phenotype may be attributed to epigenetic effects such as methylation of DNA, 
histone interactions along the chromosome or gene expression differences in a manner similar to 
SRA.  If the QTL approach was applied to a genetic cross involving T. b. rhodesiense for example, 
there would only likely be a low heritable component.  QTL analysis would be unlikely to identify 
the SRA gene directly, although it would highlight genes that respond to SRA, such as those that 
may cause the modification of transport of TLF within the cell shown by some strains when 
expressing SRA f OLI B to A (Oli et al., 2006).  There would also be suggestive trait linkage to the 
area of the genome preceding the sub-telomeric region in which SRA sits. 
In the described investigation using group 2 T. b. gambiense progeny and a HMI9 buffered survival 
assay, a single locus on chromosome 8 was identified using QTL analysis that is associated with 
human serum resistance.  This identified region contains 30 annotated genes, although it may also 
include the un-sequenced telomeric regions that might contain ESAGs, VSGs and other related 
genes. Fine mapping of the region at the sub-telomeric end of the locus will reveal if the telomeric 
region is the cause of the locus.  The process to identify the 3’ limits of the QTL is underway by 
locating extra markers that segregate in the progeny and can be used to further characterise the 
region. However, the DNA sequence in the sub-telomeric regions and telomeres contains many 
repeating structures, making it difficult to design unique PCR primers to these regions (Berriman 
et al., 2005). 
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It is also necessary to reduce the number of candidate genes within the QTL to minimise wasted 
effort.  One method to do this is to define specific properties, motifs or features of genes that 
might be required for the phenotype in group 2 T. b. gambiense. Unlike group 1 T. b. gambiense, 
the group 2 T. b. gambiense strain STIB386 has been shown to bind and internalise TLF (Chapter 
3). It is possible that the proteins involved in the human serum resistance phenotype interact 
with one or more of the TLF components in a similar manner to SRA (Xong et al., 1998). In order 
to perform this function, any putative inhibitory protein must be found on the cell surface or be a 
component of the endocytic pathway, to facilitate interaction with the serum lytic components. 
Of the 30 genes in this region, 12 appear to encode for proteins that have either signal peptides, 
transmembrane domains or GPI anchors, all of which are indicative of a cell surface location and 
as such are considered candidate genes.  Several hypothetical proteins of unknown function may 
be important to the phenotype and need to be further characterised.  None of the 30 genes in the 
region have significant homology to the SRA gene found T. b. rhodesiense although due to the fact 
the locus also includes the telomeric regions the presence of an SRA-like gene in the telomere 
cannot be ruled out and it is possible that an SRA-like gene sits in the telomere of chromosome 8. 
However, expression site switching has not been implicated in group 2 T. b. gambiense serum 
resistance (Chapter 3) suggesting that the expression of the resistance phenotype is not due to a 
gene in an telomeric expression site but rather due to variable expression of a gene in the non-
telomeric regions of the mega-chromosomes. 
The locus identified on chromosome 8 contributes to 53% of the heritable portion of the 
phenotype. This indicates that one or more other loci are also involved in determining the human 
serum resistance phenotype. Whilst these loci could lie in one of the regions of the genome not 
represented in the genetic map, there are also several suggestive linkages spread throughout the 
genome that may represent the location of loci involved to a lesser degree then the chromosome 
8 locus although the power of the QTL would need to be improved with the addition of extra 
progeny to confirm these suggestive loci. Despite the presence of a variably expressed human 
serum resistance phenotype in group 2 T. b. gambiense, there is still a significant heritable 
component involved.  Approximately 61% of the difference in the phenotypes of the progeny can 
be explained by these hereditable factors.  These may be alleles or genes that need to be present 
to activate the variable component of resistance or alternatively alleles that are activated by the 
variable component. Any of these genes that are linked to the heritable component of human 
serum resistance in group 2 T. b. gambiense would make suitable targets for therapeutic 
opportunities. 
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The identification of a human serum resistance related QTL in group 2 T. b. gambiense  has 
provided preliminary evidence for the existence of a genetic basis for the phenotype, although 
the work has been limited by time and the difficulties of formulating a new assay.  The addition of 
more progeny to the study will improve the power of analysis and clarify the suggestive loci 
identified in addition to the chromosome 8 locus by the QTL analysis. A further 25 progeny have 
been created during the process to improve the group 2 T. b. gambiense genetic map (A. Cooper, 
unpublished data). They have been genotyped and are available for phenotyping and inclusion in 
QTL analysis at a future date. In addition, the loci identified on chromosome 8 by QTL analysis can 
be used to inform and select candidate genes received from ongoing transcriptomics studies 
between the isogenic sensitive and resistance group 2 T. b. gambiense strain STIB386.  A number 
of genes have been shown to be differentially expressed between sensitive and resistant STIB386 
using Digital Gene Expression (DGE) assays (N. Veitch, unpublished data). One candidate gene in 
particular, Calpain, lies within the identified QTL and is being taken forward for analysis by reverse 
genetics. Calpain is a proteolytic protein found in the lysosome of trypanosomes, although the 
substrate is unknown.  This gene could not have been predicted to be involved in human serum 
resistance based on homology to other eukaryotic systems. This shows the power of utilising 
combinations of forward genetics approaches to identify novel genes for reverse genetics studies 
in a parasitic organism.  
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Chapter 6: The genetic relationship 
between the two groups of T. b. 
gambiense in Côte d’Ivoire 
6.1 Introduction to the relationships between T. b. gambiense 
Investigating questions concerning the human serum resistance phenotype in T. b. gambiense is 
complicated in that there are two distinct groups that differ in genetics and phenotype (Gibson, 
1986).  Group 1 T. b. gambiense causes chronic infections, is invariably human serum resistant 
and is by far the more prevalent group.  It appears to be largely a disease limited to humans, 
although some animal reservoirs have been described (Felgner et al., 1981; Gibson et al., 1978; 
Mehlitz et al., 1982).  Group 2 T. b. gambiense is more virulent and exhibits a variable resistance 
mechanism similar to T. b. rhodesiense (Mehlitz et al., 1982; Zillmann et al., 1984), although it 
does not involve the SRA gene and appears not to involve expression site switching (Chapter 3).  
This group of T. b. gambiense has only been described in Côte d’Ivoire and always in geographical 
areas that overlap with that of group 1 T. b. gambiense (Gibson, 1986). No modern analysis using 
microsatellite markers of these field populations has been performed so the relationship between 
T. b. brucei and group 1 and 2 T. b. gambiense is currently unknown.  One hypothesis for the 
origin of group 2 T. b. gambiense is that it arose due to a rare mating event between group 1 T. b. 
gambiense and T. b. brucei.  This would explain how some group 2 T. b. gambiense have come to 
possess the diagnostic group 1 T. b. gambiense gene TgsGP (Radwanska et al., 2002) and why the 
group 2 T. b. gambiense strain STIB386 possesses both a T. b. brucei-like HpHbR allele and a group 
1 T. b. gambiense-like allele (Chapter 3). It would also reveal why group 2 T. b. gambiense foci 
have only arisen where there are group 1 T. b. gambiense.   If this hypothesis is true then the 
population structure of a geographical focus containing T. b. brucei and both group 1 and 2 T. b. 
gambiense would be expected to show a degree of similarity between the three populations, with 
shared alleles between them.  This would also mean that the human serum resistance 
mechanisms in both groups of T. b. gambiense are likely to be the same, although it is variably 
expressed in group 2 parasites.  An alternative hypothesis is that group 2 T. b. gambiense is an 
extended host variant strain of T. b. brucei that is distinct from group 1 T. b. gambiense and 
possesses a novel human serum resistance mechanism. In this case there will be little overlap 
with alleles between the group 1 and 2 T. b. gambiense populations.  This situation is paralleled in 
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T. b. rhodesiense foci in which the dominant human serum resistance mechanism is SRA, although 
several human infective but SRA-negative T. brucei isolates have been described from the same 
geographic region (De Greef et al., 1989; Enyaru et al., 2006). 
Most research on T. b. gambiense field populations has focused on the more prevalent group 1. 
Previous studies with isoenzymes and AFLP have indicated that group 1 T. b. gambiense 
populations exhibit low genetic variation and are distinct from the local T. b. brucei population 
(Gibson et al., 1980; Godfrey & Kilgour, 1976; Mathieu-daude & Tibayrenc, 1994; Mehlitz et al., 
1982; Stevens & Tibayrenc, 1996; Tait et al., 1984; Zillmann et al., 1984).  This would appear to 
confirm theories that group 1 T. b. gambiense possesses a clonal population structure, despite the 
limitations inherent in the studies due to small sample number, limited diagnostic markers and 
little variation in those markers.  More modern and comprehensive microsatellite genotyping 
techniques have since been utilised to confirm that group 1 T. b. gambiense populations are 
indeed clonal and distinct from local T. b. brucei populations (Koffi et al., 2009; Morrison et al., 
2008).  It was also shown that while group 1 T. b. gambiense are clonal at several disease foci, 
they are distinctly different between geographic locations (Morrison et al., 2008). This may be 
because group 1 T. b. gambiense was more prevalent in the past but has now been reduced to 
genetic “islands” that have diverged due to random mutation.  Alternatively the situation may 
have arisen as a result of the natural spread of the disease if this occurred in a stepwise manner. If 
transfer to new foci was limited, a founder effect would lead to diverging genotypes at each focus 
by random mutation.  A less likely explanation is that an invariant human infectivity trait has 
evolved on separate occasions.  Data presented in this thesis show that SNPs in the ORF and 3’ 
UTR of the HpHbR receptor involved in TLF-1 uptake are identical between group 1 T. b. 
gambiense from different countries, which would suggest a common ancestor rather than this 
particular human infectivity arising on multiple occasions (Chapter 3). 
Several diagnostic tests have been described to distinguish between group 1 T. b. gambiense and 
other T. brucei. Initially a blood incubation infectivity test (BIIT) was considered sufficient 
(Rickman & Robson, 1970; Targett & Wilson, 1973).  Trypanosomes were exposed to human 
serum and then inoculated into a number of rodents.  If all of the rodents become infected then 
the isolate was considered invariably resistant and deemed to be a group 1 T. b. gambiense. If 
only some rodents become infected then the resistance phenotype was considered variable and 
the strain a group 2 T. b. gambiense.  If no rodents become infected then the strain was 
considered to be fully sensitive and a T. b. brucei.  There are of course inherent problems with this 
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assay technique when trying to apply it for quick and easy identification of the different T. brucei 
sub-species in the field. A more formalised and rapid test to identify group 1 T. b. gambiense was 
the card agglutination test for trypanosomiasis (CATT).  This exploits the appearance of antibodies  
to variable antigen type (VAT) LiTaT 1.3 that is usually found in patients infected by group 1 T. b. 
gambiense (Magnus et al., 1978). However, it was subsequently found that LiTaT 1.3 is absent 
from some group 1 T. b. gambiense populations in Cameroon and so is not truly diagnostic for the 
sub-species (Dukes et al., 1992).  While the CATT has proven useful for monitoring outbreaks at 
some group 1 T. b. gambiense foci, T. b. gambiense infections were found in patients that were 
CATT negative in northern Uganda. This was blamed on the low sensitivity of the CATT and this 
must be considered when using it to monitor disease (Enyaru et al., 1998).  A second diagnostic 
marker proposed was PCR with primers sensitive to the T. b. gambiense-specific flagellar pocket 
glycoprotein (TgsGP) gene (Radwanska et al., 2002). This gene was found to be conserved in all 
group 1 T. b. gambiense and appears to have evolved from VSG Tb10.v4.0178 (Gibson et al., 
2010). The function of the gene is unknown although it was initially believed to be involved in 
human serum resistance in T. b. gambiense until experiments ectopically expressing TgsGP in T. b. 
brucei did not confer resistance to human serum (Berberof et al., 2001).  The use of TgsGP PCR as 
a diagnostic for group 1 T. b. gambiense is hampered by the fact that some, but not all, group 2 T. 
b. gambiense are also positive for the gene (Radwanska et al., 2002). This would suggest that 
group 1 and group 2 T. b. gambiense are related, although information concerning the 
relationship between the two groups is sparse. 
There have been some field studies investigating the population genetics of group 2 T. b. 
gambiense, usually as a side effect of examining group 1 T. b. gambiense. The group 2 clade was 
proposed after it was noted that some human infective T. b. gambiense in a Côte d’Ivoire focus 
showed greater genetic variation and appeared more similar to local T. b. brucei (Gibson et al., 
1980; Godfrey & Kilgour, 1976; Mathieu-daude & Tibayrenc, 1994; Mehlitz et al., 1982; Stevens & 
Tibayrenc, 1996; Tait et al., 1984; Zillmann et al., 1984).  The greater variation in genetic markers 
and similarity to the T. b. brucei population suggested that group 2 T. b. gambiense may also be 
genetically competent, in contrast to the clonal group 1 T. b. gambiense population in which there 
is no evidence for genetic recombination.  The possibility that different mating structures may 
exist in the two groups of T. b. gambiense has implications in evaluating the relationships 
between them and the evolution of traits in the population, including human infectivity.  It is 
possible that this trait has evolved twice in separate populations of the T. b. gambiense or 
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conversely evolved once but due to mating events has become invariant in group 1 and variable in 
group 2 T. b. gambiense. 
Like other protozoan parasites, T. brucei can undergo mating but it is not obligatory (Sternberg et 
al., 1988; Tait, 1980; Tait & Turner, 1990). Also when mating does occur, recombinant products of 
self-fertilisation can be found (Tait et al., 1996). These genetic features led to several population 
structures in the field; clonal (Mathieu-daude & Tibayrenc, 1994; Morrison et al., 2008), epidemic 
(Hide et al., 1994; MacLeod et al., 2000; MacLeod et al., 2001; Stevens & Tibayrenc, 1996) and 
panmictic (Tait, 1980).  These different population structures can have an effect on human 
infectivity in a focus.  For example, T. b. rhodesiense isolates in Uganda exhibit a distinct clonal 
population despite occurring in a background of a larger mating T. brucei population (MacLeod et 
al., 2000). In a separate T. b. rhodesiense focus in Kenya, the T. b. rhodesiense and T. b. brucei 
populations were found to be genetically similar, although the T. b. rhodesiense isolates had less 
genetic variation (Tait et al., 1985). These facts would suggest that T. b. rhodesiense is a host 
variant of T. b. brucei that undergoes clonal expansion when the SRA gene is transferred into an 
ecologically advantageous genetic background although the apparent lack of variability could be 
due to sampling from a restricted subset of hosts that the parasite infects.  If T. b. rhodesiense is 
indeed a host variant T. b. brucei then this would have important implications on disease control 
due to evidence for mating occurring in some T. b. brucei populations (Hide et al., 1994; MacLeod 
et al., 2000; Stevens & Tibayrenc, 1996; Tait, 1980). Up to 18% of infected cattle in a disease focus 
carry SRA positive T. b. rhodesiense (Welburn et al., 2001), allowing for the possibility of re-
assortment of the genotypes associated with SRA and increasing the chance of new epidemics to 
emerge by allowing more virulent strains to evolve.  Answering the question of whether T. b. 
gambiense also undergoes mating in the field is becoming more urgent as the geographical ranges 
of the two human infective sub-species, T. b. gambiense and T. b. rhodesiense, move closer 
together in Uganda (Fevre et al., 2005; Picozzi et al., 2005). If mating can occur between T. b. 
gambiense and T. b. rhodesiense, either directly or via a T. b. brucei intermediate, this could lead 
to the generation of a new hybrid sub-species that has multiple human serum resistance 
mechanisms. More importantly, the two sub-species show different tolerances to trypanosome 
treatment options and, if mating is possible, it will raise the possibly that any hybrid generated 
would be highly tolerant to several drug families (Barrett et al., 2003).   
This chapter uses microsatellite genotyping techniques to investigate the population structure of 
a collection of T. brucei isolates from a T. b. gambiense focus in Côte d’Ivoire collected by D. 
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Mehlitz, Freie Universität Berlin. The isolates have been characterised by BIIT and defined as 
group 1 T. b. gambiense (fully resistant), group 2 T. b. gambiense (intermediate resistance) or T. b. 
brucei (fully sensitive) (Table 6.1).  In addition, the T. b. gambiense reference strain DAL972 was 
also analysed (Jackson et al., 2010). All of these samples have been collected from a similar time 
period (1978 – 1983) and from the same geographic area (Daloa, Côte d’Ivoire).  This large 
collection of isolates allows analysis of the population structure of the sub-species present in this 
geographic area at this time point and to possibly elucidate the relationships between them, 
especially those between group 1 and 2 T. b. gambiense and the implications for the evolution of 
the human infectivity trait. 
 
Table 6.1  The T. brucei collection sorted by serum resistance phenotype, indicating isolate 
name, host, phenotype and the predicted sub-species & group based on a 5 rodent BIIT 
performed by D. Mehlitz, Freie Universität Berlin. The presence/absence of the TgsGP gene was 
confirmed by a diagnostic PCR performed alongside the genotyping process. 
Isolate Host HSR Phenotype Predicted sub-species from BIIT TgsGP 
MHOM/CI/78/TH112 Human I Group 2 
MHOM/CI/78/TH170 Human I Group 2 
MKOK/BF/80/KK1 Kob I Group 2 
MKOK/BF/80/KK17 Kob I Group 2 
MHOM/CI/78/TH149 Pig I Group 2 
MSUS/CI/78/TSW100 Pig I Group 2 
MSUS/CI/78/TSW158 Pig I Group 2 
MSUS/CI/78/TSW168 Pig I Group 2 
MSUS/CI/78/TSW182 Pig I Group 2 
MSUS/CI/78/TSW190 Pig I Group 2 
MSUS/CI/78/TSW209 Pig I Group 2 
MSUS/CI/78/TSW308 Pig I Group 2 
MSUS/CI/78/TSW77 Pig I Group 2 
MBOI/BF/80/TC125 Cattle R Group 1 
MBOI/BF/80/TC126 Cattle R Group 1 
MHOM/CI/78/TH126 Cattle R Group 1 
MHOM/CI/78/DAL069 Human R Group 1 
MHOM/CI/78/DAL072A Human R Group 1 
VAVOUA/83/DAL542 (Adzam) Human R Group 1 
VAVOUA/84/DAL740 (Brazo) Human R Group 1 
GAGNEA/83/DAL595 (Kide) Human R Group 1 
DALOA/83/DAL598 (Kosu) Human R Group 1 
DALOA/83/DAL642 (Lisa) Human R Group 1 
DALOA/83/DAL645 (Mago) Human R Group 1 
DALOA/83/DAL403 (Sakon) Human R Group 1 
DALOA/83/DAL633 (Seval) Human R Group 1 
BOUAFLE/83/DAL587 (Yage) Human R Group 1 
MSUS/CI/78/TSW 115 Pig R Group 1 
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Table 6.1 continued 
MSUS/CI/78/TSW175 Pig R Group 1 
MALC/BF/80/AB14 Hartebeast S T.b.brucei 
MHOM/CI/78/TH1-032 Human S Group 2 
MKOK/BF/80/KK14 Kob S T.b.brucei 
MKOK/BF/80/KK18 Kob S T.b.brucei 
MKOK/BF/80/KK26 Kob S T.b.brucei 
MKOK/BF/80/KK33 Kob S T.b.brucei 
MKOK/BF/80/KK7 Kob S T.b.brucei 
MSUS/CI/78/TSW065-022 Pig S T.b.brucei 
MSUS/CI/78/TSW113 Pig S T.b.brucei 
MSUS/CI/78/TSW178 Pig S T.b.brucei 
MSUS/CI/78/TSW187 Pig S T.b.brucei 
MSUS/CI/78/TSW19 Pig S T.b.brucei 
MSUS/CI/78/TSW196 Pig S T.b.brucei 
MSUS/CI/78/TSW332 Pig S T.b.brucei 
MKOD/BF/80/KD3 Waterbuck S T.b.brucei 
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6.2 Results 
6.2.1 Microsatellite Genotyping 
There have been several studies examining the population structure of group 1 T. b. gambiense 
that have revealed foci to be largely clonal (Koffi et al., 2009; Morrison et al., 2008). However, 
very little is known about the relationship between group 1 T. b. gambiense and either local T. b. 
brucei or group 2 T. b. gambiense.  The relationships between these populations may reveal if the 
human serum resistance phenotype in T. b. gambiense is likely to have evolved once or separately 
in each group.  This study used 6 polymorphic microsatellite markers (PCR conditions and primer 
sequences are given in Chapter 2: Materials & methods) for 43 samples to investigate the 
relationships between the group 1 and 2 T. b. gambiense and T. b. brucei populations at a focus 
present in Côte d’Ivoire in the early 1980s.  All 6 markers are polymorphic, featuring several 
alleles at each locus (Appendix 5).  If random mating is occurring within the Côte d’Ivoire 
population then the number of heterozygous genotypes within the population should be a 
predictable proportion based on the number and frequencies of alleles present in the population.  
Most of the markers exhibit heterozygosity rates similar to those expected for a randomly mating 
population however there are markers that do not (Table 6.2).  While a perfect match between 
observed and expected heterozygosity at every marker would not be expected in a field 
population due to the presence of some non-random mating, mutation or natural selection, this 
result may also suggest there is a degree of population sub-structuring at this focus that may be 
due to separate populations of T. b. gambiense and T. b. brucei. 
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Table 6.2  Polymorphisms and heterozygosity of T. brucei at the Côte d’Ivoire Daloa focus. 
Locus Alleles 
Observed 
Heterozygosity 
Expected 
Heterozygosity 
Ch5/JS2 7 0.442 0.744 
Ch11/110 3 0.279 0.279 
Ch11/51 3 0.233 0.210 
Ch1/18 8 0.837 0.706 
Ch1/D2/7 8 0.372 0.672 
Ch2/PLC 5 0.279 0.539 
 
 
In order to further investigate the possibility of sub-structuring and possible relationships 
between the populations of different T. brucei further, a dendrogram for the focus was created 
using a 6 locus MLG to estimate the genetic distance between each isolate in the library (Figure 
6.1).  This revealed strong bootstrap support indicating a discrete population containing most of 
the isolates characterised as group 1 T. b. gambiense, the group 1 T. b. gambiense strain Eliane 
and the group 1 T. b. gambiense genome reference strain DAL972. The strains identified as T. b. 
brucei and group 2 T. b. gambiense form a separate population distinct from these group 1 T. b. 
gambiense.  There is little bootstrap support for any of the branching nodes within the T. b. brucei 
and group 2 population, suggesting that they are largely indistinguishable from each other in the 
6 locus MLG study.  Additionally, six strains identified by BIIT as being group 1 T. b. gambiense due 
to an invariant human serum resistance phenotype do not cluster with the group 1 T. b. 
gambiense population and instead cluster within the T. b. brucei and group 2 T. b. gambiense 
population.  This may indicate that they are also group 2 T. b. gambiense.  The outlier Tanzanian 
T. b. brucei strain STIB247 shows no similarity to any of the Côte d’Ivoire isolates, as is to be 
expected. 
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Figure 6.1  Dendrogram of multilocus genotypes (MLG) for the T. brucei isolates collected from 
Daloa, Côte d’Ivoire over the period of time 1978-1983 in addition to STIB247, STIB386, DAL972 
and Eliane. Bootstrap values from 100 iterations are indicated for branch nodes with a bootstrap 
value above 10.  Isolates exhibiting invariant human serum resistance by BIIT are indicated in red. 
Those expressing a variable resistance phenotype are highlighted in blue. Human serum sensitive 
lines are indicated in black. 
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6.2.2 TgsGP 
The TgsGP gene is diagnostic of group  1 T. b. gambiense and a simple nested PCR based test can 
reveal the presence or absence of this gene in isolates (Radwanska et al., 2002). While some 
group 2 T. b. gambiense do possess the gene, it is present in all strains of group 1 T. b. gambiense 
(Berberof et al., 2001; Gibson et al., 2010).  In order to determine the identity of the isolates 
characterised as group 1 T. b. gambiense in the sample library by BIIT, PCR using primers for 
TgsGP was performed for the entire collection. This analysis revealed that 13 isolates amplified for 
the presence of TgsGP gene (Table 6.1). One of these has been characterised in a BIIT as a T. b. 
brucei.  Nine of the isolates were previously characterised as group 1 T. b. gambiense and also 
cluster within the discrete group 1 T. b. gambiense population with Eliane and DAL972 in the 6 
MLG dendrogram (Figure 6.1).  Three of these isolates with TgsGP had previously been identified 
as group 2 T. b gambiense due to a variable human serum resistance phenotype in a five rodent 
BIIT. Several isolates that possess an invariant resistance phenotype cluster outside of the main 
group 1 T. b. gambiense population in the 6 MLG dendrogram. None of these isolates possess the 
group 1 diagnostic marker TgsGP. This suggests that these are misidentified group 2 T. b. 
gambiense, despite showing robust resistance to human serum. This could be due to the fact they 
do not possess the characteristic variable phenotype of group 2 T. b. gambiense or perhaps the 
isolates achieved 5 successful rodent infections in the BIIT due to chance. 
As previously mentioned, one isolate identified as T. b. brucei also possesses TgsGP.  This could be 
because even though it is a group 2 T. b. gambiense, it had 5 failed rodent infections in the BIIT by 
chance. Alternatively it could be a T. b. brucei strain that has inherited the TgsGP gene due to 
mating with a group 2 T. b. gambiense. TgsGP has not been shown to be present in T. b. brucei to 
date (Radwanska et al., 2002) but this could be a result of testing T. b. brucei from areas that do 
not possess group 2 T. b. gambiense or the general lack of data for the Côte d’Ivoire focus. Similar 
genes to TgsGP that are derived from the same ancestral VSG are present in some T. b. brucei so it 
is also possible that cross-amplification with primers for this gene explains the perceived presence 
of TgsGP in this T. b. brucei (Gibson et al., 2010).  This indicates that the TgsGP PCR assay is not an 
ideal marker to differentiate between group 1 T. b. gambiense and other T. brucei at the Daloa, 
Côte d’Ivoire focus. 
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6.2.3 Population analysis 
It appears likely from these data that there are several misidentified group 2 T. b. gambiense in 
this isolate collection and that group 2 T. b. gambiense were more prevalent then believed at this 
focus and time point.  In order to perform population analysis and reveal any relationships 
between the two groups of T. b. gambiense, three populations were created based on the new 
data.  Any T. brucei strain isolate in the collection that exhibited a variable human serum 
resistance were added to the group 2 T. b. gambiense population. In addition, the invariably 
resistant T. b. gambiense lines that did not possess TgsGP and clustered outside of the main group 
1 T. b. gambiense population were also included in this group 2 population.  The group 2 T. b. 
gambiense strain STIB386 used extensively in this thesis was also included to give a total of 21 
isolates in this group.  The isolates that clustered into the group 1 T. b. gambiense population with 
Eliane and the T. b. gambiense reference strain DAL972 were placed into the group 1 T. b. 
gambiense population to give a total of 11 isolates. Finally, all of the human serum sensitive T. 
brucei were placed into a T. b. brucei population, of which there were 13. The Tanzanian T. b. 
brucei strain STIB247 was removed from this analysis as it is a genetic outlier.   
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Table 6.3  Nei’s genetic distance between the populations of group 1 and 2 T. b. gambiense and 
T. b. brucei at the Côte d’Ivoire Daloa focus. 
 T. b. brucei Gp 2 T. b. gambiense Gp 1 T. b. gambiense 
T. b. brucei 0.000   
Gp 2 T. b. gambiense 0.052 0.000  
Gp 1 T. b. gambiense 0.516 0.319 0.000 
 
 
Table 6.4   Fst proportion indicating genetic distance between the populations of group 1 and 2 T. 
b. gambiense and T. b. brucei at the Côte d’Ivoire Daloa focus. 
 T. b. brucei Gp 2 T. b. gambiense Gp 1 T. b. gambiense 
T. b. brucei 0.000 
  
Gp 2 T. b. gambiense 0.028 0.000 
 
Gp 1 T. b. gambiense 0.223 0.144 0.000 
 
 
After the establishment of the three populations of T. brucei present at this focus using the 
human serum resistance phenotype, dendrogram and TgsGP PCR, the relationships between 
these populations were further analysed using two statistical tests.  Nei’s genetic distance and FST 
both compare the proportion of the total genetic variance contained in a subpopulation relative 
to the total genetic variance (Nei & Roychoudhury, 1974; Wright, 1978). These statistics indicate 
how similar populations are to each other, with 1 being completely different and 0 being identical.  
Both Nei’s genetic distance and the Fst statistic indicate that the T. b. brucei and group 2 T. b. 
gambiense populations are nearly indistinguishable, but both are distinct from the group 1 T. b. 
gambiense (Tables 6.3 & 6.4).  The group 2 T. b. gambiense population is more similar to the 
group 1 T. b. gambiense than the T. b. brucei, although the overall relationship is weak and may 
be a result of small sample number. As they are so alike, the T. b. brucei and group 2 T. b. 
gambiense populations were then combined for further analysis to determine if there is evidence 
for mating occurring amongst strains within these two populations. 
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Table 6.5  Hardy-Weinberg analysis for the combined population of group 2 T. b. gambiense and 
T. b. brucei at the Côte d’Ivoire Daloa focus. 
Locus DF χ2 Probability Significance 
Ch5/JS2 15 91.034 0.000 P < 0.001 
Ch11/110 3 0.525 0.913 Not Significant 
Ch11/51 3 0.072 0.995 Not Significant 
Ch1/18 28 40.983 0.054 Not Significant 
Ch1/D2/7 15 35.948 0.002 P < 0.01 
Ch2/PLC 10 14.209 0.164 Not Significant 
  
 
 
Table 6.6  Linkage disequilibrium (statistically significant disequilibrium highlighted in bold) 
between pair wise polymorphic loci in the combined T. b. brucei and group 2 T. b. gambiense 
population at the Côte d’Ivoire focus. 
Locus 1 Locus 2 Probability Standard Error 
Ch5/JS2 Ch11/110 0.177 0.013 
Ch5/JS2 Ch11/51 0.096 0.009 
Ch11/110 Ch11/51 0.438 0.009 
Ch5/JS2 Ch1/18 0.011 0.005 
Ch11/110 Ch1/18 0.144 0.017 
Ch11/51 Ch1/18 0.138 0.013 
Ch5/JS2 Ch1/D2/7 0.901 0.012 
Ch11/110 Ch1/D2/7 0.268 0.012 
Ch11/51 Ch1/D2/7 0.739 0.011 
Ch1/18 Ch1/D2/7 0.152 0.023 
Ch5/JS2 Ch2/PLC 0.036 0.008 
Ch11/110 Ch2/PLC 0.975 0.003 
Ch11/51 Ch2/PLC 0.293 0.010 
Ch1/18 Ch2/PLC 0.048 0.003 
Ch1/D2/7 Ch2/PLC 0.533 0.020 
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One method to determine the degree of mating in a population is to utilise the principles of 
Hardy-Weinberg. The Hardy-Weinberg hypothesis is a theoretical construct that states that the 
allele and genotype frequencies of a population undergoing free and random mating remain 
constant between generations and are in equilibrium.  However, a perfect Hardy-Weinberg 
equilibrium is unlikely to occur in nature due to factors that disturb the equilibrium, such as non-
random mating, mutation, natural selection, limited population size or random genetic drift.  
Despite this, the degree to which allele and genotype frequencies in a population deviate from 
Hardy-Weinberg equilibrium can be calculated to give an indication as to whether mating is 
occurring in a population. Populations closer to Hardy-Weinberg equilibrium are likely to feature 
some degree of mating.  Analysis of the alleles in the combined T. b. brucei and group 2 T. b. 
gambiense population reveal that four of the six markers did not significantly deviate from Hardy-
Weinberg equilibrium (Table 6.5).  The two markers not in equilibrium (JS2 & D2/7) possess a 
large number of alleles relative to the sample size so a Hardy-Weinberg analysis will be less robust 
for these markers. These data are consistent with the hypothesis that some degree of mating is 
occurring between the group 2 T. b. gambiense and T. b. brucei populations.  Hardy-Weinberg 
analysis of the group 1 T. b. gambiense is inappropriate due to the small sample size and markers 
being monomorphic.  
A second method to assess the degree of mating within the combined group 2 T. b. gambiense 
and T. b. brucei population is to estimate the amount of linkage disequilibrium in allele and 
genotype frequencies.  The presence of mating in a population will cause alleles to be inherited in 
an apparently randomly assorted manner and leading to linkage equilibrium between alleles, 
while a population with little mating or strong selection will have similar alleles inherited together 
and exhibit linkage disequilibrium.  This study has revealed that the majority of alleles in the 
combined T. b. brucei/group 2 T. b. gambiense population show significant linkage equilibrium 
(Table 6.6). When combined with the Hardy-Weinberg analysis, there would appear to be some 
degree of re-assortment and mating both between and within the T. b. brucei and group 2 T. b. 
gambiense populations. The group 1 T. b. gambiense alleles are largely monomorphic or 
uninformative so a linkage disequilibrium study is not possible on this population.  However the 
low number of alleles and limited variability present observed with studies of other foci suggest 
that group 1 T. b. gambiense possess a clonal population structure that is separate from that of 
the group 2 T. b. gambiense and T. b. brucei population (Koffi et al., 2009; Morrison et al., 2008). 
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Finally, principal component analysis (PCA) was performed on the isolates using two vector 
genetic distance comparisons (Figure 6.2). PCA performs a multi-dimensional comparison using 
genetic distance between individuals.  The factor that causes the greatest genetic distance 
between individuals in the populations is used for one axis, and the factor that causes the next 
most distance is the other.  In this way the structure of a population can be visualised.  This PCA 
clearly shows that group 1 T. b. gambiense are distinct from the T. b. brucei and group 2 T. b. 
gambiense populations. These two populations however are closely related. 
 
Figure 6.2  Principal component analysis (PCA) of the Côte d’Ivoire T. brucei isolates using a pair-
wise genetic distance comparison between each isolates MLG. The x-axis explains 45.86% of the 
variability in the populations and the y-axis 17.96%, for a total of 63.82%. Isolates are coloured by 
population. 
It would appear from these data that the T. b. brucei and group 2 T. b. gambiense populations 
exhibit some degree of mating, both within and between sub-species. The group 1 T. b. 
gambiense population is clonal and distinct from the sympatric T. b. brucei and group 2 T. b 
gambiense populations.  
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6.3 Discussion 
These data confirm studies from other foci that group 1 T. b. gambiense is clonal (Koffi et al., 
2009; Morrison et al., 2008). The reasons for the clonality of group 1 T. b. gambiense are unclear 
as the genes necessary for meiosis are present (Jackson et al., 2010). There is an intron present in 
the meiotic gene SPO11 in the annotated genome of the group 1 T. b. gambiense strain DAL972 
and it was believed this could disrupt function of the gene.  It has since been revealed that the 
intron is an error in the sequence assembly (C. Duffy, personal communication).  While group 1 T. 
b. gambiense possesses all of the necessary meiotic genes, it is unknown as to whether they can 
be expressed and it may be due to mis-regulation of these genes that the various group 1 T. b. 
gambiense populations have become clonal. Another reason for the low frequency of mating 
observed in group 1 T. b. gambiense is that, due to the limited number of genotypes present, the 
chances of a mixed genotype infection occurring in the tsetse is unlikely. This precludes any 
mating and the effect is compounded by a small animal reservoir and low infection prevalence 
and parasitaemias in humans. The low number of genotypes present could be due to a bottleneck 
effect that occurred to the population in the past or if group 1 T. b. gambiense underwent clonal 
expansion after it gained the human infectivity trait.    A much larger analysis of group 1 T. b. 
gambiense populations, including the vector and reservoir populations, would need to be 
performed to resolve whether clonality arose in this sub-species due to changes in biology or as a 
result of limited available genotypes. 
Despite questions as to how the clonal population structure has developed, these data show that 
the group 1 T. b. gambiense genome reference strain DAL972 is clearly a good representative of 
group 1 strains from this area, although its similarity to isolates from other foci is unknown. 
Unfortunately it was not possible to compare these data to samples analysed for other group 1 T. 
b. gambiense foci due to the necessity to include new microsatellite markers. However, previous 
studies have shown that the MLG in the populations of various group 1 T. b. gambiense foci are 
significantly different from each other (Morrison et al., 2008).  In addition, examination of alleles 
in this study with previous studies indicates that there are few shared alleles at each marker. This 
suggests that this specific Daloa focus possesses a different clonal population of group 1 T. b. 
gambiense to that found in other foci.  Interestingly, this study has also revealed that group 2 T. b. 
gambiense is less rare than originally thought in the 1980s.  Several group 1 T. b. gambiense 
identified by the BIIT now appear to be group 2.  This suggests that the BIIT is not a gold standard 
for differentiating between group 1 and group 2 T. b. gambiense.  Likewise, PCR for TgsGP and the 
CATT for LiTaT 1.3 are also unsatisfactory due to either cross reaction or absence in some group 1 
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T. b. gambiense stocks (Dukes et al., 1992; Radwanska et al., 2002). It may be possible that the 
polymorphisms shown to be present in the HpHbR receptor may serve as a diagnostic test to 
differentiate group 1 T. b. gambiense from T. b. brucei and group 2 T. b. gambiense (Chapter 3). 
Further work must be undertaken to characterise the SNPs identified for further isolates from 
more foci than the three that have been examined to date. 
This study has also shown that STIB386 is a good representative for Côte d’Ivoire group 2 T. b. 
gambiense in that it is distinct from the group 1 T. b. gambiense population and clusters with 
other group 2 T. b. gambiense strains.  Previous studies have suggested that group 2 T. b. 
gambiense are more varied than group 1 and more similar to T. b. brucei (Gibson et al., 1980; 
Godfrey & Kilgour, 1976; Mathieu-daude & Tibayrenc, 1994; Mehlitz et al., 1982; Stevens & 
Tibayrenc, 1996; Tait et al., 1984; Zillmann et al., 1984). As group 2 T. b. gambiense appear highly 
genetically variable, it would seem prudent that further group 2 T. b. gambiense strains must be 
studied in concert with STIB386. However the data presented here show that not only is there a 
large and genetically varied breeding population of group 2 T. b. gambiense, these individuals are 
almost certainly breeding with local T. b. brucei. Indeed, the T. b. brucei and group 2 T. b. 
gambiense populations are largely indistinguishable and differ only in their potential to infect 
humans. Mating between T. b. brucei and group 2 T. b. gambiense has also been shown to occur 
in a laboratory setting (Cooper et al., 2008).  Group 2 T. b. gambiense are more accurately 
described as an extended host range variant T. b. brucei than a T. b. gambiense.  Due to this, T. b. 
brucei and group 2 T. b. gambiense populations are very closely related and both are distinct from 
the group 1 T. b. gambiense population.  Group 2 T. b. gambiense is more closely related to group 
1 than the T. b. brucei are but the association is weak.  This may be because group 2 T. b. 
gambiense arose as a very rare mating event between a group 1 T. b. gambiense and a T. b. 
brucei, or that group 1 and 2 T. b. gambiense arose from a similar progenitor.  The association 
between group 1 and group 2 T. b. gambiense may have then been eroded over time due to 
group 2 T. b. gambiense mating with local T. b. brucei.  Both theories would explain how some 
group 2 T. b. gambiense have come to possess the TgsGP gene.  However, recent evidence has 
emerged that while TgsGP is a true diagnostic feature of group 1 T. b. gambiense, the TgsGP gene 
present in group 2 T. b. gambiense is actually a different derivation of the Tb10.v4.0178 VSG so 
cannot be used as evidence for relationships between group 1 and 2 T. b. gambiense, despite 
being extremely similar and amplifying with the same PCR primers (Gibson et al., 2010).  With 
regards to the human serum resistance mechanisms of the two groups, since it is not possible to 
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establish common heritage between the T. b. gambiense groups, it is prudent to assume that two 
different mechanisms have arisen and the two groups must be studied separately.  
The degree to which mating occurs in a population is an important consideration due to it acting 
as a major source of variation. While the human infectivity trait present in group 2 T. b. 
gambiense may have evolved once, it is now present in a wide range of genetic backgrounds.  This 
is in contrast to group 1 T. b. gambiense which has limited genetic diversity at each discrete 
disease focus and hence a lower capacity to evolve.  The genetic backgrounds of the group 2 T. b. 
gambiense infectivity trait may be in constant flux due to evidence suggesting the presence of 
mating within the population. This increases the possibility that the human infectivity trait will be 
placed into a background that increases its effectiveness, improving the trait by natural selection.   
The evidence suggesting mating between group 2 T. b. gambiense and T. b. brucei also makes it 
feasible that the human infectivity trait can remain in the local T. brucei population undetected, 
even if the disease is removed from the human population.  This is especially likely with the 
human infectivity trait found in group 2 T. b. gambiense as it can be variably expressed. Any 
evolutionary cost of a human infectivity trait that can be activated when needed is potentially 
lower than one that is constitutively expressed. This lack of a constitutively expressed mechanism 
may explain why type 2 T. b. gambiense isolates have been found in a wide variety of hosts, 
including humans, cattle wild deer and rodents, while all of the group 1 T. b. gambiense in this 
study were isolated from human patients.  There is some debate as to the animal reservoir for 
group 1 T. b. gambiense, although domestic pigs are believed to be a possible source (Gibson, 
Mehlitz et al. 1978; Gibson 1986; Paindavoine, Pays et al. 1986).  Several other wild fauna have 
also been shown to carry T. b. gambiense (Njiokou et al., 2006) but it is important to consider how 
these trypanosomes were identified as group 1 – several of the group 1 T. b. gambiense identified 
by the BIIT proved to be actually group 2. Diagnostic tests created using the original BIIT 
determined groups would actually only differentiate between features shared by group 1 T. b. 
gambiense and misidentified group 2 T. b. gambiense. 
An important caveat for these presented data is that the samples were collected over 27 years 
ago.  The study has provided an insight into a snapshot of time in which group 1 and 2 T. b. 
gambiense and T. b. brucei existed in the same geographic range. The current situation however is 
largely unknown.  While African sleeping sickness is still present (Kaba et al., 2006; Koffi et al., 
2009; Koffi et al., 2006), it is impossible to state how the populations of group 1 and group 2 T. b. 
gambiense have changed. Long-term temporal studies have been hampered by the fact that the 
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political situation in Côte d’Ivoire is in constant turmoil (Kaba et al., 2006).  However, the situation 
may improve with the formation of a peace accord between the Unity government and the FNCI 
rebel faction. The opportunity to sample group 1 and 2 T. b. gambiense with T. b. brucei may 
again present itself, allowing temporal comparisons providing important information on how 
group 1 and 2 T. b. gambiense foci develop over time. 
The study presented here, in conjunction with other published data, suggests that human 
infectivity has arisen on at least four occasions. In Eastern Africa the evolution of SRA and the high 
levels of mating occurring there have allowed the human infectivity trait to spread through the T. 
brucei population, generating the T. b. rhodesiense sub-species (MacLeod et al., 2000; Tait et al., 
1985). However, there are also human infective trypanosomes in this area that do not possess 
SRA, suggesting a second novel mechanism (De Greef et al., 1989; Enyaru et al., 2006).  In 
Western Africa, group 1 T. b. gambiense is the dominant form of human African sleeping sickness.  
This group of parasites has evolved a constitutively expressed resistance mechanism that does not 
depend on SRA.  After evolution of this trait, the sub-species appears to have expanded clonally to 
take advantage of the new niches offered by being human serum resistant. Just as in Eastern 
Africa, there is also a human infective T. brucei population separate from the dominant form that 
appears to have a distinct resistance mechanism. This group 2 T. b. gambiense population appears 
to be a host variant T. b. brucei and the human infectivity trait it possesses is freely transmitted 
around the local T. b. brucei population.  The presence of mating amongst group 2 T. b. 
gambiense and T. b. brucei strains makes evolution of new traits more likely and may allow the 
human infectivity trait to be combined with new phenotypes that increase its virulence. The 
possibility of mating between group 1 T. b. gambiense and T. b. rhodesiense appears unlikely due 
to the formers clonal population structure although the population structures of Ugandan group 1 
T. b. gambiense have not been investigated as efforts thus far have concentrated on foci in the 
West of the continent (Koffi et al., 2006; Morrison et al., 2008).  Understanding whether mating 
occurs in the T. b. gambiense focus of Uganda is important due to the fact that the T. b. 
gambiense and T. b. rhodesiense foci are moving closer together (Fevre et al., 2005; Picozzi et al., 
2005). In addition, T. b. rhodesiense mating with group 2 T. b. gambiense is certainly possible if 
the two foci meet and may generate a novel human infective sub-species.  Taken together, all of 
these data indicate that T. brucei has a high zoonotic potential despite specific trypanolytic 
countermeasures that have been inherited by humans. 
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Chapter 7: Final Discussion 
Very little is known about the properties or mechanisms of how the dominant human infective 
sub-species, T. b. gambiense, overcome the innate lytic factors present in humans. Matters are 
complicated in that there are two distinct groups of T. b. gambiense; group 1 T. b. gambiense are 
the more prevalent form and are invariably human serum resistant while the rarer group 2 T. b. 
gambiense exhibit a variably expressed resistance phenotype (Mehlitz et al., 1982; Zillmann et al., 
1984). The resistance mechanism of T. b. rhodesiense regulated by the expression of the serum 
resistance associated (SRA) gene, is not present in either of the two groups of T. b. gambiense so 
they must possess one or more different resistance strategies (Xong et al., 1998). At the start of 
this thesis, it was unknown as to whether the resistance mechanisms used by the two T. b. 
gambiense groups used avoidance, neutralisation (like SRA) or compensatory mechanisms.  
Indeed, it was unclear as to whether the two groups of T. b. gambiense use the same or different 
resistance mechanisms as the relationships between group 1 and 2 T. b. gambiense are poorly 
understood. It has been shown that group 1 T. b. gambiense populations are clonal and distinct 
from locally mating T. b. brucei populations (Koffi et al., 2009; Mathieu-daude & Tibayrenc, 1994; 
Morrison et al., 2008; Stevens & Tibayrenc, 1996). Group 2 T. b. gambiense show isoenzyme and 
AFLP profiles that are more varied and similar to T. b. brucei, suggesting they are undergoing 
some degree of mating (Gibson et al., 1980; Godfrey & Kilgour, 1976; Mathieu-daude & 
Tibayrenc, 1994; Mehlitz et al., 1982; Stevens & Tibayrenc, 1996; Tait et al., 1984; Zillmann et al., 
1984).  This suggests that the two groups of T. b. gambiense are distinct.  This thesis has 
elucidated several features concerning the human serum resistance phenotype in T. b. 
gambiense; including the interactions with the major lytic HDL particle TLF-1, the ability to resist 
lysis by ApoL1, the identification of a genetic locus associated with the resistance trait of group 2 
T. b. gambiense and the relationship between the two T. b. gambiense populations. 
The group 2 T. b. gambiense investigated during this thesis exhibited a variably expressed 
resistance phenotype as expected (Chapter 3).  Both isogenic resistant and sensitive T. b. 
gambiense STIB386 expressed the TLF-1 receptor HpHbR to a similar level (Chapter 3).  Therefore 
the variability of the phenotype was not due to differential uptake of TLF-1. While there was weak 
evidence that the resistant form of STIB386 uptakes TLF-1 more slowly than the sensitive form, 
this was only from one biological replicate due to poor experimental design.  In hindsight, a flow 
cytometry based analysis or multiple screenings from several smaller experiments would have 
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proved more effective in determining differences in rate of TLF-1 uptake then the single large 
experiment that was conducted in this thesis.  In addition to TLF-1, both sensitive and resistant 
STIB386 internalised ApoL1 and trafficked it to the lysosome indicating that the sub-species group 
is variably resistant to ApoL1 and suggests that the resistance mechanism is most likely to lie 
within the late endosomes or lysosome (Chapter 4). While superficially resembling the variable 
resistance phenotype displayed by T. b. rhodesiense, the mechanism does not involve SRA 
(Chapter 3). Previous research has indicated that the resistance phenotype for the group 2 T. b. 
gambiense strain TxTat correlated with a switch in the variable antigen type (VAT) of the parasite 
(Ortiz et al., 1994). This strongly suggested an expression site related mechanism that is similar to 
SRA.  However, doubts have been raised as to whether the TxTat line used in this study is a group 
2 T. b. gambiense or a T. b. rhodesiense (Grab & Kennedy, 2008) and sequencing of the ESAG6/7 
hypervariable regions in the isogenic resistant and sensitive group 2 T. b. gambiense strain 
STIB386 did not reveal any changes in expression site switching that would point towards an 
ESAG/VSG associated phenotype (Chapter 3). However, this interpretation is based on the 
assumption that group 2 T. b. gambiense has a similar ESAG repertoire to that of T. b. brucei. This 
has not yet been demonstrated and it is instead possible that group 2 T. b. gambiense possess a 
restricted ESAG repertoire similar to group 1 T. b. gambiense which would make distinguishing 
between expression sites using the ESAG sequence impossible (Young et al., 2008). Several 
different lines of evidence indicate that this is not likely; including the fact that the population 
structure of group 2 T. b. gambiense suggests that they are genetically indistinguishable from T. b. 
brucei and so are likely to possess a similar varied ESAG repertoire (Chapter 6).  In addition, it has 
been shown that group 2 T. b. gambiense isolates possess more varied metacyclic ESAGs, 
including alleles not found in group 1 T. b. gambiense (Bringaud et al., 2001).  Finally, the ESAG6/7 
genes expressed by the resistant and sensitive group 2 T. b. gambiense are identical to T. b. brucei 
alleles not found in group 1 T. b. gambiense (Chapter 3 & (Young et al., 2008)).  Another 
assumption that was made in order to interpret the sequencing of the ESAG6/7 genes in STIB386 
is that the large ESAG repertoire that T. b. brucei possesses is a feature common across the sub-
species and is likely to be shared with group 2 T. b. gambiense. So far four T. b. brucei lines have 
been investigated, and each shows a large ESAG repertoire suggesting that this is a universal 
feature (Hertz-Fowler et al., 2008; Young et al., 2008).  Despite the evidence suggesting group 2 T. 
b. gambiense possesses a large ESAG repertoire, the exact variability of ESAGs in the group can 
only be elucidated by an intensive sequencing study of genomic ESAGs and this work is currently 
ongoing. 
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Although it appears likely that the group 2 T. b. gambiense resistance mechanism is unrelated to 
the use of particular expression sites, it still exhibits a variable phenotype (Chapter 3).  Many 
eukaryote systems exhibit gene expression stochasticity and while this can be detrimental and is 
usually minimised, it is also useful in allowing organisms to adapt to an unstable and variable 
environment (Kaern et al., 2005).  This is especially applicable to bloodstream form group 2 T. b. 
gambiense in that it can find itself in a large variety of animal hosts with serum of different 
properties. The human host in particular offers the additional challenge of ApoL1 mediated lysis 
(Chapter 6).  Most gene expression stochasticity emerges as a result of complex interactions 
between gene networks (Raser & O'Shea, 2004).  Positive and negative feedback of transcription 
factors and other regulative genes, usually in concert with external promoters, can cause un-
predictable changes to whole gene cascades and create a seemingly random expression of genes 
(Raser & O'Shea, 2004; Volfson et al., 2006).  The phenomenon of gene expression stochasticity in 
eukaryotic systems has largely been limited to theory formation and modelling so very little is 
known about the systems involved.  Recent research with Saccharomyces cerevisiae successfully 
used the inherent “noise” present in the expression of transcription factors to model a large 2000 
gene expression network and predict the stochastic effects (Li et al., 2010).  They also showed 
that the gene expression “noise” is a heritable trait and hence the stochastic pattern is also 
heritable. Nothing is known about gene expression stochasticity in trypanosomes as variable 
expression is intuitively assumed to always involve a change in expression sites. The fact that gene 
expression in trypanosomes is largely regulated by RNA stability conferred by the 3’ UTR provides 
a large amount of expression “noise” to fuel stochastic expression due to random degradation of 
the RNA transcripts (Clayton & Shapira, 2007).  This makes it possible that stochastic networks 
similar to those found in other eukaryotes could exist in T. brucei. Unravelling the complex 
network of transcription factor interactions that cause the random expression of the human 
serum resistance phenotype in group 2 T. b. gambiense poses a daunting task, but information 
gleaned from QTL analysis and comparative transcriptomics will offer an insight into the genes 
that are involved in the putative stochastic network (Chapter 5). 
Interestingly procyclic form T. brucei are able to resist lysis by human serum, indicating that all T. 
brucei sub-species have the ability to vary transcription of genes that are already present and 
become human infective (Moore et al., 1995).  Originally this was believed to be because this life 
cycle stage of the parasite exhibits a 10-fold lower rate of endocytosis relative to bloodstream 
form (Morgan et al., 2001).  However, a procyclic T. b. brucei strain that was genetically modified 
to show comparable rates of endocytosis to bloodstream form remained resistant to killing by 
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human serum (Natesan et al., 2010).  This thesis has indicated that this is due the ability of 
procyclic form T. brucei to resist the effects of the trypanolytic protein ApoL1, even at extremely 
high concentrations of the protein (Chapter 4).  While it was not possible to show that ApoL1 
was internalised by procyclics, the high concentrations of ApoL1 used to overcome the lower 
endocytosis rate did not result in any reduction in the growth rate of the parasites.  The resistance 
mechanism in procyclic forms is unknown but it is interesting that one of the most heavily down-
regulated genes in procyclic forms relative to bloodstream forms is the lysosomal LAMP-like 
protein p67 (Veitch et al., 2010).  When this gene is knocked-down in bloodstream form T. b. 
brucei they become human serum resistant (Peck et al., 2008).  The modified cells also die after 
24 hours, indicating that p67 is an essential gene to bloodstream forms and may indicate why T. b. 
brucei has not evolved to down-regulate p67 expression in the field to be able to infect humans 
(Peck et al., 2008).  How the p67 protein invokes this human serum resistance mechanism is 
unknown.  One potential hypothesis is that it affects lysosomal pH which would in turn stop 
ApoL1 achieving its pore-forming confirmation.  However, knocking-down expression of p67 had 
no affect on lysosomal pH (Peck et al., 2008).  There are size changes and other morphological 
features in the lysosome in p67 knock-down T. b. brucei, although how these contribute to human 
serum resistance is again unknown.  It is also possible that human serum resistance in procyclic 
forms is unrelated to p67. Further investigation into how this interesting phenotype arises may 
reveal a new control method against the parasites when they are in the tsetse host. 
Transcriptome studies comparing isogenic bloodstream form resistant and sensitive T. b. 
gambiense strain  STIB386 have indicated p67 is not significantly differentially expressed between 
these two lines (N. Veitch, unpublished data), so it is unlikely that this is the variable component 
involved in human serum resistance in group 2 T. b. gambiense. 
Whatever the variably expressed element involved in the phenotype in group 2 T. b. gambiense is, 
there is a strong genetic component underlying the resistance mechanism revealed in the 
heritability of the trait (Chapter 5). Quantitative trait loci (QTL) mapping has revealed that a 
significant proportion of the heritable trait is located in a 30 gene region of chromosome 8 
(Chapter 5).  At present this QTL region extends into the telomeric region although efforts are 
underway to fine-map the extent of the region.  The QTL may contain a key component of the 
trait that controls or is controlled by the variable component.  Alternatively it may be a factor that 
needs to be present in order for the resistance trait to function.  Reverse genetics on the 
candidate genes will allow the determination as to which theory is correct.  If the QTL is found to 
extend into the telomeric region the candidate gene could include an ESAG or VSG related gene, 
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although it does not appear as if expression site switching is relevant to human serum resistance 
in STIB386 (Chapter 3).  Fortunately, parallel to the work identifying this QTL, a comparative 
transcriptome comparison experiment was investigating the transcript profiles of the resistant 
and sensitive isogenic group 2 T. b. gambiense strain STIB386 allowing further refinement of the 
candidate genes.  This transcriptome study has revealed over 500 genes differently expressed 
between these lines (N. Veitch, unpublished data).  This is indicative of a complex multi-gene 
network that can cause stochastic gene expression in eukaryotes (Kaern et al., 2005).  However, 
one of the most highly differentially expressed genes, Calpain, lies within the chromosome 8 QTL 
and is now being investigated further.  Trypanosome Calpain is a lysosomal protease with an 
unknown substrate (Liu et al., 2010). It is possible that STIB386 has variations in this gene that 
allow it to either digest the lytic ApoL1 protein, or perhaps has functions that compensate for the 
pores introduced by ApoL1. This work is extremely preliminary but future options include 
sequencing the gene to identify polymorphisms, the utilisation of Calpain inhibitors to investigate 
the phenotype and also ectopically expressing the group 2 T. b. gambiense alleles in a T. b. brucei 
strain to investigate any impact on human serum resistance.  Several other QTL of lower 
significance than the chromosome 8 QTL have also been highlighted (Chapter 5). These may 
indicate genes that are involved in the stochastic expression network and the addition of extra 
progeny to the QTL analysis will likely improve the power of the study and the significance of 
these suggestive QTLs. 
The group 1 T. b. gambiense strain, Eliane, investigated in this thesis invariably expressed the 
human serum resistance phenotype, confirming previous in vivo research. This thesis has shown 
that a trait common to isolates from three different group 1 T. b. gambiense foci is the down-
regulation and loss of function in the high-affinity receptor for TLF-1, HpHbR (Chapter 3).  The 
group 2 T. b. gambiense, T. b. brucei and T. b. rhodesiense strains showed normal expression of 
the HpHbR receptor.  Down-regulation of HpHbR allowed group 1 T. b. gambiense to avoid the 
major lytic particle in humans, TLF-1.  While this may suggest that group 1 T. b. gambiense utilise 
a strategy to avoid lysis by ApoL1, the group 1 T. b. gambiense strain also displayed the ability to 
resist lysis by recombinant ApoL1 despite internalising and trafficking the protein to the lysosome 
(Chapter 4). A potential explanation for this result is that TLF-2 is likely taken into the parasite 
cell due to weak interactions with the cell surface VSG and the IgM normally associated with the 
particle (Vanhollebeke & Pays, 2010).  It is difficult to envisage how group 1 T. b. gambiense 
would be able to avoid the TLF-2 particle in a manner similar to how it avoids TLF-1 so resistance 
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to ApoL1 is expected.  Despite this, why group 1 T. b. gambiense strains have evolved to avoid 
TLF-1 while also being resistant to the lytic component of that particle is unclear. 
Several hypotheses can be put forward to explain why this may be the case.  One is that TLF-1 
evolved in primates before TLF-2 so down-regulating HpHbR was a relatively straightforward way 
to achieve primate infectivity.  However the distribution of TLF-1 and TLF-2 are unknown across 
the primate species so a comprehensive zoological study would need to be undertaken to 
determine which primate species possess each of the two particles.  An alternate hypothesis is 
that the group 1 T. b. gambiense lysosome or the resistance mechanism is more sensitive to the 
un-cleaved and toxic Hpr Signal Peptide (Harrington et al., 2010).  Research into this killing 
mechanism is still preliminary but when trypanosomes are exposed to the Hpr signal peptide it 
integrates into the cell surface membrane to elicit the killing effect (Harrington et al., 2010).  
Group 1 T. b. gambiense are no more sensitive to killing by cell surface peptide integration then 
other T. brucei sub-species.  However, future studies investigating the effects of the Hpr Signal 
Peptide when it is internalised may reveal if group 1 T. b. gambiense is more susceptible if the 
peptide is in the lysosome.  A final hypothesis as to why group 1 T. b. gambiense has reduced the 
uptake of TLF-1 is that the resistance mechanism is not highly efficient and so must limit the 
amount of incoming ApoL1 to a level at which the parasite can either compensate for or 
neutralise the lytic protein.  Exposing group 1 T. b. gambiense to much higher concentrations of 
lytic protein will make it possible gauge if there is a maximal dose that the parasite can cope with, 
and therefore allow testing of this hypothesis.  An alternative test would be to conjugate ApoL1 to 
a nanobody that is easily internalised by T. brucei and investigate whether T. b. gambiense 
parasites taking up ApoL1 at an increased rate are more sensitive to lysis.  This has been 
experimentally investigated with T. b. brucei and T. b. rhodesiense, although the authors do not 
present evidence for the effects of the nanobody conjugate on T. b. gambiense (Baral et al., 
2006).  An important piece of information that emerges from the fact that group 1 T. b. 
gambiense has evolved to reduce uptake of TLF-1 is that this thesis has shown that TLF-2 is 
probably the more important TLF particle in elucidating the resistance mechanism of this sub-
species.  Most studies have previously concentrated on TLF-1 due to the fact the TLF-2 particle is 
extremely difficult to work with. Protocols are now being established to isolate TLF-2 and perform 
similar assays to those already undertaken with TLF-1. 
This thesis has also shown that methods to distinguish between group 1 and group 2 T. b. 
gambiense have proved unreliable under certain conditions or in particular geographic locations.  
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The BIIT falsely identified some group 2 T. b. gambiense as group 1 (Chapter 6). Genes similar to 
the group 1 T. b. gambiense specific gene TgsGP are also found in some group 2 and T. b. brucei 
strains, leading to cross-amplification with TgsGP primers (Gibson et al., 2010; Radwanska et al., 
2002). Finally the LiTat 1.3 based CATT is hampered due to low sensitivity and the fact that in 
some foci of group 1 T. b. gambiense LiTat 1.3 is not expressed (Dukes et al., 1992).  This thesis 
has indicated a polymorphism in the HpHbR gene that is unique to group 1 T. b. gambiense that 
may be useful as a diagnostic marker (Chapter 3). Three separate foci have been investigated in 
Côte d’Ivoire, the Democratic Republic of Congo and Cameroon but further foci will need to be 
added to truly define this as a diagnostic test. In addition, it may prove possible that down-
regulation of the gene rather than sequence variation is the true diagnostic test. More detailed 
investigation into the down-regulation of the gene and the SNPs that confer this effect via the 3’ 
UTR is needed to confirm that this is actually a common feature to the sub-species. Further 
elucidation of the human serum resistance mechanisms in group 1 and 2 T. b. gambiense will 
allow the refinement of diagnostic tests to aid in disease control, just as the identification of SRA 
now aids in the management of T. b. rhodesiense (Welburn et al., 2001).  The existence of SRA-
negative T. b. rhodesiense and the inadequacy of the BIIT, CATT and TgsGP PCR tests will create 
issues when determining treatment options and management of livestock in areas containing 
overlapping sub-species.  This is especially apparent in Uganda where the T. b. gambiense and T. 
b. rhodesiense foci are converging (Fevre et al., 2005; Picozzi et al., 2005).   
Confirming research from other group 1 T. b. gambiense disease foci, the Côte d’Ivoire population 
has proven to be clonal (Chapter 6).  The alleles present are different from other foci, indicating 
that they are distinct from other group 1 T. b. gambiense.  Differences between group 1 T. b. 
gambiense foci have been shown previously and probably arose due to random mutation in the 
clonal population rather than sexual recombination (Morrison et al., 2008).  The reasons for the 
clonal nature of group 1 T. b. gambiense are unknown. The organism possesses all the necessary 
genes for meiosis (Jackson et al., 2010) but it is possible that an inability to express one or more of 
these genes has led to the clonality of the group 1 T. b. gambiense populations.  While T. b. brucei 
and group 2 T. b. gambiense have been shown to be able to undergo mating in a laboratory 
setting, this has not been possible in group 1 T. b. gambiense, suggesting there is a biological 
barrier to mating (Cooper et al., 2008; Gibson et al., 1995; Jenni et al., 1986; MacLeod et al., 
2005b).  An alternate hypothesis for the apparent lack of mating is that the reduced number of 
alleles present in the populations results in a low frequency of mixed genotype infections 
occurring in the tsetse vector.  This low number of alleles may be due to a genetic bottleneck that 
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occurred in the past or the clonal expansion of a successful genotype after it acquired the human 
infectivity trait similar to some T. b. rhodesiense foci (MacLeod et al., 2000). The low genetic 
variability exhibited by group 1 T. b. gambiense and the small animal reservoir should in theory 
make it more vulnerable to targeted treatment.  While group 1 T. b. gambiense treatment has 
largely been hampered in the past due to political instability (Kaba et al., 2006), a targeted drug 
treatment program would have a devastating effect on the parasite due to its reduced inability to 
evolve counter-measures.   
Evidence in this thesis suggests group 2 T. b. gambiense parasites can undergo mating, both 
within the population and with local T. b. brucei (Chapter 6).  In fact, the two populations are 
virtually indistinguishable genetically and group 2 T. b. gambiense is more accurately described as 
an extended host range variant of T. b. brucei than a T. b. gambiense (Chapter 6).  The group 2 
human infectivity trait is likely to have evolved in a T. b. brucei strain but, unlike group 1 T. b. 
gambiense, there was no detectable clonal expansion and the trait has remained in the T. b. 
brucei population at a low level.  This may be due to the fact group 1 T. b. gambiense were 
already present in the primate population so group 2 T. b. gambiense was not able to exploit the 
niche fully.  Alternatively, group 2 T. b. gambiense could have evolved first but due to co-
evolution by primates and competition from group 1 T. b. gambiense it has now decreased in 
number. Despite this, group 2 T. b. gambiense possesses a considerable potential to evolve 
rapidly to overcome drug challenges, unlike group 1.  The problem is compounded in that group 2 
T. b. gambiense use an extensive animal reservoir of both domestic and wild animals (Chapter 6).  
The ability for group 2 T. b. gambiense to undergo mating also raises the potential of a mating 
event with T. b. rhodesiense, either directly or via a T. b. brucei intermediate.  This would create a 
new sub-species with multiple human serum resistance mechanisms but, more importantly, 
increased tolerances to the drugs used in the treatment of the disease (Barrett et al., 2003).  
Resistance to drug treatment options is already reported in some disease foci (de Koning, 2001; 
Maser et al., 2003; Matovu et al., 2001) and recombination and mating between sub-species may 
contribute to this issue.  However, drug tolerances are only described for group 1 T. b. gambiense 
and T. b. rhodesiense so further investigation must be done with group 2 T. b. gambiense to 
determine the drug tolerances of this sub-species group. 
It is hoped that exploiting the natural defence mechanisms that have evolved to combat 
trypanosomes infection will limit the opportunities for the parasite to evolve and overcome 
treatment options.  For example, the increasing understanding of ApoL1 has allowed the 
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formation of several possible treatments for African trypanomiasis.  One such proposed solution 
to African sleeping sickness involves the distribution of transgenic cows expressing either 
recombinant baboon ApoL1 (Thomson et al., 2009) or truncated ApoL1 (Lecordier et al., 2009).  
Both baboon ApoL1 and the truncated ApoL1 have key mutations at the SRA binding site that 
allow them to kill T. b. rhodesiense and mice expressing these genes ectopically are unable to be 
infected by either T. b. brucei or T. b. rhodesiense (Thomson et al., 2009).  Unfortunately this will 
have a limited effect on the human disease across Africa due to the fact that both the baboon and 
truncated ApoL1 used in these experiments are not able to kill T. b. gambiense (Lecordier et al., 
2009; Thomson et al., 2009). T. b. rhodesiense causes less than 10% of human African sleeping 
sickness cases across the continent (WHO, 2006).  Application of these transgenic cows is also 
likely to open new niches for non-SRA T. b. rhodesiense and T. b. gambiense due to the removal of 
not only T. b. brucei and T. b. rhodesiense from the cattle herd, but the more important animal 
trypanosomes T. congolense and T. vivax.  This will need to be considered as the T. b. gambiense 
and T. b. rhodesiense foci in Uganda converge (Fevre et al., 2005; Picozzi et al., 2005). The removal 
of so many competitors to T. b. gambiense as it expands south may result in cattle herds 
predominantly infected not with human serum sensitive species, but with T. b. gambiense.  
Until a variant of ApoL1 can be found that kills group 1 T. b. gambiense it would be prudent to 
advise caution in the use of transgenic cows that would greatly upset the natural populations of 
parasitic species.  There is some tenuous evidence that there are species of baboon that possess 
immunity to T. b. gambiense, although it is unclear if this is due to ApoL1.  In vivo studies 
comparing group 1 T. b. gambiense infections in two different baboon species showed that the 
parasite was able to establish an infection in Papio hamadryas but not Papio papio (Kageruka et 
al., 1991).  These experiments used a very small number of test subjects however so must be 
considered with caution.  As previously mentioned, primate TLF-1 is unlikely to be internalised by 
group 1 T. b. gambiense due to down-regulation of expression of HpHbR (Chapter 3), so efforts 
to find naturally occurring variants that combat group 1 T. b. gambiense must concentrate on 
other TLF particles. 
Interestingly, a mutant form of ApoL1 has recently been described in some individuals that are 
members of the African American ethnic group (Genovese et al., 2010).  This study showed that 
the mutant form of ApoL1 is able to kill T. b. rhodesiense due to mutations in the SRA-binding 
domain of ApoL1.  Patients who were homozygous for the mutant allele exhibited acute kidney 
problems during mid-life but heterozygotes were asymptomatic (Genovese et al., 2010). The 
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authors suggest that the presence of this mutant allele has been selected for in African individuals 
and may explain the observation that the Apol1 gene is under intense selection in Africa (Conrad 
et al., 2010).  There are several issues with this conclusion, including the fact that most African 
American individuals originate from Western Africa where T. b. rhodesiense is not present. It also 
seems incredulous that the sub-species of trypanosome that causes less than 10% of human 
disease could exert such strong evolutionary pressure that it caused the emergence of an ApoL1 
allele that is deadly if homozygous.  However, it is possible that the ApoL1 variant found in some 
humans of West African descent may also kill group 2 T. b. gambiense. If group 2 T. b. gambiense 
was much more prevalent in the past in Western Africa this would explain the strong selection on 
ApoL1 and the presence of the ApoL1 variant allele.  The removal of group 2 T. b. gambiense due 
to the emergence of a new ApoL1 variant has allowed the clonal expansion of group 1 T. b. 
gambiense featuring a different resistance mechanism. An alternative hypothesis is that T. b. 
rhodesiense was much more prevalent in the past and the evolutionary pressure it exerted led to 
the emergence of the ApoL1 variant. The variant is predominantly found in people of Western 
African descent who belong to the Bantu ethnic group.  This group originated in the West of Africa 
and spread eastwards over several millennia before stopping in what is now Southern Uganda. As 
the Bantu people spread eastward it would have removed T. b. rhodeseiense from majority of the 
tsetse belt.  Present-day T. b. rhodesiense is now confined to areas populated by people of Nilotic 
descent (Chapter 1).  This ethnic group migrated from the North of Africa relatively recently so 
are unlikely to possess the ApoL1 variant that can kill T. b. rhodesiense. Unfortunately this is all 
highly speculative and the utilisation of molecular clock techniques to determine when group 1, 2 
T. b .gambiense or T. b. rhodesiense emerged from a T. b. brucei ancestor relative to each other is 
complicated by the fact that the T. b. brucei and group 2 T. b. gambiense populations are 
undergoing some degree of mating (Chapter 6).  However it does introduce hope that removal of 
the clonal and drug vulnerable group 1 T. b. gambiense population will not allow the more 
genetically variable group 2 T. b. gambiense to replace it. 
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This thesis has showed that both group 1 and group 2 T. b. gambiense are able to resist lysis by 
the active component of human TLF, ApoL1. Group 1 T. b. gambiense down-regulate the HpHbR 
receptor to avoid the TLF-1 particle so investigations into the human serum resistance phenotype 
in this sub-species must concentrate on TLF-2 interactions.  Group 2 T. b. gambiense are variably 
resistant to ApoL1, but there is a potentially significant genetic component involved in the 
phenotype located on chromosome 8.  Population genetics suggests that the resistance 
mechanisms in T. b. gambiense have likely arisen on two occasions in the same geographic area.   
In addition, human infectivity has evolved on at least two further occasions in Western Africa, one 
involving the SRA gene (Xong et al., 1998) and a second that does not (De Greef et al., 1989; 
Enyaru et al., 2006).  This indicates the high potential that T. brucei possesses to jump species 
barriers and infect humans. While the divergence between T. brucei and T.  cruzi occurred 
approximately 100 million years ago (Stevens et al., 1999), the time period in which the human 
infective sub-species T. b. gambiense and T. b. rhodesiense emerged is unknown.  Fascinatingly, 
several major diseases emerged at a similar point of time that correlates with the rise of Neolithic 
farming in Africa. For the first time in history, large static populations of humans and livestock 
existed together allowing increasing rates of not only zoonotic transfer, but also transfer amongst 
large human populations.  These likely include the major diseases Plasmodium falciparum, 
measles and small pox (Brussow, 2009; Krief et al., 2010; Volkman et al., 2001). Indeed, the vast 
majority of pandemics that humans face today are caused by zoonotic transfer (Pike et al., 2010).  
Whilst T. brucei has existed for at least 100 million years (Stevens et al., 1999), ApoL1 likely 
evolved in primates at least 25 million years ago as it was present before the divergence of the 
Cercopithecidae (baboon and mandrills) and Hominidae families (Monajemi et al., 2002; 
Poelvoorde et al., 2004; Seed et al., 1990).  ApoL1 has several possible roles in apoptosis 
(Vanhollebeke & Pays, 2006) and some general anti-protozoan activity (Imrie et al., 2004; 
Samanovic et al., 2009) but it is the ability to kill trypanosomes that is its defining feature.  The 
emergence of ApoL1 would have had an immediate effect on the T. brucei population and offered 
primates with the gene a significant advantage.  ApoL1 is under purifying selection in African 
human populations (Conrad et al., 2010) and is present in many ground-dwelling primates 
exposed to high tsetse challenge (Lugli et al., 2004; Poelvoorde et al., 2004).  The gene is either 
missing or exhibits loss of function in primates that exhibit a more arboreal lifestyle, such as the 
chimpanzee (Poelvoorde et al., 2004).  This suggests a long association between ApoL1 and 
primates exposed to trypanosomes. Co-evolution of the parasite with the host however has led to 
the evolution of T. brucei strains that can overcome the innate lytic properties of the serum of 
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these primates. The ApoL1 resistance mechanisms present in these T. brucei could have evolved 
at any point in the 25 million year time period after the emergence of ApoL1.  Interestingly, both 
the Cercopithecidae and Hominidae families appear to have evolved convergent countermeasures 
to overcome the resistance mechanism of T. b. rhodesiense, highlighting the constant arms race 
between parasite and host (Genovese et al., 2010; Thomson et al., 2009).  T. brucei has 
demonstrated a high capacity to adapt and evolve so it is unlikely that this arms race is over. Key 
to combating the emergence of new diseases and pandemics is the understanding of the 
mechanisms by which organisms are able to cross the species barrier. This allows the 
identification of diagnostic markers that can be used in disease detection and also opens the 
possibility of unique treatment options that emerge from the biology involved.  This thesis has 
revealed features of the human serum resistant phenotype in both group 1 and 2 T. b. gambiense 
that will open new avenues for further research and possible diagnostic and treatment options in 
the future. 
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Appendices 
Appendix 1 The sequence of the expressed ESAG6 & ESAG7 variable regions for both the 
isogenic stably sensitive and resistant forms of the group 2 T. b. gambiense strain STIB386.  The 
hypervariable region of each gene is highlighted in red. 
 
386R_ESAG6(BES126) CATTCCAGCAGGAGTTGGAGGAAATGAGGAACGCATCCGCGTTAGCAGCAGCTGCAGCTG 
386S_ESAG6(BES126) CATTCCAGCAGGAGTTGGAGGAAATGAGGAACGCATCCGCGTTAGCAGCAGCTGCAGCTG 
 
386R_ESAG6(BES126) GGATAGCAGCTGGAAGACTGGAAGAGTGGATTTTTGTATTTGCACAGGCAGCAGGCAGGT 
386S_ESAG6(BES126) GGATAGCAGCTGGAAGACTGGAAGAGTGGATTTTTGTATTTGCACAGGCAGCAGGCAGGT 
                               Hyper variable region – identifies to L427 ES 126 
386R_ESAG6(BES126) CATCACAGTTTTGCATAAGCACGGGGAAGACTGGGCCAGCAGAATACAACAACTTGCAAG 
386S_ESAG6(BES126) CATCACAGTTTTGCATAAGCACGGGGAAGACTGGGCCAGCAGAATACAACAACTTGCAAG 
 
386R_ESAG6(BES126) AATGTTTTGATGGAACAATTGGACCTGAAACCCTTTACAAAATTGAGGATTCACGTGTAA 
386S_ESAG6(BES126) AATGTTTTGATGGAACAATTGGACCTGAAACCCTTTACAAAATTGAGGATTCACGTGTAA 
 
386R_ESAG6(BES126) AAGAGTCGGCGAAGACAAGATTGCTACTCCATGAAGTGTTATTATCCATTTCCTTCGGTA 
386S_ESAG6(BES126) AAGAGTCGGCGAAGACAAGATTGCTACTCCATGAAGTGTTATTATCCATTTCCTTCGGTA 
 
386R_ESAG6(BES126) GCTTGGGTGCGGAAAATATCCGAGGAGGAAATGGGAAGGATGGATGTAATTTGGTGAGAA 
386S_ESAG6(BES126) GCTTGGGTGCGGAAAATATCCGAGGAGGAAATGGGAAGGATGGATGTAATTTGGTGAGAA 
 
386R_ESAG6(BES126) CAGACAATAACGGTATATTAAAGGGGGGGTCACCGACACGGCACAACTTAACGTGGGGTG 
386S_ESAG6(BES126) CAGACAATAACGGTATATTAAAGGGGGGGTCACCGACACGGCACAACTTAACGTGGGGTG 
 
386R_ESAG6(BES126) GTGGAGTGATGAATTTTGGATCCTATCAAAACGGAAGTATGTACGTTGAGGGTGGTGAAT 
386S_ESAG6(BES126) GTGGAGTGATGAATTTTGGATCCTATCAAAACGGAAGTATGTACGTTGAGGGTGGTGAAT 
 
386R_ESAG6(BES126) ACGGTGATGCTACAGAGTACGGTGCAGTACGGTGGACCGAAGATCCTAGTAAAGTGAGCA 
386S_ESAG6(BES126) ACGGTGATGCTACAGAGTACGGTGCAGTACGGTGGACCGAAGATCCTAGTAAAGTGAGCA 
 
386R_ESAG6(BES126) TATTTAAGGATGTCATTCGCCTGTTTGCGCGGTTCCAAGAAGCAAAAAATGCAGTGATGA 
386S_ESAG6(BES126) TATTTAAGGATGTCATTCGCCTGTTTGCGCGGTTCCAAGAAGCAAAAAATGCAGTGATGA 
 
386R_ESAG6(BES126) AGAAAATAAAAACTACTGTGGATGAATTGACGAAATGTATAGGGCAGAAGGAGGCTGAAC 
386S_ESAG6(BES126) AGAAAATAAAAACTACTGTGGATGAATTGACGAAATGTATAGGGCAGAAGGAGGCTGAAC 
 
386R_ESAG6(BES126) TCACTAATGATCAGATTTACGAGGAATTTATCTGGGAGACCATAAACAGATTGGAGCTGT 
386S_ESAG6(BES126) TCACTAATGATCAGATTTACGAGGAATTTATCTGGGAGACCATAAACAGATTGGAGCTGT 
 
386R_ESAG6(BES126) CAAAGAGAGTGAGTGAACAA 
386S_ESAG6(BES126) CAAAGAGAGTGAGTGAACAA 
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386R_ESAG7(BES126) CGAGCGGCCGCCAGTGTGATGGATATCTGCAGAATTCGCCCTTCCGGAATTCGCTATTAT 
386S_ESAG7(BES126) CGAGCGGCCGCCAGTGTGATGGATATCTGCAGAATTCGCCCTTCCGGAATTCGCTATTAT 
 
386R_ESAG7(BES126) TAGAACAGTTTCTGTACTATATTGTAACGAAGCGGAAAGTTTTAAAAGCATAGTTTAAAA 
386S_ESAG7(BES126) TAGAACAGTTTCTGTACTATATTGTAACGAAGCGGAAAGTTTTAAAAGCATAGTTTAAAA 
 
386R_ESAG7(BES126) AAGTGATAAGGATGAGATTTTGGTTTGTGTTGTTGGCCCTTTTGGGAAAAGAAACATATG 
386S_ESAG7(BES126) AAGTGATAAGGATGAGATTTTGGTTTGTGTTGTTGGCCCTTTTGGGAAAAGAAACATATG 
 
386R_ESAG7(BES126) CGTATGAAAATGAAAGGAATGCATTAAACGCAACCGCCGCTAATAAAGTGTGTGCGCTAT 
386S_ESAG7(BES126) CGTATGAAAATGAAAGGAATGCATTAAACGCAACCGCCGCTAATAAAGTGTGTGCGCTAT 
 
386R_ESAG7(BES126) CGACCTATCTTAAAGGAATAGCGCACAGAGTAAACAGCGAAAGTGCTGTGGTTACGGAAA 
386S_ESAG7(BES126) CGACCTATCTTAAAGGAATAGCGCACAGAGTAAACAGCGAAAGTGCTGTGGTTACGGAAA 
 
386R_ESAG7(BES126) AACTATCAGATTTGAAAATGAGAAGCATCCAGTTGCAGCTAACAGTAATGCGAAACAGAG 
386S_ESAG7(BES126) AACTATCAGATTTGAAAATGAGAAGCATCCAGTTGCAGCTAACAGTAATGCGAAACAGAG 
 
386R_ESAG7(BES126) ATCCTTCTGGCGAGAAGGATTGTAAAGACATCAGGACACTCTTGAAAACAGTATTGAGGA 
386S_ESAG7(BES126) ATCCTTCTGGCGAGAAGGATTGTAAAGACATCAGGACACTCTTGAAAACAGTATTGAGGA 
 
386R_ESAG7(BES126) ATGAGTTTACATTCCAGCAGGAGTTGGAGGAAATGAGGAACGCATCCGCGTTAGCAGCAG 
386S_ESAG7(BES126) ATGAGTTTACATTCCAGCAGGAGTTGGAGGAAATGAGGAACGCATCCGCGTTAGCAGCAG 
 
386R_ESAG7(BES126) CTGCAGCTGGGATAGCAGCCGGAAGACTGGAAGAATGGATTTTTGTATTTGCACAGGCAG 
386S_ESAG7(BES126) CTGCAGCTGGGATAGCAGCCGGAAGACTGGAAGAATGGATTTTTGTATTTGCACAGGCAG 
 
386R_ESAG7(BES126) CAGGCAGGTCATCACAGTTTTGCATAAGCGTGGGGAAGCATATCCCGGCTGAGCACGGCA 
386S_ESAG7(BES126) CAGGCAGGTCATCACAGTTTTGCATAAGCGTGGGGAAGCATATCCCGGCTGAGCACGGCA 
 
386R_ESAG7(BES126) ACTTGCAAGAATGTTTTGACGGAACAATTGGACCTGAAACCCTTTACAAAATTGAGGATT 
386S_ESAG7(BES126) ACTTGCAAGAATGTTTTGACGGAACAATTGGACCTGAAACCCTTTACAAAATTGAGGATT 
 
386R_ESAG7(BES126) CACGTGTAAAAGAGTCGGCAAAGACAAGCTTGCAACTCCATGAAGTGTTATCATCCATTT 
386S_ESAG7(BES126) CACGTGTAAAAGAGTCGGCAAAGACAAGCTTGCAACTCCATGAAGTGTTATCATCCATTT 
 
386R_ESAG7(BES126) CCTTCAATAGCTTGGGTGCGGAAAGTATTGTTGAGCAAGGAGAAAACAGAGGATGTAACC 
386S_ESAG7(BES126) CCTTCAATAGCTTGGGTGCGGAAAGTATTGTTGAGCAAGGAGAAAACAGAGGATGTAACC 
 
386R_ESAG7(BES126) TAATGCGGACCGCGTACGGAGGTTTGCTGGAAAGGTGTTTGTTTGAATCGCAACTTCACA 
386S_ESAG7(BES126) TAATGCGGACCGCGTACGGAGGTTTGCTGGAAAGGTGTTTGTTTGAATCGCAACTTCACA 
 
386R_ESAG7(BES126) TGGGGTGCCGGAGTGTTGAATTTCGGATACTGTGTGGCGGGGAACCTAAAAATAAAAGGG 
386S_ESAG7(BES126) TGGGGTGCCGGAGTGTTGAATTTCGGATACTGTGTGGCGGGGAACCTAAAAATAAAAGGG 
                         Hyper variable region – identifies to L427 ES 126 
386R_ESAG7(BES126) GGAGAATACGGTGATGTCAGTTCCCACGATGCGGTACGGTGGACCGAAGATCCTAGTAAA 
386S_ESAG7(BES126) GGAGAATACGGTGATGTCAGTTCCCACGATGCGGTACGGTGGACCGAAGATCCTAGTAAA 
 
386R_ESAG7(BES126) GTGAGCATATTTAAAGGATGTCATTCGCCTGTTTGCGCGGTTCAAAGAAGCAAAAAATGC 
386S_ESAG7(BES126) GTGAGCATATTTAAAGGATGTCATTCGCCTGTTTGCGCGGTTCAAAGAAGCAAAAAATGC 
 
386R_ESAG7(BES126) AGTGATGTCTAGAGCAAGGGCGAATTCCAGCACACTGGCGGCCGTTACTA 
386S_ESAG7(BES126) AGTGATGTCTAGAGCAAGGGCGAATTCCAGCACACTGGCGGCCGTTACTA 
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Appendix 2 HpHbR ORF & 3’ UTR sequence for several strains of T. brucei. The open reading 
frame is denoted by the blue bar. Non-synonymous polymorphisms within the gene are shown in 
red, synonymous in green. In the 3’UTR polymorphisms are marked solely in red. The two 
homologues of the HpHbR region in the heterozygous type 2 T. b. gambiense strain STIB386 are 
denoted A & B. 
                          |Gene->                                                    _ 
TREU927  (T.b.b)          ATGGAGAAACCGTCTTGCAGGGGTGCCGGTTGGGCGCAGCTTTTGTGGTGTTACGGCACC 
Eliane   (Gp 1 T.b.g)     ATGGAGAAACCGTCTTGCAGGGGTGCCGGTTGGGCGCAGCTTTTGTGGTGTTACGGCACC 
STIB386A (Gp 2 T.b.g)     ATGGAGAAACCGTCTTGCAGGGGTGCCGGTTGGGCGCAGCTTTTGTGGTGTTACGGCACC 
STIB386B (Gp 2 T.b.g)     ATGGAGAAACCGTCTTGCAGGGGTGCTGGTTGGGCGCAGCTTTTGTGGTGTTACGGCACC 
                                                                                     _ 
TREU927  (T.b.b)          TGTTGCGCTCTACTCCTCCGCCTGATAGTTGAAGCCAGTCAAGCTGCTGAGGGTTTAAAA 
Eliane   (Gp 1 T.b.g)     TGTTGCGCTCTACTCCTCCGCCTGATAGTTGAAGCCAGTCAAGCTGCTGAGGGTTTAAAA 
STIB386A (Gp 2 T.b.g)     TGTTGCGCTCTACTCCTCCGCCTGATAGTTGAAGCCAGTCAAGCTGCTGAGGGTTTAAAA 
STIB386B (Gp 2 T.b.g)     TGTTGCGCTCTACTCCTCCGCCTGATAGTTGAAGCCAGTCAAGCTGCTGAGGGTTTAAAA 
                                                                                     _ 
TREU927  (T.b.b)          ACCAAAGACGAAGTTGAGAAGGCGTGCCATCTTGCACAACAACTCAAAGAAGTTTCAATT 
Eliane   (Gp 1 T.b.g)     ACCAAAGACGAAGTTGAGAAGGCGTGCCATCTTGCACAACAACTCAAAGAAGTTTCAATT 
STIB386A (Gp 2 T.b.g)     ACCAAAGACGAAGTTGAGAAGGCGTGCCATCTTGCACAACAACTCAAAGAAGTTTCAATT 
STIB386B (Gp 2 T.b.g)     ACCAAAGACGAAGTTGAGAAGGCGTGCCATCTTGCACAACAACTCAAAGAAGTTTCAATT 
                                                                                     _ 
TREU927  (T.b.b)          ACTTTGGGAGTTATTTACCGGACCACTGAACGACACTCCGTGCAAGTTGAAGCGCATAAA 
Eliane   (Gp 1 T.b.g)     ACTTTGGGAGTTATTTACCGGACCACTGAACGACACTCCGTGCAAGTTGAAGCGCATAAA 
STIB386A (Gp 2 T.b.g)     ACTTTGGGAGTTATTTACCGGACCACTGAACGACACTCCGTGCAAGTTGAAGCGCATAAA 
STIB386B (Gp 2 T.b.g)     ACTTTGGGAGTTATTTACCGGACCACTGAACGACACTCCGTGCAAGTTGAAGCGCATAAA 
                                                                                     _ 
TREU927  (T.b.b)          ACAGCCATTGACAAACATGCGGATGCGGTGTCGCGAGCTGTGGAGGCGCTCACGAGGGTG 
Eliane   (Gp 1 T.b.g)     ACAGCCATTGACAAACATGCGGATGCGGTGTCGCGAGCTGTGGAGGCGCTCACGAGGGTG 
STIB386A (Gp 2 T.b.g)     ACAGCCATTGACAAACATGCCGATGCGGTGTCGCGAGCTGTGGAGGCGCTCACGAGGGTG 
STIB386B (Gp 2 T.b.g)     ACAGCCATTGACAAACATGCGGATGCGGTGTCGCGAGCTGTGGAGGCGCTCACGAGGGTG 
                                                                                     _ 
TREU927  (T.b.b)          GATGTGGCACTTCAGCGATTGAAAGAACTCGGGAAGGCGAATGACACGAAGGCGGTGAAA 
Eliane   (Gp 1 T.b.g)     GATGTGGCACTTCAGCGATTGAAAGAACTCGGGAAGGCCAATGACACGAAGGCGGTGAAA 
STIB386A (Gp 2 T.b.g)     GATGTGGCACTTCAGCGATTGAAAGAACTCGGGAAGGCGAATGACACGAAGGCGGTGAAA 
STIB386B (Gp 2 T.b.g)     GATGTGGCACTTCAGCGATTGAAAGAACTCGGGAAGGCGAATGACACGAAGGCGGTGAAA 
                                                                                     _ 
TREU927  (T.b.b)          ATTATCGAGAACATTACCTCCGCCAGAGAAAATCTCGCTCTCTTCAATAACGAAACGCAG 
Eliane   (Gp 1 T.b.g)     ATTATCGAGAACATTACCTCCGCCAGAGAAAATCTCGCTCTCTTCAATAACGAAACGCAG 
STIB386A (Gp 2 T.b.g)     ATTATCGAGAACATTACCTCCGCCAGAGAAAATCTCGCTCTCTTCAATAACGAAACGCAG 
STIB386B (Gp 2 T.b.g)     ATTATCGAGAACATTACCTCCGCCAGAGAAAATCTCGCTCTCTTCAATAACGAAACGCAG 
                                                                                     _ 
TREU927  (T.b.b)          GCCGTACTGACGGCGAGGGATCATGTGCATAAGCATAGGGCCGCGGCATTGCAGGGGTGG 
Eliane   (Gp 1 T.b.g)     GCCGTACTGACGGCGAGGGATCATGTGCATAAGCATAGGGCCGCGGCATTGCAGGGGTGG 
STIB386A (Gp 2 T.b.g)     GCCGTACTGACGGCGAGGGATCATGTGCATAAGCATAGGGCCGCGGCATTGCAGGGGTGG 
STIB386B (Gp 2 T.b.g)     GCCGTACTGACGGCGAGGGATCATGTGCATAAGCATAGGGCCGCGGCATTGCAGGGGTGG 
                                                                                     _ 
TREU927  (T.b.b)          TCTGATGCAAAAGAAAAAGGCGATGCCGCCGCAGAGGATGTTTGGGTTCTGCTTAATGCC 
Eliane   (Gp 1 T.b.g)     TCTGATGCAAAAGAAAAAGGCGATGCCGCCGCAGAGGATGTTTGGGTTCTGCTTAATGCC 
STIB386A (Gp 2 T.b.g)     TCTGATGCAAAAGAAAAAGGCGATGCCGCCGCAGAGGATGTTTGGGTTCTGCTTAATGCC 
STIB386B (Gp 2 T.b.g)     TCTGATGCAAAAGAAAAAGGCGATGCCGCCGCAGAGGATGTTTGGGTTCTGCTTAATGCC 
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                                                                                     _ 
TREU927  (T.b.b)          GCAAAAAAAGGTAATGGCAGTGCAGACGTCAAAGCAGCTGCAGAGAAATGCTCGAGATAT 
Eliane   (Gp 1 T.b.g)     GCAAAAAAAGGTAATGGCAGTGCAGACGTCAAGGCAGCTGCAGAGAAATGCTCGAGATAT 
STIB386A (Gp 2 T.b.g)     GCAAAAAAAGGTAATGGCAGTGCAGACGTCAAGGCAGCTGCAGAGAAATGCTCGAGATAT 
STIB386B (Gp 2 T.b.g)     GCAAAAAAAGGTAATGGCAGTGCAGACGTCAAGGCAGCTGCAGAGAAATGCTCGAGATAT 
                                                                                     _ 
TREU927  (T.b.b)          TCCTCAAGCAGTACTTCAGAAACTGAGTTGCAGAAAGCTATTGACGCCGCCGCTAACGTG 
Eliane   (Gp 1 T.b.g)     TCCTCAAGCAGTACTTCAGAAACTGAGTCGCAGAAAGCTATTGACGCCGCCGCTAACGTG 
STIB386A (Gp 2 T.b.g)     TCCTCAAGCAGTACTTCAGAAACTGAGTTGCAGAAAGCTATTGACGCCGCCGCTAACGTG 
STIB386B (Gp 2 T.b.g)     TCCTCAAGCAGTACTTCAGAAACTGAGTTGCAGAAAGCTATTGACGCCGCCGCTAACGTG 
                                                                                     _ 
TREU927  (T.b.b)          GGGGGTTTGTCGGCACACAAGTCGAAATATGGCGATGTGCTGAACAAGTTTAAATTGTCT 
Eliane   (Gp 1 T.b.g)     GGGGGTTTGTCGGCACACAAGTCGAAATATGGCGATGTGCTGAACAAGTTTAAATTGTCT 
STIB386A (Gp 2 T.b.g)     GGGGGTTTGTCGGCACACAAGTCGAAATATGGCGATGTGCTGAACAAGTTTAAATTGTCT 
STIB386B (Gp 2 T.b.g)     GGGGGTTTGTCGGCACACAAGTCGAAATATGGCGATGTGCTGAACAAGTTTAAATTGTCT 
                                                                                     _ 
TREU927  (T.b.b)          AATGCTTCAGTGGGAGCAGTGAGAGACACATCCGGCCGGGGCGGTAAGCATATGGAAAAG 
Eliane   (Gp 1 T.b.g)     AATGCTTCAGTGGGAGCAGTGAGAGACACATCCGGCCGGGGCGGTAAGCATATGGAAAAG 
STIB386A (Gp 2 T.b.g)     AATGCTTCAGTGGGAGCAGTGAGAGACACATCCGGCCGGGGCGGTAAGCATATGGAAAAG 
STIB386B (Gp 2 T.b.g)     AATGCTTCAGTGGGAGCAGTGAGAGACACATCCGGCCGGGGCGGTAAGCATATGGAAAAG 
                                                                                     _ 
TREU927  (T.b.b)          GTCAATAATGTGGCAAAACTTCTTAAGGATGCAGAGGTTTCTCTTGCAGCTGCAGCAGCC 
Eliane   (Gp 1 T.b.g)     GTCAATAATGTGGCAAAACTTCTTAAGGATGCAGAGGTTTCTCTTGCAGCTGCAGCAGCC 
STIB386A (Gp 2 T.b.g)     GTCAATAATGTGGCAAAACTTCTTAAGGATGCAGAGGTTTCTCTTGCAGCTGCAGCAGCC 
STIB386B (Gp 2 T.b.g)     GTCAATAATGTGGCAAAACTTCTTAAGGATGCAGAGGTTTCTCTTGCAGCTGCAGCAGCC 
                                                                                     _ 
TREU927  (T.b.b)          GAAATTGAGGAGGTTAAAAATGCACATGAAACAAAAGCACAGGAAGAGATGAAGCGCAAT 
Eliane   (Gp 1 T.b.g)     GAAATTGAGGAGGTTAAAAATGCACATGAAACAAAAGTACAGGAAGAGATGAAGCGCAAT 
STIB386A (Gp 2 T.b.g)     GAAATTGAGGAGGTTAAAAATGCACATGAAACAAAAGTACAGGAAGAGATGAAGCGCAAT 
STIB386B (Gp 2 T.b.g)     GAAATTGAGGAGGTTAAAAATGCACATGAAACAAAAGCACAGGAAGAGATGAAGCGCAAT 
                                                                                     _ 
TREU927  (T.b.b)          GGGAACCCGATCGAAAATGAATCAGAGACTAATTCAGGGGGGAATGCGGAATCACAAGGT 
Eliane   (Gp 1 T.b.g)     GGGAACCCGATCGAAAATGAATCAGAGACTAATTCAGGGGGGAATGCGGAATCACAAGGT 
STIB386A (Gp 2 T.b.g)     GGGAACCCGATCGAAAATGAATCAGAGACTAATTCAGGGGGGAATGCGGAATCACAAGGT 
STIB386B (Gp 2 T.b.g)     GGGAACCCGATCGAAAATGAATCAGGGACTAATTCAGGGGGGAATGCGGAATCACAAGGT 
                                                                                     _ 
TREU927  (T.b.b)          AATGGAGATCGTGAAGATAAGAACGACGAGCAACAACAGGTCGATGAGGAGGAAACAAAG 
Eliane   (Gp 1 T.b.g)     AATGGAGATCGTGAAGATAAGAACGACGAGCAACAACAGGTCGATGAGGAGGAAACAAAG 
STIB386A (Gp 2 T.b.g)     AATGGAGATTGTGAAGATAAGAACGACGAGCAACAACAGGTCGATGAGGAGGAAACAAAG 
STIB386B (Gp 2 T.b.g)     ACTGGAGATCGTGAAGATAAGAACGACGAGCAACAACAGGTCGATGAGGAGGAAACAAAG 
                                                                                     _ 
TREU927  (T.b.b)          GTGGAAAATGGAAGCAGCGAGGAGGGGTCTTGTTGTGGAAACGAAAGTAACGGTCCCCAT 
Eliane   (Gp 1 T.b.g)     GTGGAAAATGGAAGCAGCGAGGAGGGGTCTTGTTGTGGAAACGAAAGTAACGGTCCCCAT 
STIB386A (Gp 2 T.b.g)     GTGGAAAATGGAAGCAGCGAGGAGGGGTCTTGTTGTGGAAACGAAAGTAACGGTCCCCAT 
STIB386B (Gp 2 T.b.g)     GTGGAAAATGGAAGCAGCGAGGAGAGGTCTTGTTGTGGAAACGAAAGTAACGGTCCCCAT 
                                                                                     _ 
TREU927  (T.b.b)          GTGATGAAAAAACGTCATGGGGTTGAGGGACCAAGGCCCGTTGACGTGGTTAGTGGTTTC 
Eliane   (Gp 1 T.b.g)     GTGATGAAAAAACGTCATGGGGTTGGGGCACCAAGGCCCGTTGACGTGGTTAGTGGTTTC 
STIB386A (Gp 2 T.b.g)     GTGATGAAAAAACGTCATGGGGTTGGGGCACCAAGGCCCGTTGACGTGGTTAGTGGTTTC 
STIB386B (Gp 2 T.b.g)     GTGATGAAAAAACGTCATGGGGTTGAGGGACCAAGGCCCGTTGACGTGGTTAGTGGTTTC 
                                                                                     _ 
TREU927  (T.b.b)          CGCAGTTATGCCAGTGCTTCTTTTGCTCTGCTTTCTCTTGTCCGTGTCGGTATGCTCCAG 
Eliane   (Gp 1 T.b.g)     CGCAGTTATGCCAGCGCTTCTTTTGCTCTGCTTTCTCTTGTCCGTGTCGGTATTCTCCAG 
STIB386A (Gp 2 T.b.g)     CGCAGTTATGCCAGCGCTTCTTTTGCTCTGCTTTCTCTTGTCCGTGTCGGTATGCTCCAG 
STIB386B (Gp 2 T.b.g)     CGCAGTTATGCCAGCGCTTCTTTTGCTCTGCTTTCTCTTGTCCGTGTCGGTATTCTCCAG 
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TREU927  (T.b.b)          GTGGTGGTGTAGAAAAGACACCGTTTCTTCCAAAGACTGCGCGGGAGTTGCTCCTAAATT 
Eliane   (Gp 1 T.b.g)     GTGGTGGTGTAGAAAAGACACCGTTTCTTCCAAAGACTGCGCGGGAGTTGCTCCTAAATT 
STIB386A (Gp 2 T.b.g)     GTGGTGGTGTAGAAAAGACACCGTTTCTTCCAAAGACTGCGCGGGAGTTGCTCCTAAATT 
STIB386B (Gp 2 T.b.g)     GTGGTGGTGTAGAAAAGACACCGTTTCTTCCAAAGACTGCGCGGGAGTTGCTCCCAAATT 
 
TREU927  (T.b.b)          GCATTTCCTTCTCTCCTCGTAACATTAAGTGGTCGTGTTGTTGTTTTTTCTTCTTTCCTC 
Eliane   (Gp 1 T.b.g)     GCATTTCCTTCTCTCCTCGTAACATTAAGTGGTCGTTTTGTTGTTTTTTCTTCTTTCCTC 
STIB386A (Gp 2 T.b.g)     GCATTTCCTTCTCTCCTCGTAACATTAAGTGGTCGTGTTGTTGTTTTTTCTTCTTTCCTC 
STIB386B (Gp 2 T.b.g)     GCATTTCCTTCTCTCCTCGTAACATTAAGTGGTCGTGTTGTTGTTTTTTCTTCTTTCCTC 
 
TREU927  (T.b.b)          TCGCGTGTGGAGGCGAGGCTGAAGACGAACTGCGGCGTCAGACTGCCAAGTGTGAGAAAG 
Eliane   (Gp 1 T.b.g)     TCGCGTGTGGAGGCGAGGCTGAAGACGAACTGCAGCGTCAGACTGCCAAGTGTGAGAAAG 
STIB386A (Gp 2 T.b.g)     TCGCGTGTGGAGGCGAGGCTGAAGACGAACTGCGGCGTCAGACTGCCAAGTGTGAGAAAG 
STIB386B (Gp 2 T.b.g)     TCGCGTGTGGAGGCGAGGCTGAAGACGAACTGCAGCGTCAGACTGCCAAGTGTGAGAAAG 
 
TREU927  (T.b.b)          AGCGTGAAGTGGTGTGGGGATGATGCCAACGAAGATCTTTTTAATTTTTGGATGTGGGCT 
Eliane   (Gp 1 T.b.g)     AGCGTGAAGTGGTGTGGGGATGATGCCAACGAAGATCTTTTTAATTTTTGGATGTGGGCT 
STIB386A (Gp 2 T.b.g)     AGCGTGAAGTGGTGTGGGGATGATGCCAACGAAGATCTTTTTAATTTTTGGATGTGGGCT 
STIB386B (Gp 2 T.b.g)     AGCGTGAAGTGGTGTGGGGATGATGCCAACGAAGATCTTTTTAATTTTTGGATGTGGGCT 
 
TREU927  (T.b.b)          TACGTAGTTCGCTGGTAAATATACTTAAGATCTTTCTTTTTTTTTTT--TGTTGTTGTAT 
Eliane   (Gp 1 T.b.g)     TACGTAGTTCGCTGGTAAATATACTTAAGATCTTTCTTTTTTTTTTTGTTGTTGTTGTAT 
STIB386A (Gp 2 T.b.g)     TACGTAGTTCGCTGGTAAATATACTTAAGATCTTTCTTTTTTTTTTTTTT--TGTTGTAT 
STIB386B (Gp 2 T.b.g)     TACGTAGTTCGCTGGTAAATATACTTAAGATCTTTCTTTTTTTTTTTGTTGTTGTTGTAT 
 
TREU927  (T.b.b)          GTCTTTTTGATTTTGTTGTATTGATTGAATTATTCCCCTTGAGCTTTCTTGTCTTGTACG 
Eliane   (Gp 1 T.b.g)     GTCTTTTTGATTTTGTTGTATTGACTGAATTATTCCCCTTGAGCTTTCTTGTCTTGTACG 
STIB386A (Gp 2 T.b.g)     GTCTTTTTGATTTTGTTGTATTGACTGAATTATTCCCCTTGAGCTTTCTTGTCTTGTACG 
STIB386B (Gp 2 T.b.g)     GTCTTTTTGATTTTGTTGTATTGACTGAATTATTCCCCTTGAGCTTTCTTGTCTTGTACG 
 
TREU927  (T.b.b)          ATACGTTGGCGAGAAGCTGGTTAAACGAAAACTTTGAAGGAAAAAAATGTGGGATGTGTT 
Eliane   (Gp 1 T.b.g)     ATACGTTGGCGAGAAGCTGGTTAAACGAAAACTTTGAAGGAAAAAAATGTGGGATGTGTT 
STIB386A (Gp 2 T.b.g)     ATACGTTGGCGAGAAGCTGGTTAAACGAAAACTTTGAAGGAAAAAAATGTGGGATGTGTT 
STIB386B (Gp 2 T.b.g)     ATACGTTGGCGAGAAGCTGGTTAAACGAAAACTTTGAAGGAAAAAAATGTGGGATGTGTT 
 
TREU927  (T.b.b)          TGTGTCTGCTTGTGTGTGTAAACGTAATGGAGGCTTCCCCCCCC------ATTAGTGGCA 
Eliane   (Gp 1 T.b.g)     TGTGTCTGTTTGTGTGTGTAAACGTAATGGAGGCTTCCCCCCCCCCC---ATTAGTGGCA 
STIB386A (Gp 2 T.b.g)     TGTGTCTGTTTGTGTGTGTAAACGTAATGGAGGCTTCCCCCCCCCCCCCCATTAGTGGCA 
STIB386B (Gp 2 T.b.g)     TGTGTCTGTTTGTGTGTGTAAACGTAATGGAGGCTTCCCCCCCCCCCCCCATTAGTGGCA 
 
TREU927  (T.b.b)          TGCATGCATTTCCGATGCCGACATGCGGTTTTCGGTGAGGGAACAATGCGCCTCACCGTA 
Eliane   (Gp 1 T.b.g)     TGGATGCATTTCCGATGCCGACATGCGGTTTTCGGTGAGGGAACAATGCGCCTCACCGTA 
STIB386A (Gp 2 T.b.g)     TGCATGCATTTCCGATGCCGACATGCGGTTTTCGGTGAGGGAACAATGCGCCTCACCGTA 
STIB386B (Gp 2 T.b.g)     TGCATGCATTTCCGATGCCGACATGCGGTTTTCGGTGAGGGAACAATGCGCCTCACCGTA 
 
TREU927  (T.b.b)          TCATGTACCGTGAACTACAAGCCACAAAAATATGTGCTTGAATAGTAAGTCCTCCCAACT 
Eliane   (Gp 1 T.b.g)     TCATGTACCGTGAACTACAAGCCACAAAAATATGTGCTTGAATAGTAAGTCCTCCCAACT 
STIB386A (Gp 2 T.b.g)     TCATGTACCGTGAACTACAAGCCACAAAAATATGTGCTTGAATAGTAAGTCCTCCCAACT 
STIB386B (Gp 2 T.b.g)     TCATGTACCGTGAACTACAAGCCACAAAAATATGTGCTTGAATAGTAAGTCCTCCCAACT 
 
TREU927  (T.b.b)          TCATTTCATGACCAGGAAATTAATCATGTCAAGCCATTGAGCAACTTTTTCTCTTCAGTG 
Eliane   (Gp 1 T.b.g)     TCATTTCATGACCAGGAAATTAATCATGTCAAGCCATTGAGCAACTTTTTCTCTTCAGTG 
STIB386A (Gp 2 T.b.g)     TCATTTCATGACCAGGAAATTAATCATGTCAAGCCATTGAGCAACTTTTTCTCTTCAGTG 
STIB386B (Gp 2 T.b.g)     TCATTTCATGACCAGGAAATTAATCATGTCAAGCCATTGAGCAACTTTTTCTCTTCAGTG 
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TREU927  (T.b.b)          GTATGCCTTTGTTCGTTTTCAAAAAAAAAAA--GGAAGAATAAAGAGAAAGGGAGTGGGA 
Eliane   (Gp 1 T.b.g)     GTATGCCTTTGTTCGTTTTCAAAAAAAAAAAAAGGAAGAATAAAGAGAAAGGGAGTGGGA 
STIB386A (Gp 2 T.b.g)     GTATGCCTTTGTTCGTTTTCAAAAAAAAAAAAAGGAAGAATAAAGAGAAAGGGAGTGGGA 
STIB386B (Gp 2 T.b.g)     GTATGCCTTTGTTCGTTTTCAAAAAAAAAAAAAGGAAGAATAAAGAGAAAGGGAGTGGGA 
 
TREU927  (T.b.b)          AAACTTTTTTTTTTTTGCTACATGTGCCTTTTCTAGTGTGTGCGAGCGCCCGCTGCGAGG 
Eliane   (Gp 1 T.b.g)     AAACTTTTTTTTTT--GCTATATGTGCCTTTTCTAGTGTGTGCGAGTGCCCGCTGCGAGG 
STIB386A (Gp 2 T.b.g)     AAACTTTTTTTTTTTTGCTATATGCGCCTTTTCTAGTGTGTGCGAGTGCCCGCTGCGAGG 
STIB386B (Gp 2 T.b.g)     AAACTTTTTTTTTTT-GCTATATGTGCCTTTTCTAGTGTGTGCGAGTGCCCGCTGCGAGG 
 
TREU927  (T.b.b)          AATTGAGCTTTCTCCTTTCCTTCCTTTTCCTCCTTTC 
Eliane   (Gp 1 T.b.g)     AATTGAGCTTTCTCCTTTCCTTCCTTTTCCTCCTTTC 
STIB386A (Gp 2 T.b.g)     AATTGAGCTTTCTCCTTTCCTTCCTTTTCCTCCTTTC 
STIB386B (Gp 2 T.b.g)     AATTGAGCTTTCTCCTTTCCTTCCTTTTCCTCCTTTC 
 
Appendix 3 HpHbR ORF & 3’ UTR sequence for several strains of T. b. gambiense from different 
disease foci.  Eliane originated from Côte d’Ivoire, Bim from Cameroon and Pa from the 
Democratic Republic of Congo.  The ORF is denoted by the blue bar and non-identical base 
positions are highlighted in red. 
                |Gene->                                                    _ 
Eliane          ATGGAGAAACCGTCTTGCAGGGGTGCCGGTTGGGCGCAGCTTTTGTGGTGTTACGGCACC 
Bim             ATGGAGAAACCGTCTTGCAGGGGTGCCGGTTGGGCGCAGCTTTTGTGGTGTTACGGCACC 
Pa              ATGGAGAAACCGTCTTGCAGGGGTGCCGGTTGGGCGCAGCTTTTGTGGTGTTACGGCACC 
                                                                           _ 
Eliane          TGTTGCGCTCTACTCCTCCGCCTGATAGTTGAAGCCAGTCAAGCTGCTGAGGGTTTAAAA 
Bim             TGTTGCGCTCTACTCCTCCGCCTGATAGTTGAAGCCAGTCAAGCTGCTGAGGGTTTAAAA 
Pa              TGTTGCGCTCTACTCCTCCGCCTGATAGTTGAAGCCAGTCAAGCTGCTGAGGGTTTAAAA 
                                                                           _ 
Eliane          ACCAAAGACGAAGTTGAGAAGGCGTGCCATCTTGCACAACAACTCAAAGAAGTTTCAATT 
Bim             ACCAAAGACGAAGTTGAGAAGGCGTGCCATCTTGCACAACAACTCAAAGAAGTTTCAATT 
Pa              ACCAAAGACGAAGTTGAGAAGGCGTGCCATCTTGCACAACAACTCAAAGAAGTTTCAATT 
                                                                           _ 
Eliane          ACTTTGGGAGTTATTTACCGGACCACTGAACGACACTCCGTGCAAGTTGAAGCGCATAAA 
Bim             ACTTTGGGAGTTATTTACCGGACCACTGAACGACACTCCGTGCAAGTTGAAGCGCATAAA 
Pa              ACTTTGGGAGTTATTTACCGGACCACTGAACGACACTCCGTGCAAGTTGAAGCGCATAAA 
                                                                           _ 
Eliane          ACAGCCATTGACAAACATGCGGATGCGGTGTCGCGAGCTGTGGAGGCGCTCACGAGGGTG 
Bim             ACAGCCATTGACAAACATGCGGATGCGGTGTCGCGAGCTGTGGAGGCGCTCACGAGGGTG 
Pa              ACAGCCATTGACAAACATGCGGATGCGGTGTCGCGAGCTGTGGAGGCGCTCACGAGGGTG 
                                                                           _ 
Eliane          GATGTGGCACTTCAGCGATTGAAAGAACTCGGGAAGGCCAATGACACGAAGGCGGTGAAA 
Bim             GATGTGGCACTTCAGCGATTGAAAGAACTCGGGAAGGCCAATGACACGAAGGCGGTGAAA 
Pa              GATGTGGCACTTCAGCGATTGAAAGAACTCGGGAAGGCCAATGACACGAAGGCGGTGAAA 
                                                                           _ 
Eliane          ATTATCGAGAACATTACCTCCGCCAGAGAAAATCTCGCTCTCTTCAATAACGAAACGCAG 
Bim             ATTATCGAGAACATTACCTCCGCCAGAGAAAATCTCGCTCTCTTCAATAACGAAACGCAG 
Pa              ATTATCGAGAACATTACCTCCGCCAGAGAAAATCTCGCTCTCTTCAATAACGAAACGCAG 
                                                                           _ 
Eliane          GCCGTACTGACGGCGAGGGATCATGTGCATAAGCATAGGGCCGCGGCATTGCAGGGGTGG 
Bim             GCCGTACTGACGGCGAGGGATCATGTGCATAAGCATAGGGCCGCGGCATTGCAGGGGTGG 
Pa              GCCGTACTGACGGCGAGGGATCATGTGCATAAGCATAGGGCCGCGGCATTGCAGGGGTGG 
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                                                                           _ 
Eliane          TCTGATGCAAAAGAAAAAGGCGATGCCGCCGCAGAGGATGTTTGGGTTCTGCTTAATGCC 
Bim             TCTGATGCAAAAGAAAAAGGCGATGCCGCCGCAGAGGATGTTTGGGTTCTGCTTAATGCC 
Pa              TCTGATGCAAAAGAAAAAGGCGATGCCGCCGCAGAGGATGTTTGGGTTCTGCTTAATGCC 
                                                                           _ 
Eliane          GCAAAAAAAGGTAATGGCAGTGCAGACGTCAAGGCAGCTGCAGAGAAATGCTCGAGATAT 
Bim             GCAAAAAAAGGTAATGGCAGTGCAGACGTCAAGGCAGCTGCAGAGAAATGCTCGAGATAT 
Pa              GCAAAAAAAGGTAATGGCAGTGCAGACGTCAAGGCAGCTGCAGAGAAATGCTCGAGATAT 
                                                                           _ 
Eliane          TCCTCAAGCAGTACTTCAGAAACTGAGTCGCAGAAAGCTATTGACGCCGCCGCTAACGTG 
Bim             TCCTCAAGCAGTACTTCAGAAACTGAGTCGCAGAAAGCTATTGACGCCGCCGCTAACGTG 
Pa              TCCTCAAGCAGTACTTCAGAAACTGAGTCGCAGAAAGCTATTGACGCCGCCGCTAACGTG 
                                                                           _ 
Eliane          GGGGGTTTGTCGGCACACAAGTCGAAATATGGCGATGTGCTGAACAAGTTTAAATTGTCT 
Bim             GGGGGTTTGTCGGCACACAAGTCGAAATATGGCGATGTGCTGAACAAGTTTAAATTGTCT 
Pa              GGGGGTTTGTCGGCACACAAGTCGAAATATGGCGATGTGCTGAACAAGTTTAAATTGTCT 
                                                                           _ 
Eliane          AATGCTTCAGTGGGAGCAGTGAGAGACACATCCGGCCGGGGCGGTAAGCATATGGAAAAG 
Bim             AATGCTTCAGTGGGAGCAGTGAGAGACACATCCGGCCGGGGCGGTAAGCATATGGAAAAG 
Pa              AATGCTTCAGTGGGAGCAGTGAGAGACACATCCGGCCGGGGCGGTAAGCATATGGAAAAG 
                                                                           _ 
Eliane          GTCAATAATGTGGCAAAACTTCTTAAGGATGCAGAGGTTTCTCTTGCAGCTGCAGCAGCC 
Bim             GTCAATAATGTGGCAAAACTTCTTAAGGATGCAGAGGTTTCTCTTGCAGCTGCAGCAGCC 
Pa              GTCAATAATGTGGCAAAACTTCTTAAGGATGCAGAGGTTTCTCTTGCAGCTGCAGCAGCC 
                                                                           _ 
Eliane          GAAATTGAGGAGGTTAAAAATGCACATGAAACAAAAGTACAGGAAGAGATGAAGCGCAAT 
Bim             GAAATTGAGGAGGTTAAAAATGCACATGAAACAAAAGTACAGGAAGAGATGAAGCGCAAT 
Pa              GAAATTGAGGAGGTTAAAAATGCACATGAAACAAAAGTACAGGAAGAGATGAAGCGCAAT 
                                                                           _ 
Eliane          GGGAACCCGATCGAAAATGAATCAGAGACTAATTCAGGGGGGAATGCGGAATCACAAGGT 
Bim             GGGAACCCGATCGAAAATGAATCAGAGACTAATTCAGGGGGGAATGCGGAATCACAAGGT 
Pa              GGGAACCCGATCGAAAATGAATCAGAGACTAATTCAGGGGGGAATGCGGAATCACAAGGT 
                                                                           _ 
Eliane          AATGGAGATCGTGAAGATAAGAACGACGAGCAACAACAGGTCGATGAGGAGGAAACAAAG 
Bim             AATGGAGATCGTGAAGATAAGAACGACGAGCAACAACAGGTCGATGAGGAGGAAACAAAG 
Pa              AATGGAGATCGTGAAGATAAGAACGACGAGCAACAACAGGTCGATGAGGAGGAAACAAAG 
                                                                           _ 
Eliane          GTGGAAAATGGAAGCAGCGAGGAGGGGTCTTGTTGTGGAAACGAAAGTAACGGTCCCCAT 
Bim             GTGGAAAATGGAAGCAGCGAGGAGGGGTCTTGTTGTGGAAACGAAAGTAACGGTCCCCAT 
Pa              GTGGAAAATGGAAGCAGCGAGGAGGGGTCTTGTTGTGGAAACGAAAGTAACGGTCCCCAT 
                                                                           _ 
Eliane          GTGATGAAAAAACGTCATGGGGTTGGGGCACCAAGGCCCGTTGACGTGGTTAGTGGTTTC 
Bim             GTGATGAAAAAACGTCATGGGGTTGGGGCACCAAGGCCCGTTGACGTGGTTAGTGGTTTC 
Pa              GTGATGAAAAAACGTCATGGGGTTGGGGCACCAAGGCCCGTTGACGTGGTTAGTGGTTTC 
                                                                           _ 
Eliane          CGCAGTTATGCCAGCGCTTCTTTTGCTCTGCTTTCTCTTGTCCGTGTCGGTATTCTCCAG 
Bim             CGCAGTTATGCCAGCGCTTCTTTTGCTCTGCTTTCTCTTGTCCGTGTCGGTATTCTCCAG 
Pa              CGCAGTTATGCCAGCGCTTCTTTTGCTCTGCTTTCTCTTGTCCGTGTCGGTATTCTCCAG 
                _____<-Gene| 
Eliane          GTGGTGGTGTAGAAAAGACACCGTTTCTTCCAAAGACTGCGCGGGAGTTGCTCCTAAATT 
Bim             GTGGTGGTGTAGAAAAGACACCGTTTCTTCCAAAGACTGCGCGGGAGTTGCTCCTAAATT 
Pa              GTGGTGGTGTAGAAAAGACACCGTTTCTTCCAAAGACTGCGCGGGAGTTGCTCCTAAATT 
Eliane          GCATTTCCTTCTCTCCTCGTAACATTAAGTGGTCGTTTTGTTGTTTTTTCTTCTTTCCTC 
Bim             GCATTTCCTTCTCTCCTCGTAACATTAAGTGGTCGTTTTGTTGTTTTTTCTTCTTTCCTC 
Pa              GCATTTCCTTCTCTCCTCGTAACATTAAGTGGTCGTTTTGTTGTTTTTTCTTCTTTCCTC 
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Eliane          TCGCGTGTGGAGGCGAGGCTGAAGACGAACTGCAGCGTCAGACTGCCAAGTGTGAGAAAG 
Bim             TCGCGTGTGGAGGCGAGGCTGAAGACGAACTGCAGCGTCAGACTGCCAAGTGTGAGAAAG 
Pa              TCGCGTGTGGAGGCGAGGCTGAAGACGAACTGCAGCGTCAGACTGCCAAGTGTGAGAAAG 
 
Eliane          AGCGTGAAGTGGTGTGGGGATGATGCCAACGAAGATCTTTTTAATTTTTGGATGTGGGCT 
Bim             AGCGTGAAGTGGTGTGGGGATGATGCCAACGAAGATCTTTTTAATTTTTGGATGTGGGCT 
Pa              AGCGTGAAGTGGTGTGGGGATGATGCCAACGAAGATCTTTTTAATTTTTGGATGTGGGCT 
 
Eliane          TACGTAGTTCGCTGGTAAATATACTTAAGATCTTTCTTTTTTTTTTTGTTGTTGTTGTAT 
Bim             TACGTAGTTCGCTGGTAAATATACTTAAGATCTTTCTTTTTTTTTTTGTTGTTGTTGTAT 
Pa              TACGTAGTTCGCTGGTAAATATACTTAAGATCTTTCTTTTTTTTTTTGTTGTTGTTGTAT 
 
Eliane          GTCTTTTTGATTTTGTTGTATTGACTGAATTATTCCCCTTGAGCTTTCTTGTCTTGTACG 
Bim             GTCTTTTTGATTTTGTTGTATTGACTGAATTATTCCCCTTGAGCTTTCTTGTCTTGTACG 
Pa              GTCTTTTTGATTTTGTTGTATTGACTGAATTATTCCCCTTGAGCTTTCTTGTCTTGTACG 
 
Eliane          ATACGTTGGCGAGAAGCTGGTTAAACGAAAACTTTGAAGGAAAAAAATGTGGGATGTGTT 
Bim             ATACGTTGGCGAGAAGCTGGTTAAACGAAAACTTTGAAGGAAAAAAATGTGGGATGTGTT 
Pa              ATACGTTGGCGAGAAGCTGGTTAAACGAAAACTTTGAAGGAAAAAAATGTGGGATGTGTT 
 
Eliane          TGTGTCTGTTTGTGTGTGTAAACGTAATGGAGGCTTCCCCCCCCCCC-ATTAGTGGCATG 
Bim             TGTGTCTGTTTGTGTGTGTAAACGTAATGGAGGCTTCCCCCCCCCCCCATTAGTGGCATG 
Pa              TGTGTCTGTTTGTGTGTGTAAACGTAATGGAGGCTTCCCCCCCCCCC-ATTAGTGGCATG 
 
Eliane          GATGCATTTCCGATGCCGACATGCGGTTTTCGGTGAGGGAACAATGCGCCTCACCGTATC 
Bim             GATGCATTTCCGATGCCGACATGCGGTTTTCGGTGAGGGAACAATGCGCCTCACCGTATC 
Pa              GATGCATTTCCGATGCCGACATGCGGTTTTCGGTGAGGGAACAATGCGCCTCACCGTATC 
 
Eliane          ATGTACCGTGAACTACAAGCCACAAAAATATGTGCTTGAATAGTAAGTCCTCCCAACTTC 
Bim             ATGTACCGTGAACTACAAGCCACAAAAATATGTGCTTGAATAGTAAGTCCTCCCAACTTC 
Pa              ATGTACCGTGAACTACAAGCCACAAAAATATGTGCTTGAATAGTAAGTCCTCCCAACTTC 
 
Eliane          ATTTCATGACCAGGAAATTAATCATGTCAAGCCATTGAGCAACTTTTTCTCTTCAGTGGT 
Bim             ATTTCATGACCAGGAAATTAATCATGTCAAGCCATTGAGCAACTTTTTCTCTTCAGTGGT 
Pa              ATTTCATGACCAGGAAATTAATCATGTCAAGCCATTGAGCAACTTTTTCTCTTCAGTGGT 
 
Eliane          ATGCCTTTGTTCGTTTTCAAAAAAAAAAAAAGGAAGAATAAAGAGAAAGGGAGTGGGAAA 
Bim             ATGCCTTTGTTCGTTTTCAAAAAAAAAAAAAGGAAGAATAAAGAGAAAGGGAGTGGGAAA 
Pa              ATGCCTTTGTTCGTTTTCAAAAAAAAAAAAAGGAAGAATAAAGAGAAAGGGAGTGGGAAA 
 
Eliane          ACTTTTTTTTTTGCTATATGTGCCTTTTCTAGTGTGTGCGAGTGCCCGCTGCGAGGAATT 
Bim             ACTTTTTTTTTTGCTATATGTGCCTTTTCTAGTGTGTGCGAGTGCCCGCTGCGAGGAATT 
Pa              ACTTTTTTTTTTGCTATATGTGCCTTTTCTAGTGTGTGCGAGTGCCCGCTGCGAGGAATT 
 
Eliane          GAGCTTTCTCCTTTCCTTCCTTTTCCTCCTTTC 
Bim             GAGCTTTCTCCTTTCCTTCCTTTTCCTCCTTTC 
Pa              GAGCTTTCTCCTTTCCTTCCTTTTCCTCCTTTC 
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Appendix 4 DNA sequences of the ApoL1 cDNA clone used for the generation of recombinant 
ApoL1 aligned to the dominant human reference ApoL1 cDNA transcript (www.ncbi.nlm.nih.gov). 
Non-synonymous mutations are highlighted in red, synonymous in green. 
ApoL-1 Reference              ATGAGTGCACTTTTCCTTGGTGTGAGAGTGAGGGCAGAGGAAGCTGGAGCGAGGGTGCAA 
ApoL1-cDNA                    ATGAGTGCACTTTTCCTTGGTGTGGGAGTGAGGGCAGAGGAAGCTGGAGCGAGGGTGCAA 
 
ApoL-1 Reference              CAAAACGTTCCAAGTGGGACAGATACTGGAGATCCTCAAAGTAAGCCCCTCGGTGACTGG 
ApoL1-cDNA                    CAAAACGTTCCAAGTGGGACAGATACTGGAGATCCTCAAAGTAAGCCCCTCGGTGACTGG 
 
ApoL-1 Reference              GCTGCTGGCACCATGGACCCAGAGAGCAGTATCTTTATTGAGGATGCCATTAAGTATTTC 
ApoL1-cDNA                    GCTGCTGGCACCATGGACCCAGAGAGCAGTATCTTTATTGAGGATGCCATTAAGTATTTC 
 
ApoL-1 Reference              AAGGAAAAAGTGAGCACACAGAATCTGCTACTCCTGCTGACTGATAATGAGGCCTGGAAC 
ApoL1-cDNA                    AAGGAAAAAGTGAGCACACAGAATCTGCTACTCCTGCTGACTGATAATGAGGCCTGGAAC 
 
ApoL-1 Reference              GGATTCGTGGCTGCTGCTGAACTGCCCAGGAATGAGGCAGATGAGCTCCGTAAAGCTCTG 
ApoL1-cDNA                    GGATTCGTGGCTGCTGCTGAACTGCCCAGGAATGAGGCAGATGAGCTCCGTAAAGCTCTG 
 
ApoL-1 Reference              GACAACCTTGCAAGACAAATGATCATGAAAGACAAAAACTGGCACGATAAAGGCCAGCAG 
ApoL1-cDNA                    GACAACCTTGCAAGACAAATGATCATGAAAGACAAAAACTGGCACGATAAAGGCCAGCAG 
 
ApoL-1 Reference              TACAGAAACTGGTTTCTGAAAGAGTTTCCTCGGTTGAAAAGTAAGCTTGAGGATAACATA 
ApoL1-cDNA                    TACAGAAACTGGTTTCTGAAAGAGTTTCCTCGGTTGAAAAGTAAGCTTGAGGATAACATA 
 
ApoL-1 Reference              AGAAGGCTCCGTGCCCTTGCAGATGGGGTTCAGAAGGTCCACAAAGGCACCACCATCGCC 
ApoL1-cDNA                    AGAAGGCTCCGTGCCCTTGCAGATGGGGTTCAGAAGGTCCACAAAGGCACCACCATCGCC 
 
ApoL-1 Reference              AATGTGGTGTCTGGCTCTCTCAGCATTTCCTCTGGCATCCTGACCCTCGTCGGCATGGGT 
ApoL1-cDNA                    AATGTGGTGTCTGGCTCTCTCAGCATTTCCTCTGGCATCCTGACCCTCGTCGGCATGGGT 
 
ApoL-1 Reference              CTGGCACCCTTCACAGAGGGAGGCAGCCTTGTACTCTTGGAACCTGGGATGGAGTTGGGA 
ApoL1-cDNA                    CTGGCACCCTTCACAGAGGGAGGCAGCCTTGTACTCTTGGAACCTGGGATGGAGTTGGGA 
 
ApoL-1 Reference              ATCACAGCCGCTTTGACCGGGATTACCAGCAGTACCATAGACTACGGAAAGAAGTGGTGG 
ApoL1-cDNA                    ATCACAGCAGCTTTGACCGGGATTACCAGCAGTACCATAGACTACGGAAAGAAGTGGTGG 
 
ApoL-1 Reference              ACACAAGCCCAAGCCCACGACCTGGTCATCAAAAGCCTTGACAAATTGAAGGAGGTGAAG 
ApoL1-cDNA                    ACACAAGCCCAAGCCCACGACCTGGTCATCAAAAGCCTTGACAAATTGAAGGAGGTGAAG 
 
ApoL-1 Reference              GAGTTTTTGGGTGAGAACATATCCAACTTTCTTTCCTTAGCTGGCAATACTTACCAACTC 
ApoL1-cDNA                    GAGTTTTTGGGTGAGAACATATCCAACTTTCTTTCCTTAGCTGGCAATACTTACCAACTC 
 
ApoL-1 Reference              ACACGAGGCATTGGGAAGGACATCCGTGCCCTCAGACGAGCCAGAGCCAATCTTCAGTCA 
ApoL1-cDNA                    ACACGAGGCATTGGGAAGGACATCCGTGCCCTCAGACGAGCCAGAGCCAATCTTCAGTCA 
 
ApoL-1 Reference              GTACCGCATGCCTCAGCCTCACGCCCCCGGGTCACTGAGCCAATCTCAGCTGAAAGCGGT 
ApoL1-cDNA                    GTACCGCATGCCTCAGCCTCACGCCCCCGGGTCACTGAGCCAATCTCAGCTGAAAGCGGT 
 
ApoL-1 Reference              GAACAGGTGGAGAGGGTTAATGAACCCAGCATCCTGGAAATGAGCAGAGGAGTCAAGCTC 
ApoL1-cDNA                    GAACAGGTGGAGAGAGTTAATGAACCCAGCATCCTGGAAATGAGCAGAGGAGTCAAGCTC 
 
ApoL-1 Reference              ACGGATGTGGCCCCTGTAAGCTTCTTTCTTGTGCTGGATGTAGTCTACCTCGTGTACGAA 
ApoL1-cDNA                    ACGGATGTGGCCCCTGTAAGCTTCTTTCTTGTGCTGGATGTAGTCTACCTCGTGTACGAA 
 
ApoL-1 Reference              TCAAAGCACTTACATGAGGGGGCAAAGTCAGAGACAGCTGAGGAGCTGAAGAAGGTGGCT 
ApoL1-cDNA                    TCAAAGCACTTACATGAGGGGGCAAAGTCAGAGACAGCTGAGGAGCTGAAGAAGGTGGCT 
 
ApoL-1 Reference              CAGGAGCTGGAGGAGAAGCTAAACATTCTCAACAATAATTATAAGATTCTGCAGGCGGAC 
ApoL1-cDNA                    CAGGAGCTGGAGGAGAAGCTAAACATTCTCAACAATAATTATAAGATTCTGCAGGCGGAC 
 
ApoL-1 Reference              CAAGAACTGTGA 
ApoL1-cDNA                    CAAGAACTGTGA 
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Appendix 5 The allele sizes determined using Genescan® analysis for 6 different microsatellite 
markers for several T. brucei isolates, predominantly from the Daloa, Côte d’Ivoire Sleeping 
Sickness focus.  Alleles are coloured by the bin the allele was placed into and the bin ranges are 
also indicated. 
 
JS2 11/110 11/51 18 D2/7 PLC
Name Population A B A B A B A B A B A B
STIB247 Tanzania 97 174 162 174 87 162 165 219 143 155 169 169
STIB386 Cote d'ivorie 125 158 162 174 94 105 166 193 138 163 174 217
MALC/BF/80/AB14 Cote d'ivorie 118 118 170 178 92 92 162 162 155 155 185 185
MBOI/BF/80/TC125 Cote d'ivorie 123 123 162 162 105 105 171 171 138 138 172 172
MBOI/BF/80/TC126 Cote d'ivorie 133 162 176 188 96 96 170 183 140 143 176 176
MHOM/CI/78/DAL069 Cote d'ivorie 180 180 170 170 97 97 163 171 143 143 175 175
MHOM/CI/78/DAL072 A Cote d'ivorie 117 117 170 170 97 97 163 171 148 148 149 175
MHOM/CI/78/TH1-032 Cote d'ivorie 116 116 171 171 98 98 161 178 143 143 181 181
MHOM/CI/78/TH112 Cote d'ivorie 108 123 174 174 99 99 169 182 140 143 185 218
MHOM/CI/78/TH126 Cote d'ivorie 108 108 170 174 97 97 169 182 139 139 169 169
MHOM/CI/78/TH149 Cote d'ivorie 134 134 169 169 97 97 163 172 138 143 175 175
MHOM/CI/78/TH170 Cote d'ivorie 134 134 172 178 96 96 164 172 136 245 176 184
MKOD/BF/80/KD3 Cote d'ivorie 136 162 163 163 106 106 178 178 159 169 170 170
MKOK/BF/80/KK1 Cote d'ivorie 119 119 174 178 91 96 162 172 167 173 176 176
MKOK/BF/80/KK14 Cote d'ivorie 134 162 163 174 96 96 166 201 140 165 176 184
MKOK/BF/80/KK17 Cote d'ivorie 114 114 169 173 96 96 163 171 140 161 170 170
MKOK/BF/80/KK18 Cote d'ivorie 112 112 163 163 96 96 169 223 140 163 186 186
MKOK/BF/80/KK26 Cote d'ivorie 112 112 163 174 96 96 169 223 140 164 185 185
MKOK/BF/80/KK33 Cote d'ivorie 136 136 174 174 94 94 195 195 142 173 183 183
MKOK/BF/80/KK7 Cote d'ivorie 134 162 163 174 99 99 165 201 140 140 176 184
MSUS/CI/78/TSW 115 [CLONE B] Cote d'ivorie 123 123 173 173 95 95 225 279 143 143 180 180
MSUS/CI/78/TSW065-022 Cote d'ivorie 127 127 163 174 92 92 162 170 143 143 173 173
MSUS/CI/78/TSW100 Cote d'ivorie 126 126 162 171 92 92 162 170 138 143 173 173
MSUS/CI/78/TSW113 Cote d'ivorie 123 138 174 174 94 94 155 225 143 143 180 199
MSUS/CI/78/TSW158 Cote d'ivorie 138 138 174 174 94 94 164 164 143 152 175 180
MSUS/CI/78/TSW168 Cote d'ivorie 122 138 176 186 99 99 181 228 140 173 185 185
MSUS/CI/78/TSW175 Cote d'ivorie 108 126 163 176 99 158 170 170 136 161 168 168
MSUS/CI/78/TSW178 Cote d'ivorie 98 98 174 174 92 92 170 170 136 161 168 168
MSUS/CI/78/TSW182 Cote d'ivorie 108 126 163 176 99 99 170 170 136 160 174 174
MSUS/CI/78/TSW187 Cote d'ivorie 127 127 176 176 95 95 162 170 143 143 184 184
MSUS/CI/78/TSW19 Cote d'ivorie 98 103 174 174 94 94 170 185 140 173 187 218
MSUS/CI/78/TSW190 Cote d'ivorie 100 140 162 176 94 94 162 180 136 140 181 181
MSUS/CI/78/TSW196 Cote d'ivorie 125 125 163 174 99 99 170 162 141 153 175 175
MSUS/CI/78/TSW209 Cote d'ivorie 109 125 174 174 94 94 166 228 138 138 148 174
MSUS/CI/78/TSW308 Cote d'ivorie 123 123 174 174 99 99 164 164 150 150 175 217
MSUS/CI/78/TSW332 Cote d'ivorie 121 127 178 178 99 99 170 183 140 143 185 185
MSUS/CI/78/TSW77 Cote d'ivorie 138 138 169 169 97 155 169 225 140 140 174 184
VAVOUA/83/DAL542 (Adzam) Cote d'ivorie 133 214 170 170 98 105 163 172 248 248 175 175
VAVOUA/84/DAL740 (Brazo) Cote d'ivorie 134 215 170 170 98 98 163 172 200 243 171 175
Eliane Cote d'ivorie 137 219 170 170 96 96 164 172 242 242 174 174
GAGNEA/83/DAL595 (Kide) Cote d'ivorie 133 213 170 170 98 104 163 171 257 257 170 170
DALOA/83/DAL598 (Kosu) Cote d'ivorie 136 213 170 170 98 104 163 172 256 256 175 175
DALOA/83/DAL642 (Lisa) Cote d'ivorie 183 217 169 169 96 104 163 172 248 248 171 174
DALOA/83/DAL645 (Mago) Cote d'ivorie 134 215 170 170 98 104 163 171 255 255 171 175
DALOA/83/DAL403 (Sakon) Cote d'ivorie 183 217 170 170 96 104 163 172 248 248 175 175
DALOA/83/DAL633 (Seval) Cote d'ivorie 134 215 170 170 98 104 163 172 253 253 171 171
BOUAFLE/83/DAL587 (Yage) Cote d'ivorie 181 215 170 170 96 96 164 172 242 242 171 174
DAL972 Cote d'ivorie 134 215 170 170 98 98 163 172 253 253 171 174
1 96-102 1 161-163 1 91-99 1 162-165 1 135-142 1 148-149
2 108 2 169-177 2 103-105 2 169-172 2 160-164 2 168-176
3 112-236 3 185-187 3 153-157 3 155 3 242-248 3 180-186
4 134-138 4 162-163 4 177-184 4 173.25 4 217-218
5 179-182 5 87 5 274-278 5 149-155 5 199
6 157-161 6 201 6 252-256
7 213-218 7 193-195 7 182
8 173-174 8 225-228 8 158
9 219 9 167
10 199
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